

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 September 2008 (25.09.2008)

PCT

(10) International Publication Number  
**WO 2008/114149 A2**

- (51) International Patent Classification: **Not classified**
- (21) International Application Number: PCT/IB2008/001286
- (22) International Filing Date: 20 March 2008 (20.03.2008)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/896,201 21 March 2007 (21.03.2007) US
- (71) Applicant (for all designated States except US): **ID BIOMEDICAL CORPORATION OF QUEBEC** [CA/CA]; 525 Cartier Boulevard West, Laval, H7V 3S8 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BLAIS, Normand** [CA/CA]; 525 Cartier Quest, Laval, Quebec H6V 3S8 (CA). **BURT, David, S.** [CA/CA]; 525 Cartier Quest, Laval, Quebec H7V 3S8 (CA). **CYR, Sonya, L.** [CA/CA]; 525 Cartier Quest, Laval, Quebec H7V 3S8 (CA). **MARTIN, Denis, L.** [CA/CA]; 525 Cartier Quest, Laval, Quebec H7V 3S8 (CA). **RHEAULT, Patrick** [CA/CA]; 525 Cartier Quest, Laval, Quebec H7V 3S8 (CA).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- without international search report and to be republished upon receipt of that report
  - the filing date of the international application is within two months from the date of expiration of the priority period



**WO 2008/114149 A2**

(54) Title: CHIMERIC ANTIGENS

(57) Abstract: Chimeric respiratory syncytial virus (RSV) polypeptide antigens are provided. The disclosed polypeptides include in an N-terminal to C-terminal direction: a first F protein polypeptide domain; a G protein polypeptide domain; and a second F protein polypeptide domain. The disclosure also provides nucleic acids that encode, and pharmaceutical compositions that contain, the chimeric RSV polypeptides, as well as methods for their production and use.

## **CHIMERIC ANTIGENS**

### **CROSS-REFERENCE TO RELATED APPLICATIONS**

[001] This application claims benefit of the filing date of United States Provisional Application No. 60/896,201, filed 21 March 2007, the disclosure of which is incorporated herein by reference in its entirety.

### **COPYRIGHT NOTIFICATION PURSUANT TO 37 C.F.R. § 1.71(E)**

[002] A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.

### **FIELD**

[003] This disclosure concerns the field of immunology. More particularly, this disclosure relates to compositions and methods for eliciting an immune response specific for Respiratory Syncytial Virus (RSV).

### **BACKGROUND**

[004] Human Respiratory Syncytial Virus (RSV) is the most common worldwide cause of lower respiratory tract infections (LRI) in infants less than 6 months of age and premature babies less than or equal to 35 weeks of gestation. The RSV disease spectrum includes a wide array of respiratory symptoms from rhinitis and otitis to pneumonia and bronchiolitis, the latter two diseases being associated with considerable morbidity and mortality. Humans are the only known reservoir for RSV. Spread of the virus from contaminated nasal secretions occurs via large respiratory droplets, so close contact with an infected individual or contaminated surface is required for transmission. RSV can persist for several hours on toys or other objects, which explains the high rate of nosocomial RSV infections, particularly in paediatric wards.

[005] The global annual infection and mortality figures for RSV are estimated to be 64 million and 160,000 respectively. In the U.S. alone RSV is estimated to be responsible for 18,000 to 75,000 hospitalizations and 90 to 1900 deaths annually. In temperate climates, RSV is well documented as a cause of yearly winter epidemics of acute LRI, including bronchiolitis and

pneumonia. In the USA, nearly all children have been infected with RSV by two years of age. The incidence rate of RSV-associated LRI in otherwise healthy children was calculated as 37 per 1000 child-year in the first two years of life (45 per 1000 child-year in infants less than 6 months old) and the risk of hospitalization as 6 per 1000 child-years (11 per 1000 child-years in the first six months of life). Incidence is higher in children with cardio-pulmonary disease and in those born prematurely, who constitute almost half of RSV-related hospital admissions in the USA. Children who experience a more severe LRI caused by RSV later have an increased incidence of childhood asthma. The costs of caring for children with severe LRI and their sequelae are substantial, and RSV is also increasingly recognized as a important cause of morbidity from influenza-like illness in the elderly, highlighting the need for a safe and effective vaccine capable of protecting against RSV-induced disease.

### **SUMMARY**

[006] This disclosure concerns chimeric respiratory syncytial virus (RSV) antigens. The chimeric RSV antigens include, in an N-terminal to C-terminal direction: a first F protein polypeptide domain; a G protein polypeptide domain; and a second F protein polypeptide domain. The disclosed antigens elicit an immune response when administered to a subject, and can be used to treat and/or prevent the symptoms of RSV infection. Also disclosed are nucleic acids that encode the chimeric antigens, immunogenic compositions that contain the chimeric antigens, and methods for producing and using the chimeric antigens.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

[007] FIG. 1A is a schematic illustration highlighting structural features of the RSV F protein (574 amino acids). FIG. 1B is a schematic illustration highlighting structural features of the RSV G protein (298 amino acids). FIG. 1C is a schematic illustration highlighting structural features of an exemplary eukaryotic F2GF1 chimeric RSV antigen (562 amino acids).

[008] FIG. 2 is a schematic illustration of exemplary F2GF1 chimeric RSV antigens.

[009] FIG. 3 schematically illustrates an exemplary expression construct including a polynucleotide sequence that encodes a F2GF1 chimeric RSV antigen.

[010] FIGS. 4A-L are a sequence alignment illustrating similarity and variation between F proteins of different strains (or isolates) of RSV.

[011] FIGS. 5A-QQ are a sequence alignment illustrating similarity and variation between G proteins of different strains (or isolates) of RSV.

[012] FIG. 6 is a bar graph illustrating human sera neutralization by F2GF1 chimeric RSV antigen.

[013] FIG. 7 is a graph showing protection against RSV following administration of F2GF1 chimeric antigen.

[014] FIG. 8 is a bar graph showing serum neutralization by antibodies elicited by immunization with F2GF1 chimeric antigen.

### **DESCRIPTION OF THE SEQUENCE LISTING**

[015] SEQ ID NO:1: Nucleotide sequence of RSV Long strain Fusion (F) protein.

[016] SEQ ID NO:2: Amino acid sequence of RSV Long strain Fusion (F) protein.

[017] SEQ ID NO:3: Nucleotide sequence of RSV Long strain G protein.

[018] SEQ ID NO:4: Amino acid sequence of RSV Long strain G protein.

[019] SEQ ID NO:5: Nucleotide sequence encoding P3-1 chimeric F2GF1 polypeptide.

Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1809 encode amino acids 161 to 524 of the F0 protein. Two 6 nucleotides bridges between the F and the G regions at position 400 to 405 and 712 to 717 were generated to link each fragment together. Both bridges code for 2 glycine amino acid residues.

[020] SEQ ID NO:6: Amino acid sequence of P3-1 F2GF1 polypeptide. Amino acids 1 to 26 are from the vector and include a 10 histidines N-terminal tag. Amino acids 27 to 133 correspond to the amino acids 24 to 130 of the F0 protein (F2). Amino acids 136 to 237 correspond to the amino acids 128 to 229 of the G protein. Amino acids 240 to 603 correspond to the amino acids 161 to 524 of the F0 protein. Linkers between the F and the G regions are located at position 134 to 135 and 238 to 239.

[021] SEQ ID NO:7: Nucleotide sequence encoding P3-2 chimeric F2GF1 polypeptide.

Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides

79 to 330 encode amino acids 24 to 107 of the F0 protein (F2). Nucleotides 337 to 579 encode amino acids 149 to 229 of the G protein. Nucleotides 586 to 1677 encode amino acids 161 to 524 of the F0 protein. Two 6 nucleotides bridges between the F and the G regions at position 331 to 336 and 580 to 585 were generated to link each fragment together. Both bridges code for 2 glycine amino acid residues.

[022] SEQ ID NO:8: Amino acid sequence of P3-2 F2GF1 polypeptide. Amino acids 1 to 26 are from the vector and include a 10 histidines N-terminal tag. Amino acids 27 to 110 correspond to the amino acids 24 to 107 of the F0 protein (F2). Amino acids 113 to 193 correspond to the amino acids 149 to 229 of the G protein. Amino acids 196 to 559 correspond to the amino acids 161 to 524 of the F0 protein (F1). Linkers between the F and the G regions are located at position 111 to 112 and 194 to 195.

[023] SEQ ID NO:9: Nucleotide sequence encoding P3-3 chimeric F2GF1 polypeptide. Amino acids 1 to 26 are from the vector and include a 10 histidines N-terminal tag. Amino acids 27 to 110 correspond to the amino acids 24 to 107 of the F0 protein (F2). Amino acids 113 to 193 correspond to the amino acids 149 to 229 of the G protein. Amino acids 196 to 559 correspond to the amino acids 161 to 524 of the F0 protein (F1). Linkers between the F and the G regions are located at position 111 to 112 and 194 to 195.

[024] SEQ ID NO:10: Amino acid sequence of P3-3 F2GF1 polypeptide. Amino acids 1 to 26 are from the vector and include a 10 histidines N-terminal tag. Amino acids 27 to 110 correspond to the amino acids 24 to 107 of the F0 protein (F2). Amino acids 113 to 214 correspond to the amino acids 128 to 229 of the G protein. Amino acids 217 to 580 correspond to the amino acids 161 to 524 of the F0 protein (F1). Linkers between the F and the G regions are located at position 111 to 112 and 215 to 216.

[025] SEQ ID NO:11: Nucleotide sequence encoding P3-4 chimeric F2GF1 polypeptide. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 648 encode amino acids 149 to 229 of the G protein. Nucleotides 655 to 1746 encode amino acids 161 to 524 of the F0 protein. Two 6 nucleotides bridges between the F and the G regions at position 400 to 405 and 649 to 654 were generated to link each fragment together. Both bridges code for 2 glycine amino acid residues.

[026] SEQ ID NO:12: Amino acid sequence of P3-4 F2GF1 polypeptide. Amino acids 1 to 26 are from the vector and include a 10 histidines N-terminal tag. Amino acids 27 to 133 correspond to the amino acids 24 to 130 of the F0 protein (F2). Amino acids 136 to 216 correspond to the amino acids 149 to 229 of the G protein. Amino acids 219 to 582 correspond to the amino acids 161 to 524 of the F0 protein. Linkers between the F and the G regions are located at position 134 to 135 and 217 to 218.

[027] SEQ ID NO: 13: Nucleotide sequence encoding P3-5 chimeric F2GF1 polypeptide. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1809 encode amino acids 161 to 524 of the F0 protein. Two 6 nucleotides bridges between the F and the G regions at position 400 to 405 and 712 to 717 were generated to link each fragment together. Both bridges code for 2 glycine amino acid residues.

[028] SEQ ID NO:14: Amino acid sequence of P3-5 F2GF1 polypeptide. Amino acids 1 to 26 are from the vector and include a 10 histidines N-terminal tag. Amino acids 27 to 133 correspond to the amino acids 24 to 130 of the F0 protein (F2). Amino acids 136 to 237 correspond to the amino acids 128 to 229 of the G protein. Amino acids 240 to 603 correspond to the amino acids 161 to 524 of the F0 protein. Linkers between the F and the G regions are located at position 134 to 135 and 238 to 239.

[029] SEQ ID NO:15: Nucleotide sequence encoding P3-6 chimeric F2GF1 polypeptide. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 330 encode amino acids 24 to 107 of the F0 protein (F2). Nucleotides 337 to 579 encode amino acids 149 to 229 of the G protein. Nucleotides 586 to 1677 encode amino acids 161 to 524 of the F0 protein. Two 6 nucleotides bridges between the F and the G regions at position 331 to 336 and 580 to 585 were generated to link each fragment together. Both bridges code for 2 glycine amino acid residues.

[030] SEQ ID NO:16: Amino acid sequence of P3-6 F2GF1 polypeptide. Amino acids 1 to 26 are from the vector and include a 10 histidines N-terminal tag. Amino acids 27 to 110 correspond to the amino acids 24 to 107 of the F0 protein (F2). Amino acids 113 to 193 correspond to the amino acids 149 to 229 of the G protein. Amino acids 196 to 559 correspond to the amino acids

161 to 524 of the F0 protein (F1). Linkers between the F and the G regions are located at position 111 to 112 and 194 to 195.

[031] SEQ ID NO:17: Nucleotide sequence encoding P3-7 F2GF1 polypeptide. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 330 encode amino acids 24 to 107 of the F0 protein (F2). Nucleotides 337 to 642 encode amino acids 128 to 229 of the G protein. Nucleotides 649 to 1740 encode amino acids 161 to 524 of the F0 protein. Two 6 nucleotides bridges between the F and the G regions at position 331 to 336 and 643 to 648 were generated to link each fragment together. Both bridges code for 2 glycine amino acid residues.

[032] SEQ ID NO:18: Amino acid sequence of P3-7 F2GF1 polypeptide. Amino acids 1 to 26 are from the vector and include a 10 histidines N-terminal tag. Amino acids 27 to 110 correspond to the amino acids 24 to 107 of the F0 protein (F2). Amino acids 113 to 214 correspond to the amino acids 128 to 229 of the G protein. Amino acids 217 to 580 correspond to the amino acids 161 to 524 of the F0 protein (F1). Linkers between the F and the G regions are located at position 111 to 112 and 215 to 216.

[033] SEQ ID NO:19: Nucleotide sequence encoding P3-8 F2GF1 polypeptide. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 648 encode amino acids 149 to 229 of the G protein. Nucleotides 655 to 1746 encode amino acids 161 to 524 of the F0 protein. Two 6 nucleotides bridges between the F and the G regions at position 400 to 405 and 649 to 654 were generated to link each fragment together. Both bridges code for 2 glycine amino acid residues.

[034] SEQ ID NO:20: Amino acid sequence of P3-8 F2GF1 polypeptide. Amino acids 1 to 26 are from the vector and include a 10 histidines N-terminal tag. Amino acids 27 to 133 correspond to the amino acids 24 to 130 of the F0 protein (F2). Amino acids 136 to 216 correspond to the amino acids 149 to 229 of the G protein. Amino acids 219 to 582 correspond to the amino acids 161 to 524 of the F0 protein. Linkers between the F and the G regions are located at position 134 to 135 and 217 to 218.

[035] SEQ ID NO:21: Nucleotide sequence encoding F2GF1-1 C-V1 (SEQ ID NO:22 is the encoded amino acid sequence). Nucleotides 1 to 78 are from the vector and include a 10

histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1809 encode amino acids 161 to 524 of the F0 protein. Two 6 nucleotides bridges between the F and the G regions at position 400 to 405 and 712 to 717 were generated to link each fragment together. Both bridges code for 2 glycine amino acid residues. Four altered codons encode cysteine to serine substitutions at nucleotide positions: 1175, 1235, 1265 and 1553 (amino acid residues 392, 412, 422 and 518).

[036] SEQ ID NO:23: Nucleotide sequence encoding F2GF1-1 C-V2 (SEQ ID NO:24 is the encoded amino acid sequence). Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1809 encode amino acids 161 to 524 of the F0 protein. Two 6 nucleotides bridges between the F and the G regions at position 400 to 405 and 712 to 717 were generated to link each fragment together. Both bridges code for 2 glycine amino acid residues. Four altered codons encode cysteine to serine substitutions at nucleotide positions: 119, 215, 872 and 1202 (amino acid residues 40, 72, 291 and 401).

[037] SEQ ID NO:25: Nucleotide sequences encoding F2GF1-1 C-V12 (SEQ ID NO:26 is the encoded amino acid sequence). Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1809 encode amino acids 161 to 524 of the F0 protein. Two 6 nucleotides bridges between the F and the G regions at position 400 to 405 and 712 to 717 were generated to link each fragment together. Both bridges code for 2 glycine amino acid residues. Eight altered codons encode cysteine to serine substitutions at positions nucleotide positions 119, 215, 872, 1175, 1202, 1235, 1265 and 1553 (amino acid residues 40, 72, 291, 392, 401, 412, 422 and 518).

[038] SEQ ID NO:27: Nucleotide sequences encoding F2GF1-1 C-V12' (SEQ ID NO:28 is the encoded amino acid sequence). Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1809 encode amino acids 161 to 524 of the F0 protein. Two 6 nucleotides bridges between the F and the G regions at position 400 to 405 and 712 to 717 were generated to link each fragment



together. Both bridges code for 2 glycine amino acid residues. Twelve altered codons encode cysteine to serine substitutions at nucleotide positions 106, 107, 116, 118, 121, 122, 215, 872, 1175, 1198, 1199, 1201, 1202, 1235, 1265 and 1553.

[039] SEQ ID NO:29: Nucleotide sequence encoding F2GF1-1 del1 (SEQ ID NO:30 is the encoded amino acid sequence). This is a version of F2GF1-1 in which a F1 portion was truncated to delete the first 47 amino acids of F1. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1668 encode amino acids 208 to 524 of the F0 protein.

[040] SEQ ID NO:31: Nucleotide sequence encoding F2GF1-1 del2 (SEQ ID NO:32 is the encoded amino acid sequence). This is a version of F2GF1-1 in which a F1 portion was truncated to delete the first 42 amino acids of the F1. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1683 encode amino acids 203 to 524 of the F0 protein.

[041] SEQ ID NO:33: Nucleotide sequence encoding F2GF1-1 del3 (SEQ ID NO:34 is the encoded amino acid sequence). This is a version of F2GF1-1 in which a F1 portion was truncated to delete the 24 first amino acids of the F1 are deleted.. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1737 encode amino acids 185 to 524 of the F0 protein.

[042] SEQ ID NO:35: Nucleotide sequence encoding F2GF1-1 del4 (SEQ ID NO:36 is the encoded amino acid sequence). This is a version of F2GF1-1 in which a F1 portion was truncated. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1677 encode amino acids 205 to 524 of the F0 protein.

[043] SEQ ID NO:37: Nucleotide sequence encoding F2GF1-1 del5 (SEQ ID NO:38 is the encoded amino acid sequence). This is a version of F2GF1-1 in which both extremities of the F1 portion were truncated. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-

terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1545 encode amino acids 206 to 481 of the F0 protein.

[044] SEQ ID NO:39: Nucleotide sequence encoding F2GF1-1 del6 (SEQ ID NO:40 is the encoded amino acid sequence). This is a version of F2GF1-1 in which both extremities of the F1 portion were truncated. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1569 encode amino acids 206 to 481 of the F0 protein.

[045] SEQ ID NO:41: Nucleotide sequence encoding F2GF1-1 del5 C-V12 (SEQ ID NO:42 is the encoded amino acid sequence). This is a version of F2GF1-1 in which both extremities of the F1 portion were truncated. 8 codons were also modified at nucleotide positions 119, 215, 737, 1040, 1067, 1100, 1130 and 1418. It is a combination of the del5 and C-V12 modifications. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1545 encode amino acids 206 to 481 of the F0 protein. The modified codons are highlighted.

[046] SEQ ID NO:43: Nucleotide sequence encoding F2GF1-1 del6 C-V12 (SEQ ID NO:44 is the encoded amino acid sequence). This is a version of F2GF1-1 in which both extremities of the F1 portion were truncated. 8 codons were also modified at the nucleotide positions 119, 215, 755, 1058, 1085, 1118, 1148 and 1436. It is a combinaison of the del6 and C-V12 modifications. Nucleotides 1 to 78 are from the vector and include a 10 histidines N-terminal tag. Nucleotides 79 to 399 encode amino acids 24 to 130 of the F0 protein (F2). Nucleotides 406 to 711 encode amino acids 128 to 229 of the G protein. Nucleotides 718 to 1569 encode amino acids 206 to 481 of the F0 protein.

[047] SEQ ID NO:45: Nucleotide sequence encoding An-G polypeptide (SEQ ID NO:46 is the encoded amino acid sequence). Nucleotides 1 to 72 encode N-terminal histidine tag. Nucleotides 73 to 378 encode amino acids 128 to 229 of the G protein.

[048] SEQ ID NO:47: Nucleotide sequence encoding An-G-O polypeptide (SEQ ID NO:48 is the encoded amino acid sequence). Codon optimized G protein polypeptide. Nucleotides 1 to 72

encode N-terminal histidine tag. Nucleotides 73 to 378 encode amino acids 128 to 229 of the G protein.

[049] SEQ ID NO:49: Nucleotide sequence encoding An-GT polypeptide (SEQ ID NO:50 is the encoded amino acid sequence). Nucleotides 1 to 72 encode N-terminale histidine tag. Nucleotides 73 to 312 encode amino acids 149 to 229 of the G protein.

[050] SEQ ID NO:51: Nucleotide sequence encoding An-GT-O polypeptide (SEQ ID NO:52 is the encoded amino acid sequence). Nucleotides 1 to 72 encode N-terminale histidine tag. Nucleotides 73 to 312 encode amino acids 149 to 229 of the G protein.

[051] SEQ ID NO:53: Nucleotide sequence encoding F1 polypeptide (SEQ ID NO:54 is the encoded amino acid sequence). Nucleotides 1 to 78 are part the vector (pET19b) and include a 10 histidines N-terminal tag. Nucleotides 79 to 1158 encode amino acids 162 to 524 of the F0 protein.

[052] SEQ ID NO:55: Nucleotide sequence encoding F1 del5 (SEQ ID NO:56 is the encoded amino acid sequence). Version of the F1 polypeptide truncated at both extremities of the F1 coding sequence. Nucleotides 1 to 78 are parts the vector (pET19b) and includes a 10 histidines N-terminal tag. Nucleotides 79 to 900 encode amino acids 208 to 481 of the F0 protein.

[053] SEQ ID NO:57: Nucleotide sequence encoding F1 del5 C-V1 (SEQ ID NO:58 is the encoded amino acid sequence). This version of the F polypeptide is similar to F1 del5. Four codons were altered to generate 4 cysteine to serine point mutations.

[054] SEQ ID NO:59: Nucleotide sequence encoding F1 del5 C-V2' (SEQ ID NO:60 is the encoded amino acid sequence). This version of the F polypeptide is similar to F1 del5. Three codons were altered to generate 3 point mutations.

[055] SEQ ID NO:61: Nucleotide sequence encoding F1 del5 C-V12' (SEQ ID NO:62 is the encoded amino acid sequence). This version of the F polypeptide is similar to F1 del5. Seven codons were changed to generate point mutations, combining the substitutions of F1 del5 C-V1 and F1 del5 C-V2' together.

[056] SEQ ID NO:63: Nucleotide sequence encoding F2 polypeptide (SEQ ID NO:64 is the encoded amino acid sequence). Nucleotides 1 to 72 are from the vector (pET19b) and includes a 10 histidines N-terminal tag. Nucleotides 73 to 393 encode amino acids 24 to 130 of the F0 protein.

[057] SEQ ID NO:65: Nucleotide sequence encoding F2 C-V2' (SEQ ID NO:66 is the encoded amino acid sequence). This version is similar to F2 (SEQ ID NO:41). Five codons were changed to generate point mutations.

[058] SEQ ID NO:67: Nucleotide sequence encoding an exemplary eukaryotic chimeric F2GF1 polypeptide.

[059] SEQ ID NO:68: Amino acid sequence of eukaryotic chimeric F2GF1 polypeptide.

[060] SEQ ID NO:69: Nucleotide sequence encoding an exemplary eukaryotic chimeric F2GF1 polypeptide with a deletion of the furin cleavage sites (eukaryotic F2GF1 delfur).

[061] SEQ ID NO:70: Amino acid sequence of eukaryotic F2GF1 delfur.

## **DETAILED DESCRIPTION**

### INTRODUCTION

[062] Development of vaccines that protect against the symptoms and sequelae caused by RSV infection has been complicated by the fact that host immune responses appear to play a role in the pathogenesis of the disease. Early studies in the 1960s showed that children vaccinated with a formalin-inactivated RSV vaccine suffered from more severe disease on subsequent exposure to the virus as compared to unvaccinated control subjects. These early trials resulted in the hospitalization of 80% of vaccinees and two deaths. The enhanced severity of disease has been reproduced in animal models and is thought to result from inadequate levels of serum-neutralizing antibodies, lack of local immunity, and excessive induction of a type 2 helper T-cell-like (Th2) immune response with pulmonary eosinophilia and increased production of IL-4 and IL-5 cytokines. In contrast, a successful vaccine that protects against RSV infection induces a Th1-type immune response, characterized by production of IL-2 and  $\gamma$ -interferon (IFN- $\gamma$ ).

[063] Various approaches have been attempted in efforts to produce a safe and effective RSV vaccine that produces durable and protective immune responses in healthy and at risk populations. However, none of the candidate evaluated to date have proven safe and effective as vaccines for the purpose of preventing RSV infection and/or reducing or preventing RSV disease, including lower respiratory infections (LRIs).

[064] The present disclosure concerns chimeric RSV antigens that include the predominant immunoprotective epitope of the G protein internally positioned within the RSV F protein

polypeptide, such that a readily soluble chimeric RSV antigen can be produced in a recombinant expression system. These novel chimeric RSV antigens overcome several significant drawbacks encountered in previous attempts to produce safe and effective chimeric RSV antigens that are suitable for administration as prophylactic and therapeutic vaccines.

[065] In one aspect, the disclosure relates to a respiratory syncytial virus (RSV) antigen including a chimeric polypeptide comprising in an N terminal to C terminal direction: a first F protein polypeptide domain; a G protein polypeptide domain; and a second F protein polypeptide domain. Such chimeric antigens are designated herein F2GF1 chimeric RSV antigens. The first F protein polypeptide domain can include at least an amino acid subsequence of the F2 (or F<sub>2</sub>) subunit (or domain) produced *in vivo* by furin cleavage, for example, an amino acid sequence from residues 24 to 107 of a native F protein polypeptide. The native F protein polypeptide can be selected from any F protein of an RSV A or RSV B strain. In certain exemplary embodiments, the F protein is selected from the RSV Long strain (represented by SEQ ID NO:2 ATCC catalog # VR-26, GenBank # AY911262). To facilitate understanding of this disclosure, all amino acid residue positions are given with reference to (that is, the amino acid residue position corresponds to) the amino acid position of the RSV Long strain, although a comparable amino acids can be used from any RSV A or B strain. Comparable amino acid positions of any other RSV A or B strain can be determined easily by those of ordinary skill in the art by aligning the amino acid sequences of the selected RSV strain with that of Long strain using readily available and well-known alignment algorithms (such as BLAST, *e.g.*, using default parameters, as shown in FIGS. 4 and 5). Additionally, the first F protein polypeptide domain can also include all or part of the amino acid sequence of “pep27” (for example, including all or a portion of amino acid residues 110 to 130 of a native F protein polypeptide). Additionally, or alternatively, the first F protein polypeptide domain can include signal peptide. Such a signal peptide can be the native F0 signal peptide (*e.g.*, amino acids 1-23 of the F0 polypeptide), or it can be a heterologous signal peptide, for example selected based on the expression system of choice. In one exemplary embodiment, the F2 domain that includes a signal peptide includes amino acid residues 1-109 of a native F0 polypeptide.

[066] Optionally, the first F protein polypeptide domain of the chimeric RSV antigen includes one or more amino acid modifications relative to a naturally occurring RSV F protein polypeptide. For example, such an amino acid modification can improve (*e.g.*, increase) the

solubility and/or stability of the chimeric RSV antigen. Such a modification can be a substitution of one or more amino acids, a deletion of one or more amino acids or an addition of one or more amino acids. In one example, the chimeric RSV antigen includes a first F protein polypeptide domain that has an amino acid other than methionine (such as an isoleucine) at position 79 (as compared to the native F0 polypeptide). This exemplary chimeric RSV antigen has been engineered to eliminate a secondary start site within the first F protein polypeptide domain. In another example, the amino acid modification includes an amino acid deletion or substitution that eliminates a furin cleavage site present in a naturally occurring RSV F protein. For example, the exemplary chimeric RSV antigen can be modified to eliminate a naturally occurring furin cleavage site that separates subunit F2 from pep27, *e.g.*, by removal (either by deletion and/or substitution) of all or part of the furin cleavage site at positions 106-109.

[067] The second F protein polypeptide domain typically includes all or part of the amino acid sequence of the F1 (or F<sub>1</sub>) subunit (or domain) produced *in vivo* by furin cleavage. For example, the second F protein polypeptide domain can include all or part of an amino acid sequence from 161 to 524 of a native F protein polypeptide (*e.g.*, from amino acid 151 to amino acid 524 of a native F protein). Optionally, the second F protein polypeptide domain comprises at least one amino acid modification that improves (*e.g.*, increases) solubility and/or stability of the chimeric RSV antigen.

[068] Located between the first F protein polypeptide domain, and the second F protein polypeptide domain in the chimeric RSV antigen is a G protein polypeptide domain. The intervening G protein polypeptide domain can include all or part of a native G protein polypeptide, such as the Long strain G protein represented by SEQ ID NO:4. In one exemplary embodiment, the G protein polypeptide is a subsequence (or fragment) of a native G protein polypeptide that includes all or part of amino acid residues 151-229 (*e.g.*, from 149 to 229) of a native G protein polypeptide. In another embodiment, the G protein polypeptide domain includes an amino acid sequence from residues 128 to 229 of a native G protein polypeptide.

[069] In certain embodiments of the chimeric RSV antigen, the G protein domain has been modified to reduce or prevent vaccine enhanced viral disease when the RSV antigen is administered to a subject (such as a human subject). Such a chimeric RSV antigen favorably includes a substitution of asparagine by alanine at position 191 (N191A) of the G protein.

[070] In certain embodiments, at least one, sometimes two, and in some cases all three of the the first F protein polypeptide domain, the G protein polypeptide domain, and/or the second F protein polypeptide domain correspond in sequence to the RSV A Long strain. Alternatively, one or more of the domains corresponds in sequence (or is derived from) another RSV A or B strain. Thus, the chimera can include F protein and G proteins amino acid sequences from one or more strain of RSV, such that the each of the two F protein components and the G protein component can be from the same strain, or from different strains. Where different strains are selected, the F protein and G protein components can each be from an A strain, or from a B strain, or from a combination of A and B strains.

[071] In some instances, one or more of the polypeptide domains has one or more amino acid modification relative to the amino acid sequence of the naturally occurring strain from which it is derived. For example, the modification can be a substitution of one or more amino acids (such as two amino acids, three amino acids, four amino acids, five amino acids, up to about ten amino acids, or more). In certain embodiments, the RSV antigens can include one or more amino acid substitutions that replace a cysteine residue, such as a cysteine residue selected from amino acid residues 40, 72, 291, 392, 401, 412, 422, and/or 518 of the F2GF1 polypeptide (corresponding to residues 37, 69, 212, 313, 322, 333, 343 and 439 of the native F0 polypeptide. Alternatively, one or more of the cysteines can be replaced by a hydrophobic residue, such as leucine, isoleucine or valine. Additionally or alternatively, the chimeric RSV antigen can include one or more amino acid substitutions that replace a hydrophobic amino acid, such as a hydrophobic amino acid selected from positions 36 to 41 and/or positions 400 to 401, corresponding to residues 33-39 and 321-322 of F0.

[072] Alternatively or additionally, the modification can include a deletion of one or more amino acids and/or an addition of one or more amino acids. Indeed, if desired, one or more of the polypeptide domains can be a synthetic polypeptide that does not correspond to any single strain, but includes component subsequences from multiple strains, or even from a consensus sequence deduced by aligning multiple strains of RSV virus polypeptides. In certain embodiments, one or more of the polypeptide domains is modified by the addition of an amino acid sequence that constitutes a tag, which facilitates subsequent processing or purification. Such a tag can be an antigenic or epitope tag, an enzymatic tag or a polyhistidine tag. Typically

the tag is situated at one or the other end of the chimeric protein, such as at the C-terminus or N-terminus of the chimeric antigen or fusion protein.

[073] Exemplary RSV antigens are represented by the amino acid sequences of SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, and 20. Nucleotide sequences encoding these exemplary F2GF1 polypeptides are designated SEQ ID NOs: 5, 7, 9, 11, 13, 15, 17 and 19, respectively. Additional exemplary RSV antigens are represented by SEQ ID NOs:21-43, with exemplary eukaryotic F2GF1 polypeptides represented by SEQ ID NOs:68 and 70 (nucleotide sequences SEQ ID NOs:67 and 69).

[074] When expressed, the chimeric RSV antigens fold into a conformation that closely resembles the assembly of a mature cleaved F protein. The G protein component is situated between the F2 and F1 polypeptide subunits, forming a loop in which the immunodominant G protein epitope is located on the outside of the folded protein. In certain embodiments, the RSV antigen is a multimer of chimeric polypeptides. For example, the RSV antigen can favorably assemble into a trimer of F2GF1 chimeric RSV polypeptides, or into a higher order assembly or complex of multimers.

[075] Another feature of this disclosure concerns immunogenic compositions that contain or include a F2GF1 chimeric RSV antigen in combination with a pharmaceutically acceptable carrier or excipient. Pharmaceutically acceptable carriers and excipients are well known and can be selected by those of skill in the art. For example, the carrier or excipient can favorably include a buffer. Optionally, the carrier or excipient also contains at least one component that stabilizes solubility and/or stability. Examples of solubilizing/stabilizing agents include detergents, for example, laurel sarcosine and/or tween. Alternative solubilizing/stabilizing agents include arginine, and glass forming polyols (such as sucrose, trehalose and the like).

[076] Optionally, the immunogenic compositions also include an adjuvant. In the context of an immunogenic composition suitable for administration to a subject for the purpose of eliciting a protective immune response against RSV, the immunogenic composition (combination of antigen and adjuvant) is selected to elicit a Th1-type immune response.

[077] The adjuvant is selected to be safe and minimally reactogenic in the subject, or population of subjects, to whom the immunogenic composition is administered. In the context of immunogenic compositions containing chimeric F2GF1 polypeptide antigens, to be safe, the



adjuvant when administered in combination with the antigen, does not result in an immunopathological response, such as exacerbated RSV disease associated with a Th2-type immune response, in the subject. When the immunogenic composition is to be administered to a subject of a particular age group susceptible to (or at increased risk of) RSV infection, the adjuvant is selected to be safe and effective in the subject or population of subjects. Thus, when formulating an immunogenic composition containing a chimeric RSV antigen for administration in an elderly subject (such as a subject greater than 65 years of age), the adjuvant is selected to be safe and effective in elderly subjects. Similarly, when the immunogenic composition containing the chimeric RSV antigen is intended for administration in neonatal or infant subjects (such as subjects between birth and the age of two years), the adjuvant is selected to be safe and effective in neonates and infants.

[078] Additionally, the adjuvant is typically selected to enhance a protective immune response when administered via a route of administration, by which the immunogenic composition is administered. For example, when formulating an immunogenic composition containing a chimeric RSV antigen for nasal administration, proteosome and protollin are favorable Th1 biasing adjuvants. In contrast, when the immunogenic composition is formulated for intramuscular administration, adjuvants including one or more of 3D-MPL, squalene (*e.g.*, QS21), liposomes, and/or oil and water emulsions are favorably selected.

[079] In certain exemplary embodiment, the immunogenic composition containing the chimeric RSV antigen is formulated for intramuscular injection in pharmaceutically acceptable excipient containing a buffer and an adjuvant that includes 3D-MPL, optionally with alum or with QS21, *e.g.* in a liposomal formulation, at a concentration suitable for administration to neonates. In another embodiment, the chimeric RSV antigen is formulated in an oil-in-water emulsion (*e.g.*, with or without 3D-MPL) In another exemplary embodiment, the immunogenic composition containing the chimeric RSV antigen is similarly formulated with a concentration of adjuvant that enhances an immune response in an elderly subject. In another exemplary embodiment, the immunogenic composition containing the chimeric RSV antigen is formulated for intranasal administration with a proteosome or protollin adjuvant.

[080] In certain embodiments, the immunogenic compositions are administered (*e.g.*, prophylactically) to reduce or prevent infection with RSV. In some embodiments, the immunogenic compositions are administered prophylactically to reduce or prevent a pathological

response following infection with RSV. Optionally, the immunogenic compositions containing a chimeric RSV antigen are formulated with at least one additional antigen of a pathogenic organism other than RSV. For example, the pathogenic organism can be a pathogen of the respiratory tract (such as a virus or bacterium that causes a respiratory infection). In certain cases, the immunogenic composition contains an antigen derived from a pathogenic virus other than RSV, such as a virus that causes an infection of the respiratory tract, such as influenza or parainfluenza. In other embodiments, the additional antigens are selected to facilitate administration or reduce the number of inoculations required to protect a subject against a plurality of infectious organisms. For example, the antigen can be derived from any one or more of hepatitis B, diphtheria, tetanus, pertussis, Hemophilus influenza, poliovirus, or Pneumococcus, among others.

[081] Another aspect of this disclosure concerns recombinant nucleic acids that encode chimeric RSV antigens as described above. In certain embodiments, the recombinant nucleic acids are codon optimized for expression in a selected prokaryotic or eukaryotic host cell. To facilitate replication and expression, the nucleic acids can be incorporated into a vector, such as a prokaryotic or a eukaryotic expression vector. Host cells including recombinant F2GF1 chimeric RSV antigen-encoding nucleic acids are also a feature of this disclosure. Favorable host cells include prokaryotic (*i.e.*, bacterial) host cells, such as *E. coli*, as well as numerous eukaryotic host cells, including fungal (*e.g.*, yeast) cells, insect cells, plant cells, and mammalian cells (such as CHO cells).

[082] Accordingly, the use of the chimeric RSV F2GF1 polypeptides, and nucleic acids that encode them, in the preparation of a medicament (for example, an immunogenic composition) for treating (either therapeutically following or prophylactically prior to) exposure to or infection by RSV is also a feature of this disclosure. Likewise, methods for eliciting an immune response against RSV in a subject are a feature of this disclosure. Such methods include administering an immunogenically effective amount of a composition comprising a F2GF1 chimeric RSV antigen to a subject, such as a human subject. Commonly, the composition includes an adjuvant that enhances the immune response. The composition is formulated to elicit an immune response specific for RSV without enhancing viral disease following contact with RSV. That is, the immunogenic composition is formulated to, and results in an immune response that reduces or prevents infection with a RSV and/or reduces or prevents a pathological response following

infection with a RSV. Although the composition can be administered by a variety of different routes, most commonly, the immunogenic compositions are delivered by an intramuscular or intranasal route of administration.

### TERMS

[083] Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Definitions of common terms in molecular biology can be found in Benjamin Lewin, *Genes V*, published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew *et al.* (eds.), *The Encyclopedia of Molecular Biology*, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), *Molecular Biology and Biotechnology: a Comprehensive Desk Reference*, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).

[084] The singular terms “a,” “an,” and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. The term “plurality” refers to two or more. It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description. Additionally, numerical limitations given with respect to concentrations or levels of a substance, such as an antigen, are intended to be approximate. Thus, where a concentration is indicated to be at least (for example) 200 pg, it is intended that the concentration be understood to be at least approximately (or “about” or “~”) 200 pg.

[085] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. The term “comprises” means “includes.” Thus, unless the context requires otherwise, the word “comprises,” and variations such as “comprise” and “comprising” will be understood to imply the inclusion of a stated compound or composition (*e.g.*, nucleic acid, polypeptide, antigen) or step, or group of compounds or steps, but not to the exclusion of any other compounds, composition, steps, or groups thereof. The abbreviation, “*e.g.*” is derived from the Latin *exempli gratia*, and is used herein to indicate a non-limiting example. Thus, the abbreviation “*e.g.*” is synonymous with the term “for example.”

[086] In order to facilitate review of the various embodiments of this disclosure, the following explanations of terms are provided. Additional terms and explanations can be provided in the context of this disclosure.

[087] Respiratory syncytial virus (RSV) is a pathogenic virus of the family Paramyxoviridae, subfamily Pneumovirinae, genus Pneumovirus. The genome of RSV is a 15,222 nucleotide-long, single-stranded, negative-sense RNA molecule, which encodes 11 proteins. Tight association of the RNA genome with the viral N protein forms a nucleocapsid wrapped inside the viral envelope. Two groups of human RSV strains have been described, the A and B groups, based on differences in the antigenicity of the G glycoprotein. Numerous strains of RSV have been isolated to date. Exemplary strains are indicated by GenBank and/or EMBL Accession number in FIGS. 4 and 5. Additional strains of RSV are likely to be isolated, and are encompassed within the genus of RSV. Similarly, the genus of RSV encompasses variants arising from naturally occurring (*e.g.*, previously or subsequently identified strains) by genetic drift, or artificial synthesis and/or recombination.

[088] The term “F protein” or “Fusion protein” or “F protein polypeptide” or “Fusion protein polypeptide” refers to a polypeptide or protein having all or part of an amino acid sequence of an RSV Fusion protein polypeptide. Similarly, the term “G protein” or “G protein polypeptide” refers to a polypeptide or protein having all or part of an amino acid sequence of an RSV Attachment protein polypeptide. Numerous RSV Fusion and Attachment proteins have been described and are known to those of skill in the art. FIGS. 4 and 5 set out exemplary F and G protein variants (for example, naturally occurring variants) publicly available as of the filing date of this disclosure.

[089] A “chimeric F2GF1 polypeptide” or an “F2GF1 antigen” or “F2GF1 polypeptide antigen” is a chimeric polypeptide that incorporates polypeptide components, typically including antigenic determinants or epitopes of both an RSV F protein and an RSV G protein, and includes in an N-terminal to C-terminal orientation: at least one subsequence or fragment of an F2 subunit or domain (*e.g.*, including all or part of amino acid residues 1-107 of a native F protein polypeptide, and optionally including a pep27 domain, for example amino acid residues 108-130 of F0); at least one subsequence of a G protein polypeptide; and at least one subsequence of an F1 subunit or domain (*e.g.*, including all or part of amino acids 151-524 of a native F protein polypeptide). The term subunit and domain are used interchangeably in reference to structural

domains of the F protein and/or F0 polypeptide. *In vivo*, proteolytic cleavage of the mature F0 polypeptide by a furin protease at two conserved furin consensus sequences, RAR/KR<sup>109</sup> (FCS-2) and KKRKRR<sup>136</sup> (FCS-1), resulting in the generation of three proteolytic fragments, the large membrane-anchored subunit F1 with a hydrophobic fusion peptide at its N terminus, the small subunit F2 which is linked to F1 via a disulfide bridge, and a small peptide composed of 27 amino acids (pep27) originally located between the two cleavage sites. It will be recognized by those of skill in the art that the abbreviations F0, F1 and F2 are commonly designated F<sub>0</sub>, F<sub>1</sub> and F<sub>2</sub> in the scientific literature. The term chimeric in this context includes polypeptides in which the F and G protein components are both from the same serotype or strain, as well as polypeptides in which the individual F and G protein components are from different serotypes or strains.

[090] A “variant” when referring to a nucleic acid or a protein (*e.g.*, an RSV F or G protein or protein domain, or an F2GF1 chimeric polypeptide) is a nucleic acid or a polypeptide that differs from a reference nucleic acid or protein. Usually, the difference(s) between the variant and the reference nucleic acid or protein constitute a proportionally small number of differences as compared to the reference. Such differences can be amino acid additions, deletions or substitutions. Thus, a variant typically differs by no more than about 1%, or 2%, or 5%, or 10%, or 15%, or 20% of the nucleotide or amino acid residues. Thus, a variant in the context of an RSV F or G protein, or a chimeric F2GF1 polypeptide, typically shares at least 80%, or 85%, more commonly, at least about 90% or more, such as 95%, or even 98% or 99% sequence identity with a reference protein, *e.g.*, the reference sequences illustrated in SEQ ID NO:2 and 4, or any of the exemplary F2GF1 polypeptides disclosed herein. Additional variants included as a feature of this disclosure are chimeric F2GF1 polypeptides that incorporate an F2 (*e.g.*, comprising all or part of amino acids 24-107, numerically designated by alignment with SEQ ID NO:2) and/or F1 component (*e.g.*, comprising all or part of amino acids 161-524, numerically designated by alignment with SEQ ID NO:2) from any of the exemplary sequences provided in FIG. 4 (either the same or different strain) and a G protein component (*e.g.*, all or part of amino acids 149-229, numerically designated by alignment to SEQ ID NO:4) selected from any of the exemplary sequences provided in FIG. 5. Variants can arise through genetic drift, or can be produced artificially using site directed or random mutagenesis, or by recombination of two or more preexisting variants. For example, a variant F2GF1 polypeptide can include 1, or 2, or 5 or

10, or 15, or 50 or up to about 100 nucleotide differences as compared to the exemplary F2GF1 chimeras of SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18 and 20.

[091] A “domain” of a polypeptide or protein is a structurally defined element within the polypeptide or protein. In the context of this disclosure, a “furin cleavage domain” is a domain defined by cleavage of a precursor polypeptide by a furin protease. For example, the F protein is synthesized as a single polypeptide, designated F0. The F0 polypeptide is subsequently cleaved at two consensus furin recognition motifs by a furin protease to produce two structurally independent polypeptide units designated F2 and F1. F2 extends from amino acid 24 (following the signal peptide) to the first (in an N- to C- terminal direction) furin cleavage recognition site. F1 extends from the second furin cleavage site to the C-terminal end of the F0 polypeptide.

[092] The terms “native” and “naturally occurring” refer to an element, such as a protein, polypeptide or nucleic acid, that is present in the same state as it is in nature. That is, the element has not been modified artificially. It will be understood, that in the context of this disclosure, there are numerous native/naturally occurring variants of RSV proteins or polypeptides, *e.g.*, obtained from different naturally occurring strains or isolates of RSV.

[093] The term “polypeptide” refers to a polymer in which the monomers are amino acid residues which are joined together through amide bonds. The terms “polypeptide” or “protein” as used herein are intended to encompass any amino acid sequence and include modified sequences such as glycoproteins. The term “polypeptide” is specifically intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically produced. The term “fragment,” in reference to a polypeptide, refers to a portion (that is, a subsequence) of a polypeptide. The term “immunogenic fragment” refers to all fragments of a polypeptide that retain at least one predominant immunogenic epitope of the full-length reference protein or polypeptide. Orientation within a polypeptide is generally recited in an N-terminal to C-terminal direction, defined by the orientation of the amino and carboxy moieties of individual amino acids. Polypeptides are translated from the N or amino-terminus towards the C or carboxy-terminus.

[094] A “signal peptide” is a short amino acid sequence (*e.g.*, approximately 18-25 amino acids in length) that direct newly synthesized secretory or membrane proteins to and through membranes, *e.g.*, of the endoplasmic reticulum. Signal peptides are frequently but not universally located at the N-terminus of a polypeptide, and are frequently cleaved off by signal

peptidases after the protein has crossed the membrane. Signal sequences typically contain three common structural features: an N-terminal polar basic region (n-region), a hydrophobic core, and a hydrophilic c-region).

[095] The terms “polynucleotide” and “nucleic acid sequence” refer to a polymeric form of nucleotides at least 10 bases in length. Nucleotides can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. The term includes single and double forms of DNA. By “isolated polynucleotide” is meant a polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. In one embodiment, a polynucleotide encodes a polypeptide. The 5' and 3' direction of a nucleic acid is defined by reference to the connectivity of individual nucleotide units, and designated in accordance with the carbon positions of the deoxyribose (or ribose) sugar ring. The informational (coding) content of a polynucleotide sequence is read in a 5' to 3' direction.

[096] A “recombinant” nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, *e.g.*, by genetic engineering techniques. A “recombinant” protein is one that is encoded by a heterologous (*e.g.*, recombinant) nucleic acid, which has been introduced into a host cell, such as a bacterial or eukaryotic cell. The nucleic acid can be introduced, on an expression vector having signals capable of expressing the protein encoded by the introduced nucleic acid or the nucleic acid can be integrated into the host cell chromosome.

[097] The term “purification” (*e.g.*, with respect to a pathogen or a composition containing a pathogen) refers to the process of removing components from a composition, the presence of which is not desired. Purification is a relative term, and does not require that all traces of the undesirable component be removed from the composition. In the context of vaccine production, purification includes such processes as centrifugation, dialization, ion-exchange chromatography, and size-exclusion chromatography, affinity-purification or precipitation. Thus, the term “purified” does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified nucleic acid preparation is one in which the specified protein is

more enriched than the nucleic acid is in its generative environment, for instance within a cell or in a biochemical reaction chamber. A preparation of substantially pure nucleic acid or protein can be purified such that the desired nucleic acid represents at least 50% of the total nucleic acid content of the preparation. In certain embodiments, a substantially pure nucleic acid will represent at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, or at least 95% or more of the total nucleic acid or protein content of the preparation.

[098] An “isolated” biological component (such as a nucleic acid molecule, protein or organelle) has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, such as, other chromosomal and extra-chromosomal DNA and RNA, proteins and organelles. Nucleic acids and proteins that have been “isolated” include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids and proteins.

[099] An “antigen” is a compound, composition, or substance that can stimulate the production of antibodies and/or a T cell response in an animal, including compositions that are injected, absorbed or otherwise introduced into an animal. The term “antigen” includes all related antigenic epitopes. The term “epitope” or “antigenic determinant” refers to a site on an antigen to which B and/or T cells respond. The “predominant antigenic epitopes” are those epitopes to which a functionally significant host immune response, *e.g.*, an antibody response or a T-cell response, is made. Thus, with respect to a protective immune response against a pathogen, the predominant antigenic epitopes are those antigenic moieties that when recognized by the host immune system result in protection from disease caused by the pathogen. The term “T-cell epitope” refers to an epitope that when bound to an appropriate MHC molecule is specifically bound by a T cell (via a T cell receptor). A “B-cell epitope” is an epitope that is specifically bound by an antibody (or B cell receptor molecule).

[0100] An “adjuvant” is an agent that enhances the production of an immune response in a non-specific manner. Common adjuvants include suspensions of minerals (alum, aluminum hydroxide, aluminum phosphate) onto which antigen is adsorbed; emulsions, including water-in-oil, and oil-in-water (and variants thereof, including double emulsions and reversible emulsions), liposaccharides, lipopolysaccharides, immunostimulatory nucleic acids (such as CpG



oligonucleotides), liposomes, Toll Receptor agonists (particularly, TLR2, TLR4, TLR7/8 and TLR9 agonists), and various combinations of such components.

[0101] An “immunogenic composition” is a composition of matter suitable for administration to a human or animal subject that is capable of eliciting a specific immune response, *e.g.*, against a pathogen, such as RSV. As such, an immunogenic composition includes one or more antigens (for example, polypeptide antigens) or antigenic epitopes. An immunogenic composition can also include one or more additional components capable of eliciting or enhancing an immune response, such as an excipient, carrier, and/or adjuvant. In certain instances, immunogenic compositions are administered to elicit an immune response that protects the subject against symptoms or conditions induced by a pathogen. In some cases, symptoms or disease caused by a pathogen is prevented (or reduced or ameliorated) by inhibiting replication of the pathogen (*e.g.*, RSV) following exposure of the subject to the pathogen. In the context of this disclosure, the term immunogenic composition will be understood to encompass compositions that are intended for administration to a subject or population of subjects for the purpose of eliciting a protective or palliative immune response against RSV (that is, vaccine compositions or vaccines).

[0102] An “immune response” is a response of a cell of the immune system, such as a B cell, T cell, or monocyte, to a stimulus. An immune response can be a B cell response, which results in the production of specific antibodies, such as antigen specific neutralizing antibodies. An immune response can also be a T cell response, such as a CD4+ response or a CD8+ response. In some cases, the response is specific for a particular antigen (that is, an “antigen-specific response”). If the antigen is derived from a pathogen, the antigen-specific response is a “pathogen-specific response.” A “protective immune response” is an immune response that inhibits a detrimental function or activity of a pathogen, reduces infection by a pathogen, or decreases symptoms (including death) that result from infection by the pathogen. A protective immune response can be measured, for example, by the inhibition of viral replication or plaque formation in a plaque reduction assay or ELISA-neutralization assay, or by measuring resistance to pathogen challenge *in vivo*.

[0103] A “Th1” type immune response is characterized CD4+ T helper cells that produce IL-2 and IFN- $\gamma$ . In contrast, a “Th2” type immune response is characterized by CD4+ helper cells that produce IL-4, IL-5, and IL-13.

[0104] A “immunologically effective amount” is a quantity of a composition (typically, an immunogenic composition) used to elicit an immune response in a subject. Commonly, the desired result is the production of an antigen (*e.g.*, pathogen)-specific immune response that is capable of or contributes to protecting the subject against the pathogen. However, to obtain a protective immune response against a pathogen can require multiple administrations of the immunogenic composition. Thus, in the context of this disclosure, the term immunologically effective amount encompasses a fractional dose that contributes in combination with previous or subsequent administrations to attaining a protective immune response.

[0105] The adjective “pharmaceutically acceptable” indicates that the subject is suitable for administration to a subject (*e.g.*, a human or animal subject). Remington’s Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations (including diluents) suitable for pharmaceutical delivery of therapeutic and/or prophylactic compositions, including immunogenic compositions.

[0106] “Solubility” is a measure the amount of a substance, in the context of this disclosure, a polypeptide, that will dissolve in a given amount of another substance, usually a liquid. Thus, an increase insolubility is an increase in the amount of a the polypeptide that remains without aggregating or separating from the substance (*e.g.*, liquid) in which it is dissolved.

[0107] When referring to a polypeptide, “stability is a measure of the polypeptide’s resistance to degradation. Thus, an increase in stability reflects an increase in the ability of the polypeptide to withstand degradation, for example, measured as an increased half-life *in vivo*, or an increased shelf life *in vitro*.

[0108] The term “modulate” in reference to a response, such as an immune response, means to alter or vary the onset, magnitude, duration or characteristics of the response. An agent that modulates an immune response alters at least one of the onset, magnitude, duration or characteristics of an immune response following its administration, or that alters at least one of the onset, magnitude, duration or characteristic as compared to a reference agent.

[0109] The term “reduces” is a relative term, such that an agent reduces a response or condition if the response or condition is quantitatively diminished following administration of the agent, or if it is diminished following administration of the agent, as compared to a reference agent.

Similarly, the term “prevents” does not necessarily mean that an agent completely eliminates the

response or condition, so long as at least one characteristic of the response or condition is eliminated. Thus, an immunogenic composition that reduces or prevents an infection or a response, such as a pathological response, *e.g.*, vaccine enhanced viral disease, can, but does not necessarily completely eliminate such an infection or response, so long as the infection or response is measurably diminished, for example, by at least about 50%, such as by at least about 70%, or about 80%, or even by about 90% of (that is to 10% or less than) the infection or response in the absence of the agent, or in comparison to a reference agent.

[0110] A “subject” is a living multi-cellular vertebrate organism. In the context of this disclosure, the subject can be an experimental subject, such as a non-human animal, *e.g.*, a mouse, a cotton rat, or a non-human primate. Alternatively, the subject can be a human subject.

#### F2GF1 CHIMERIC RSV ANTIGENS

[0111] The viral envelope of RSV includes virally encoded F, G and SH glycoproteins. The F and G glycoproteins are the only two components of the RSV virion that are known to induce RSV-specific neutralizing antibodies. The chimeric F2GF1 polypeptides disclosed herein were designed to incorporate structural features of the native F protein while simultaneously exhibiting important immunodominant epitopes of the RSV G protein. To facilitate folding and assembly during production, the two domains of the F protein produced by post-translational cleavage of the F0 precursor polypeptide by a furin protease (F1 and F2) were expressed in a single amino acid chain. The antigenic portion of the RSV G protein was incorporated between the F2 and F1 domains, taking into account the conformational distance constraints between F2 and F1. The design of these constructs was modeled based on the 3D model of the post-fusion state of the protein. This conformer has been predicted to be the most stable form of the protein.

[0112] FIG. 1A schematically illustrates an exemplary RSV F protein and specific structural regions domains described herein. The F protein of RSV is translated as a single polypeptide precursor, designated F0. F0 folds and is subject to proteolysis and other post-translational modifications. First, a signal peptide (Sp) targets the translation of the nascent polypeptide to the reticulum endoplasmic (RE) and is later cleaved by a signal peptidase. The nascent polypeptide is then N-glycosylated in the RE at 3 sites represented by white triangles. F2 and F1 are generated by furin-cleavage (black inverted triangles) and folded together as a trimer of heterodimer (3 times F2-F1). Furin is a calcium-dependent serine endoprotease that can

efficiently cleave precursor proteins at paired basic amino acid processing sites. Typically, such processing sites include a basic amino acid target sequence (canonically, Arg-X-(Arg/Lys) - Arg'). The RSV F protein includes two furin cleavage sites at positions 109 and 136. A description of furin processing of the RSV F protein, along with definitions of the art-accepted terminology is found in Zimmer *et al.* "Proteolytic activation of Respiratory Syncytial Virus fusion protein." *J. Biol. Chem.* 276:31642-31650, 2001, and Zimmer *et al.*, "Cleavage at the furin consensus sequence RAR/KR109 and presence of the intervening peptide of the Respiratory Syncytial Virus fusion protein are dispensable for virus replication in cell culture." *J. Virol.* 76:9218-9224, 2002. The protein is anchored to the membrane using its transmembrane helix shown by the white lozenge (TM) in the C-terminal region. In addition, the RSV F protein features 15 Cysteines residues, 4 characterized neutralizing epitopes, 2 coiled-coil regions and a lipidation motif.

[0113] FIG. 1B schematically represents an exemplary RSV G protein (298 amino acids). The G protein is anchored to the virion membrane by its transmembrane hydrophobic region (amino acids 41-63). Amino acids 65-298 includes the portion of the G protein that is exposed at the surface of RSV. At each extremities are located highly O-glycosylated mucin-like regions. Five N-glycosylation motifs are also present in these two regions. The non-glycosylated central includes several important structural motifs, including: 1) a cysteine noose (aa173-190), which is the only portion of the G for which structural data are available; 2) an immunodominant MHC class II epitope at aa183-203; and 3) chemokine fractalkine receptor (CXCR3) and glycosaminoglycan (GAG) binding motifs, which are implicated in the process of viral attachment on the host cell surface.

[0114] This disclosure concerns chimeric RSV antigens that include in a N-terminal to C-terminal direction: a first polypeptide component corresponding to a subsequence of an RSV F protein; a polypeptide component including an immunodominant epitope of an RSV G protein; and a second polypeptide component corresponding to a subsequence of an RSV F protein. An exemplary F2GF1 polypeptide is schematically represented in FIG. 1C.

[0115] It will be evident to those of skill in the art that any RSV F and/or G protein sequences can be employed in the construction of recombinant chimeric RSV F2GF1 polypeptides. In the exemplary embodiments disclosed herein, the Long strain has been selected as a model. The sequence of the F protein, which is responsible for fusion of the virus envelope with the target

cell membrane, is highly conserved among RSV isolates. In contrast, that of the G protein, which is responsible for virus attachment, is relatively variable. An alignment of RSV F and G protein sequences, illustrating identity and variation between the different proteins, are provided as FIGS. 4 and 5, respectively. Conserved and variable regions are readily apparent from these alignments.

[0116] In selecting F2 and F1 domains of the F protein, one of skill in the art will recognize that it is not strictly necessary to include the entire F2 and/or F1 domain. Typically, conformational considerations are of importance when selecting a subsequence (or fragment) of the F2 domain. Thus, the F2 domain typically includes a portion of the F2 domain that facilitates assembly and stability of the chimeric polypeptide. In certain exemplary variants, the F2 domain includes amino acids 24-107. Optionally, the F2 domain can include a signal peptide of the native F0 polypeptide (*e.g.*, amino acids 1-23). Similarly, the F2 domain can optionally include additional amino acids, such as the pep27 domain. For example, in certain exemplary variants, the F2 domain includes amino acids 24-130.

[0117] Typically, at least a subsequence (or fragment) of the F1 domain is selected and designed to maintain a stable conformation that includes immunodominant epitopes of the F protein. For example, it is generally desirable to select a subsequence of the F1 polypeptide domain that includes epitopes recognized by neutralizing antibodies in the regions of amino acids 262-275 (palivizumab neutralization) and 423-436 (Centocor's ch101F MAb). Additionally, desirable to include T cell epitopes, *e.g.*, in the region of amino acids 328-355. Most commonly, as a single contiguous portion of the F1 subunit (*e.g.*, spanning amino acids 262-436) but epitopes could be retained in a synthetic sequence that includes these immunodominant epitopes as discontinuous elements assembled in a stable conformation. Thus, an F1 domain polypeptide comprises at least about amino acids 262-436 of an RSV F protein polypeptide. In one non-limiting example provided herein, the F1 domain comprises amino acids 161 to 524 of a native F protein polypeptide. In another non-limiting example, the F1 domain includes amino acids 151-524 of a native F protein polypeptide. One of skill in the art will recognize that additional shorter subsequences can be used at the discretion of the practitioner.

[0118] Similarly, the G protein polypeptide component is selected to include at least a subsequence (or fragment) of the G protein that retains the immunodominant T cell epitope(s),

*e.g.*, in the region of amino acids 183-197. Exemplary variants disclosed herein include, for example subsequences or fragments of the G protein that include amino acids 151-229, 149-229, or 128-229 of a native G protein. One of skill in the art will readily appreciate that longer or shorter portions of the G protein can also be used, so long as the portion selected does not conformationally destabilize or disrupt expression, folding or processing of the F2GF1 chimera. Optionally, the G protein domain includes an amino acid substitution at position 191, which has previously been shown to be involved in reducing and/or preventing enhanced disease characterized by eosinophilia associated with formalin inactivated RSV vaccines. A thorough description of the attributes of naturally occurring and substituted (N191A) G proteins can be found, *e.g.*, in US Patent Publication No. 2005/0042230, which is incorporated herein by reference for all purposes.

[0119] If so desired, additional T cell epitopes can be identified using anchor motifs or other methods, such as neural net or polynomial determinations, known in the art, see, *e.g.*, RANKPEP (available on the world wide web at: [mif.dfci.harvard.edu/Tools/rankpep.html](http://mif.dfci.harvard.edu/Tools/rankpep.html)); ProPredI (available on the world wide web at: [imtech.res.in/raghava/propredI/index.html](http://imtech.res.in/raghava/propredI/index.html)); Bimas (available on the world wide web at: [www-bimas.dcrn.nih.gov/molbi/hla\\_bind/index.html](http://www-bimas.dcrn.nih.gov/molbi/hla_bind/index.html)); and SYFPEITH (available on the world wide web at: [syfpeithi.bmi-heidelberg.com/scripts/MHCServer.dll/home.htm](http://syfpeithi.bmi-heidelberg.com/scripts/MHCServer.dll/home.htm)). For example, algorithms are used to determine the “binding threshold” of peptides, and to select those with scores that give them a high probability of MHC or antibody binding at a certain affinity. The algorithms are based either on the effects on MHC binding of a particular amino acid at a particular position, the effects on antibody binding of a particular amino acid at a particular position, or the effects on binding of a particular substitution in a motif-containing peptide. Within the context of an immunogenic peptide, a “conserved residue” is one which appears in a significantly higher frequency than would be expected by random distribution at a particular position in a peptide. Anchor residues are conserved residues that provide a contact point with the MHC molecule. T cell epitopes identified by such predictive methods can be confirmed by measuring their binding to a specific MHC protein and by their ability to stimulate T cells when presented in the context of the MHC protein.

[0120] Eight exemplary prokaryotic variants were initially produced to demonstrate immunogenicity of chimeric F2GF1 polypeptide antigens. The following modifications were

incorporated to enhance expression of the chimeric polypeptide. The native signal peptide, as well as the hydrophobic fusion peptide, and the C-terminal region of the protein starting from the transmembrane alpha helical structure, were removed. Exemplary F2GF1 chimeric RSV antigens are represented by SEQ ID NOs:6, 8, 10, 12, 14, 16, 18 and 20, which are schematically illustrated in FIG. 2. As shown in FIG. 2, these variants represent combinations of different subsequences of the F2 and G domains, such that subsequences extending from amino acid 24 through either amino acid 107 or 130 are combined with subsequences of the G protein extending from amino acid 149 to 229 or 128-229. P3-1, P3-2, P3-3 and P3-4 (SEQ ID NOs:6, 8, 10 and 12, respectively) include a single amino acid substitution at the position corresponding to amino acid position 191 of the native G protein, whereas, P3-5, P3-6, P3-7 and P3-8 include a naturally occurring asparagines at position 191. Additional details are provided below in the examples section.

[0121] Additional exemplary variants include chimeric F2GF1 polypeptides that are modified to remove specific cysteines that can be involved in the formation of disulfide bridges. There are 2 such cysteines in the F2 domain, 4 in the G domain, and 12 in the F1 domain. Accordingly variants can be produced that eliminate 1 or more of these cysteines, for example, by substituting the amino acid serine in place of one or more cysteines, *e.g.*, at the positions corresponding to amino acids 40, 72, 291, 392, 401, 412, 422 and/or 518 of the P3-1 F2GF1 sequence.

Alternatively, rather than substituting a serine (or another amino acid) for cysteine, hydrophobic residues (such as leucine, isoleucine, or valine) can be substituted for or near to cysteines. For example, the following amino acid substitutions replace one or more amino acids in the vicinity of positions 40 and 401 with one or more hydrophobic residues: Y36L, T39I, C40G, S41V and L400S, C401I.

[0122] Other exemplary embodiments are variants that have a deletion of one or more amino acids. For example, variants can be produced that omit a portion of the coiled coil structure at amino acids 51-66. Because the coiled coil structure is driven by hydrophobic interaction, reduction in the size of this structure is predicted to increase solubility of the chimeric polypeptide. Alternatively, variants can include additional amino acids. For example, the variants can include additional amino acids, that facilitate purification, (*e.g.*, polyhistidine tags), or additional amino acids that increase stability, for example, stabilizing domains such as an isoleucine zipper domain.

[0123] In other examples, the polynucleotides that encode the F2GF1 chimeric RSV antigens are designed for and incorporated into expression vectors that are suitable for introduction and expression in eukaryotic (*e.g.*, insect, plant, or mammalian cells). Favorably, such nucleic acids are codon optimized for expression in the selected vector/host cell. Exemplary eukaryotic chimeric F2GF1 polypeptides can be produced with minor differences as compared to the prokaryotic constructs described above. These modifications have been introduced to enhance expression and stability of the chimeric polypeptides when produced in a eukaryotic expression system, where glycosylation and other post-translational processing of the polypeptide can occur. For example, eukaryotic constructs are typically designed to include a signal peptide corresponding to the expression system, for example, a mammalian or viral signal peptide, such as the RSV F0 native signal sequence is favorably selected when expressing the chimeric polypeptide in mammalian cells. Alternatively, a signal peptide (such as a baculovirus signal peptide, or the melittin signal peptide, can be substituted for expression, in insect cells. Suitable plant signal peptides are known in the art, if a plant expression system is preferred. If desired, one or both furin cleavage sites can be removed to eliminate processing by furin protease in eukaryotic cells. Additionally, in the exemplary embodiments described herein, the G and F1 boundaries are slightly different from the boundaries of the prokaryotic constructs, showing additional suitable variations in F2GF1 polypeptide antigens. For example, in specific examples, the G peptide domain includes amino acids 152-229, instead of aa149-229 for the prokaryotic versions, and the F1 domain includes amino acids 151-524, instead of 161-524 present in the prokaryotic versions. Thus, this exemplary eukaryotic chimeric F2GF1 polypeptide includes the following sequence. From the N-terminus, the chimeric polypeptide includes amino acids 1-109 of the F0 polypeptide. There is a glycine linker at amino acid 110, followed by amino acids 152-229 of the G protein (either from a naturally occurring G protein, or incorporating a substitution of alanine in the place of asparagines at position 191) at positions 111-188. Following the G protein domain at positions 189-562 are amino acids 151-524 of the F1 domain. Thus, in this variant, the native pep27, fusion peptide and one or both furin recognition motifs are replaced by the G protein domain. It will be understood that any of the additional modifications can also be introduced into a eukaryotic F2GF1 chimeric polypeptide.



NUCLEIC ACIDS THAT ENCODE CHIMERIC F2GF1 POLYPEPTIDE ANTIGENS

[0124] Another aspect of this disclosure concerns recombinant nucleic acids that encode the chimeric F2GF1 polypeptides described above. The recombinant nucleic acids include in a 5' to 3' direction, a first polynucleotide sequence that encodes at least a portion or fragment of an RSV F protein polypeptide furin cleavage domain 2 (F2 domain); a second polynucleotide sequence that encodes at least a portion or fragment of an RSV G protein polypeptide; and a third polynucleotide sequence that encodes at least a portion or fragment of an RSV F protein polypeptide furin cleavage domain 1 (F1 domain). The three component polynucleotide sequences are typically joined such that the encoded polypeptide segments are produced in a single contiguous chimeric polypeptide that includes in an N-terminal to C-terminal orientation: an F2 polypeptide component; a G protein component; and an F1 polypeptide component.

[0125] In certain embodiments, the recombinant nucleic acids are codon optimized for expression in a selected prokaryotic or eukaryotic host cell, such as a mammalian, plant or insect cell. To facilitate replication and expression, the nucleic acids can be incorporated into a vector, such as a prokaryotic or a eukaryotic expression vector. Although the nucleic acids disclosed herein can be included in any one of a variety of vectors (including, for example, bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, pseudorabies, adenovirus, adeno-associated virus, retroviruses and many others), most commonly the vector will be an expression vector suitable for generating polypeptide expression products. In an expression vector, the nucleic acid encoding the F2GF1 chimera is typically arranged in proximity and orientation to an appropriate transcription control sequence (promoter, and optionally, one or more enhancers) to direct mRNA synthesis. That is, the polynucleotide sequence of interest is operably linked to an appropriate transcription control sequence. Examples of such promoters include: the immediate early promoter of CMV, LTR or SV40 promoter, polyhedron promoter of baculovirus, *E. coli* lac or trp promoter, phage T7 and lambda P<sub>L</sub> promoter, and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector typically also contains a ribosome binding site for translation initiation, and a transcription terminator. The vector optionally includes appropriate sequences for amplifying expression. In addition, the expression vectors optionally comprise one or more selectable marker genes to provide a phenotypic trait for

selection of transformed host cells, such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in *E. coli*.

[0126] The expression vector can also include additional expression elements, for example, to improve the efficiency of translation. These signals can include, *e.g.*, an ATG initiation codon and adjacent sequences. In some cases, for example, a translation initiation codon and associated sequence elements are inserted into the appropriate expression vector simultaneously with the polynucleotide sequence of interest (*e.g.*, a native start codon). In such cases, additional translational control signals are not required. However, in cases where only a polypeptide coding sequence, or a portion thereof, is inserted, exogenous translational control signals, including an ATG initiation codon is provided for expression of the chimeric F2GF1 sequence. The initiation codon is placed in the correct reading frame to ensure translation of the polynucleotide sequence of interest. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. If desired, the efficiency of expression can be further increased by the inclusion of enhancers appropriate to the cell system in use (Scharf *et al.* (1994) Results Probl Cell Differ 20:125-62; Bitter *et al.* (1987) Methods in Enzymol 153:516-544).

[0127] Exemplary procedures sufficient to guide one of ordinary skill in the art through the production of recombinant F2GF1 nucleic acids can be found in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, 1989; Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 3d ed., Cold Spring Harbor Press, 2001; Ausubel *et al.*, *Current Protocols in Molecular Biology*, Greene Publishing Associates, 1992 (and Supplements to 2003); and Ausubel *et al.*, *Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology*, 4th ed., Wiley & Sons, 1999.

[0128] Exemplary nucleic acids that encode chimeric F2GF1 polypeptides are represented by SEQ ID NOs: 5, 7, 9, 11, 13, 15, 17, and 19. Additional variants of can be produced by assembling analogous F2, F1 and G protein polypeptide sequences selected from any of the known (or subsequently) discovered strains of RSV, *e.g.*, as shown in FIGS. 4 and 5. Additional sequence variants that share sequence identity with the exemplary variants can be produced by those of skill in the art. Typically, the nucleic acid variants will encode polypeptides that differ by no more than 1%, or 2%, or 5%, or 10%, or 15%, or 20% of the nucleotide or amino acid

residues. That is, the encoded polypeptides share at least 80%, or 85%, more commonly, at least about 90% or more, such as 95%, or even 98% or 99% sequence identity. It will be immediately understood by those of skill in the art, that the polynucleotide sequences encoding the F2GF1 polypeptides, can themselves share less sequence identity due to the redundancy of the genetic code.

[0129] It will be understood by those of skill in the art, that the similarity between chimeric F2GF1 polypeptide and polynucleotide sequences, as for polypeptide and nucleotide sequences in general, can be expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity); the higher the percentage, the more similar are the primary structures of the two sequences. In general, the more similar the primary structures of two amino acid (or polynucleotide) sequences, the more similar are the higher order structures resulting from folding and assembly. Variants of a chimeric F2GF1 polypeptide and polynucleotide sequences can have one or a small number of amino acid deletions, additions or substitutions but will nonetheless share a very high percentage of their amino acid, and generally their polynucleotide sequence.

[0130] Methods of determining sequence identity are well known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, *Adv. Appl. Math.* 2:482, 1981; Needleman and Wunsch, *J. Mol. Biol.* 48:443, 1970; Higgins and Sharp, *Gene* 73:237, 1988; Higgins and Sharp, *CABIOS* 5:151, 1989; Corpet *et al.*, *Nucleic Acids Research* 16:10881, 1988; and Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444, 1988. Altschul *et al.*, *Nature Genet.* 6:119, 1994, presents a detailed consideration of sequence alignment methods and homology calculations. The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul *et al.*, *J. Mol. Biol.* 215:403, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. A description of how to determine sequence identity using this program is available on the NCBI website on the internet.

[0131] Another indicia of sequence similarity between two nucleic acids is the ability to hybridize. The more similar are the sequences of the two nucleic acids, the more stringent the conditions at which they will hybridize. The stringency of hybridization conditions are

sequence-dependent and are different under different environmental parameters. Thus, hybridization conditions resulting in particular degrees of stringency will vary depending upon the nature of the hybridization method of choice and the composition and length of the hybridizing nucleic acid sequences. Generally, the temperature of hybridization and the ionic strength (especially the Na<sup>+</sup> and/or Mg<sup>++</sup> concentration) of the hybridization buffer will determine the stringency of hybridization, though wash times also influence stringency. Generally, stringent conditions are selected to be about 5°C to 20°C lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength and pH. The T<sub>m</sub> is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Conditions for nucleic acid hybridization and calculation of stringencies can be found, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001; Tijssen, *Hybridization With Nucleic Acid Probes, Part I: Theory and Nucleic Acid Preparation*, Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Ltd., NY, NY, 1993. and Ausubel *et al.* *Short Protocols in Molecular Biology*, 4<sup>th</sup> ed., John Wiley & Sons, Inc., 1999.

[0132] For purposes of the present disclosure, “stringent conditions” encompass conditions under which hybridization will only occur if there is less than 25% mismatch between the hybridization molecule and the target sequence. “Stringent conditions” can be broken down into particular levels of stringency for more precise definition. Thus, as used herein, “moderate stringency” conditions are those under which molecules with more than 25% sequence mismatch will not hybridize; conditions of “medium stringency” are those under which molecules with more than 15% mismatch will not hybridize, and conditions of “high stringency” are those under which sequences with more than 10% mismatch will not hybridize. Conditions of “very high stringency” are those under which sequences with more than 6% mismatch will not hybridize. In contrast nucleic acids that hybridize under “low stringency conditions include those with much less sequence identity, or with sequence identity over only short subsequences of the nucleic acid. It will, therefore, be understood that the various variants of nucleic acids that are encompassed by this disclosure are able to hybridize to at least one of SEQ ID NOs: 5, 7, 9, 11, 13, 15, 17, 19, 67 or 69, over substantially their entire length.

## METHODS OF PRODUCING CHIMERIC RSV ANTIGENIC POLYPEPTIDES

[0133] The F2GF1 chimeric RSV polypeptides disclosed herein are produced using well established procedures for the expression and purification of recombinant proteins. Procedures sufficient to guide one of skill in the art can be found in, for example, Sambrook and the Ausubel references cited above. Additional and specific details are provided hereinbelow.

[0134] Recombinant nucleic acids that encode the F2GF1 chimeric RSV antigens, such as (but not limited to) the exemplary nucleic acids represented by SEQ ID NOs:5, 7, 9, 11, 13, 15, 17, 19, 67 and/or 69, are introduced into host cells by any of a variety of well-known procedures, such as electroporation, liposome mediated transfection, Calcium phosphate precipitation, infection, transfection and the like, depending on the selection of vectors and host cells.

[0135] Host cells that include recombinant F2GF1 chimeric RSV antigen-encoding nucleic acids are, thus, also a feature of this disclosure. Favorable host cells include prokaryotic (*i.e.*, bacterial) host cells, such as *E. coli*, as well as numerous eukaryotic host cells, including fungal (*e.g.*, yeast, such as *Saccharomyces cerevisiae* and *Pichia pastoris*) cells, insect cells, plant cells, and mammalian cells (such as CHO cells). Recombinant F2GF1 nucleic acids are introduced (*e.g.*, transduced, transformed or transfected) into host cells, for example, via a vector, such as an expression vector. As described above, the vector is most typically a plasmid, but such vectors can also be, for example, a viral particle, a phage, etc. Examples of appropriate expression hosts include: bacterial cells, such as *E. coli*, *Streptomyces*, and *Salmonella typhimurium*; fungal cells, such as *Saccharomyces cerevisiae*, *Pichia pastoris*, and *Neurospora crassa*; insect cells such as *Drosophila* and *Spodoptera frugiperda*; mammalian cells such as 3T3, COS, CHO, BHK, HEK 293 or Bowes melanoma; plant cells, including algae cells, etc.

[0136] The host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants, or amplifying the inserted polynucleotide sequences. The culture conditions, such as temperature, pH and the like, are typically those previously used with the host cell selected for expression, and will be apparent to those skilled in the art and in the references cited herein, including, *e.g.*, Freshney (1994) Culture of Animal Cells, a Manual of Basic Technique, third edition, Wiley- Liss, New York and the references cited therein. Expression products corresponding to the nucleic acids of the invention can also be produced in non-animal cells such as plants, yeast, fungi, bacteria and the like. In addition to Sambrook, Berger and Ausubel, details regarding cell culture can be found in Payne *et al.* (1992)

Plant Cell and Tissue Culture in Liquid Systems John Wiley & Sons, Inc. New York, NY; Gamborg and Phillips (eds) (1995) Plant Cell, Tissue and Organ Culture; Fundamental Methods Springer Lab Manual, Springer-Verlag (Berlin Heidelberg New York) and Atlas and Parks (eds) The Handbook of Microbiological Media (1993) CRC Press, Boca Raton, FL.

[0137] In bacterial systems, a number of expression vectors can be selected depending upon the use intended for the expressed product. For example, when large quantities of a polypeptide or fragments thereof are needed for the production of antibodies, vectors which direct high level expression of fusion proteins that are readily purified are favorably employed. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the coding sequence of interest, *e.g.*, a polynucleotide of the invention as described above, can be ligated into the vector in-frame with sequences for the amino-terminal translation initiating Methionine and the subsequent 7 residues of beta-galactosidase producing a catalytically active beta galactosidase fusion protein; pIN vectors (Van Heeke & Schuster (1989) J Biol Chem 264:5503-5509); pET vectors (Novagen, Madison WI), in which the amino-terminal methionine is ligated in frame with a histidine tag; and the like.

[0138] Similarly, in yeast, such as *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH can be used for production of the desired expression products. For reviews, *see* Berger, Ausubel, and, *e.g.*, Grant *et al.* (1987; Methods in Enzymology 153:516-544). In mammalian host cells, a number expression systems, including both plasmis and viral-based systems, can be utilized.

[0139] A host cell is optionally chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the protein include, but are not limited to, glycosylation, (as well as, *e.g.*, acetylation, carboxylation, phosphorylation, lipidation and acylation). Post-translational processing for example, which cleaves a precursor form into a mature form of the protein (for example, by a furin protease) is optionally performed in the context of the host cell. Different host cells such as 3T3, COS, CHO, HeLa, BHK, MDCK, 293, WI38, etc. have specific cellular machinery and characteristic mechanisms for such post-translational activities and can be chosen to ensure the correct modification and processing of the introduced, foreign protein.

[0140] For long-term, high-yield production of recombinant chimeric F2GF1 polypeptide encoded by the nucleic acids disclosed herein, stable expression systems are typically used. For

example, cell lines which stably express a chimeric F2GF1 polypeptide are introduced into the host cell using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells are allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. For example, resistant groups or colonies of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. Host cells transformed with a nucleic acid encoding a chimeric F2GF1 polypeptide are optionally cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture.

[0141] Following transduction of a suitable host cell line and growth of the host cells to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. The secreted polypeptide product is then recovered from the culture medium. Alternatively, cells can be harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Eukaryotic or microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, or other methods, which are well known to those skilled in the art.

[0142] Expressed chimeric F2GF1 polypeptides can be recovered and purified from recombinant cell cultures by any of a number of methods well known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography (e.g., using any of the tagging systems noted herein), hydroxylapatite chromatography, and lectin chromatography. Protein refolding steps can be used, as desired, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed in the final purification steps. In addition to the references noted above, a variety of purification methods are well known in the art, including, e.g., those set forth in Sandana (1997) Bioseparation of Proteins, Academic Press, Inc.; and Bollag *et al.* (1996) Protein Methods, 2<sup>nd</sup> Edition Wiley-Liss, NY; Walker (1996) The Protein Protocols Handbook Humana Press, NJ, Harris and Angal (1990) Protein Purification

Applications: A Practical Approach IRL Press at Oxford, Oxford, U.K.; Scopes (1993) Protein Purification: Principles and Practice 3<sup>rd</sup> Edition Springer Verlag, NY; Janson and Ryden (1998) Protein Purification: Principles, High Resolution Methods and Applications, Second Edition Wiley-VCH, NY; and Walker (1998) Protein Protocols on CD-ROM Humana Press, NJ.

[0143] In certain examples, the nucleic acids are introduced into vectors suitable for introduction and expression in prokaryotic cells, *e.g.*, *E. coli* cells. For example, a nucleic acid including a polynucleotide sequence that encodes a F2GF1 chimeric RSV antigen can be introduced into any of a variety of commercially available or proprietary vectors, such as the pET series of expression vectors (*e.g.*, pET19b and pET21d). Expression of the coding sequence is inducible by IPTG, resulting in high levels of protein expression. The polynucleotide sequence encoding the chimeric RSV antigen is transcribed under the phage T7 promoter. Alternate vectors, such as pURV22 that include a heat-inducible lambda pL promoter are also suitable.

[0144] The expression vector is introduced (*e.g.*, by electroporation) into a suitable bacterial host. Numerous suitable strains of *E. coli* are available and can be selected by one of skill in the art (for example, the Rosetta and BL21 (DE3) strains have proven favorable for expression of recombinant vectors containing polynucleotide sequences that encode F2GF1 chimeric RSV antigens.

[0145] In another example, the polynucleotides that encode the chimeric RSV antigens are cloned into a vector suitable for introduction into mammalian cells (*e.g.*, CHO cells). In this exemplary embodiment, the polynucleotide sequence that encodes the chimeric RSV antigen is introduced into the the pEE14 vector developed by Lonza Biologicals firm. The chimeric polypeptide is expressed under a constitutive promoter, the immediate early CMV (CytoMegalovirus) promoter. Selection of the stably transfected cells expressing the chimera is made based on the ability of the transfected cells to grow in the absence of a glutamine source. Cells that have successfully integrated the pEE14 are able to grow in the absence of exogenous glutamine, because the pEE14 vector expresses the GS (Glutamine Synthetase) enzyme. Selected cells can be clonally expanded and characterized for expression of the chimeric polypeptide.

[0146] In another example, the polynucleotide sequence that encodes the F2GF1 chimeric RSV antigen is introduced into insect cells using a Baculovirus Expression Vector System (BEVS). Recombinant baculovirus capable of infecting insect cells can be generated using commercially



available vectors, kits and/or systems, such as the BD BaculoGold system from BD BioScience. Briefly, the polynucleotide sequence encoding a F2GF1 chimeric RSV antigen is inserted into the pAcSG2 transfer vector. Then, host cells SF9 (*Spodoptera frugiperda*) are co-transfected by pAcSG2-chimer plasmid and BD BaculoGold, containing the linearized genomic DNA of the baculovirus *Autographa californica nuclear polyhedrosis virus* (AcNPV). Following transfection, homologous recombination occurs between the pACSG2 plasmid and the Baculovirus genome to generate the recombinant virus. In one example, the chimeric RSV antigen is expressed under the regulatory control of the polyhedrin promoter (pH). Similar transfer vectors can be produced using other promoters, such as the basic (Ba) and p10 promoters. Similarly, alternative insect cells can be employed, such as SF21 which is closely related to the SF9, and the High Five (Hi5) cell line derived from a cabbage looper, *Trichoplusia ni*.

[0147] Following transfection and induction of expression (according to the selected promoter and/or enhancers or other regulatory elements), the expressed chimeric polypeptides are recovered (*e.g.*, purified or enriched) and renatured to ensure folding into an antigenically active conformation. The following is an exemplary procedure for enrichment and renaturation of RSV F2GF1 chimeric antigens.

[0148] In an exemplary procedure for production from prokaryotic cells, RSV F2GF1 chimeric antigens are produced in bacterial (*e.g.*, *E. coli*) cells. To facilitate purification, the F2GF1 chimeric antigens include a C-terminal or N-terminal his tag. In brief, the *E. coli* cell pellet is resuspended in lysis buffer and the cells are disrupted by sonication, French press, microfluidizer and/or emulsifier. The cell lysate is centrifuged between 10000 and 20000 x g for 20 min at 4 °C and supernatant is discarded. The inclusion body (IB) pellet is resuspended in wash buffer and agitated at room temperature for at least 1 hour with 225 RPM agitation. The washed lysate is centrifuged between 10000 and 20000 x g for 20 min at 4 °C and supernatant is discarded. Washed inclusion bodies are resuspended in solubilisation buffer (20 ml/g of IB) and incubated at room temperature for 4 hours with 225 RPM agitation. This mixture is then centrifuged at 20000 x g for 20 min at 4 °C and pellet is discarded.

[0149] Solubilized inclusion bodies are loaded on an IMAC resin (Immobilized Metal Affinity Chromatography) previously equilibrated in IMAC loading buffer. The chimeric protein is then eluted from the column in IMAC eluting buffer. F2GF1 containing fractions are pooled, and the

pooled fractions are concentrated on an ultrafiltration membrane for a size exclusion chromatography step. The concentrated IMAC pool is loaded on a size exclusion chromatography column equilibrated with SEC buffer, and the chimeric protein is eluted in the same buffer. Eluted fractions containing F2GF1 protein are again pooled, then quantified by absorbance at 280nm, aliquoted and frozen at -20°C until renaturation.

[0150] The following is an exemplary procedure for the renaturation of RSV F2GF1 chimeric antigens. F2GF1 protein concentration is brought to 1 mg/ml by dilution in SEC buffer. The protein is diafiltered in pre-refolding buffer to decrease lauroylsarcosine concentration up to 0.1% using tangential flow filtration (TFF). Protein at 1 mg/ml in pre-refolding buffer is rapidly diluted 10 times in pre-chilled refolding buffer, and the resulting mixture is stirred for 30 minutes at 4 °C, then incubated without stirring overnight at 4 °C.

[0151] During the subsequent renaturation process the chimeric protein is maintained at 4 °C until use or freezing. After the overnight incubation, the mixture is concentrated 10X by TFF. Resulting retentate volume is diafiltered with the same TFF cartridge with 5-10 volumes of 1M arginine refolding buffer, keeping the volume constant. The resulting retentate is then diafiltered with 5-10 volumes of final 300mM arginine refolding buffer, again maintaining a constant volume. The retentate is then centrifuged at 20000 x g for 20 min at 4 °C, and the supernatant is harvested. Protein concentration is determined using the RCDC assay from BioRad (modified Lowry colorimetric assay). Renatured F2GF1 is aliquoted and stored at -20 °C for in vitro and/or in vivo use.

[0152] Table 1 provides a description of the buffers used during the purification and renaturation process.

[0153] Alternative excipients for renaturation, which are also suitable for inclusion in immunogenic compositions for administration to animal (*e.g.*, human) subjects are further described below.

Table 1: Buffer compositions.

<b>Lysis buffer</b> 50 mM Tris 20 mM TCEP 20 mM EDTA pH 8.0	<b>Wash buffer</b> 50 mM Tris 10-20 mM TCEP 5mM EDTA 2% Triton X-100 pH 8.0	<b>Solubilisation buffer</b> 50 mM Tris 5%-30% lauroylsarcosine 5% glycerol 5-20 mM TCEP 0.5 mM EDTA pH 8.0
<b>IMAC loading buffer</b> 50 mM Tris 2% lauroylsarcosine 5% glycerol 5 -20 mM TCEP pH 8.5	<b>IMAC eluting buffer</b> 50 mM Tris 2% lauroylsarcosine 5% glycerol 5-20 mM TCEP 500 mM imidazole pH 8.5	<b>SEC buffer</b> 50 mM Tris 2% lauroylsarcosine 5% glycerol 5-20 mM TCEP pH 8.5
<b>Pre-refolding buffer</b> 10 mM Tris 0.05 mM EDTA 1 mM TCEP 0.06%-0.1% lauroylsarcosine pH 8.5		<b>Refolding buffer</b> 50mM Tris 250-500 mM NaCl 270-1000 mM sucrose 1mM EDTA 500-1000 mM L-arginine 3.8-10 mM reduced glutathione (GSH) 1.2-10 mM oxidized glutathione (GSSG) pH 8.5
<b>1M arginine refolding buffer</b> 50 mM Tris 250-500 mM NaCl 270-1000 mM sucrose 1mM EDTA 1M L-arginine 3.8-10 mM reduced glutathione (GSH) 1.2-10 mM oxidized glutathione (GSSG) pH 8.5		<b>300 mM arginine refolding buffer</b> 50 mM Tris 250 mM NaCl 270-1000 mM sucrose 1mM EDTA 100-300 mM L-arginine 3.8-10 mM reduced glutathione (GSH) 1.2-10 mM oxidized glutathione (GSSG) pH 8.5

### IMMUNOGENIC COMPOSITIONS AND METHODS

[0154] Also provided are immunogenic compositions including a chimeric RSV F2GF1 antigen and a pharmaceutically acceptable diluent, carrier or excipient. Numerous pharmaceutically acceptable diluents and carriers and/or pharmaceutically acceptable excipients are known in the art and are described, *e.g.*, in *Remington's Pharmaceutical Sciences*, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975).

[0155] In general, the nature of the diluent, carrier and/or excipient will depend on the particular mode of administration being employed. For instance, parenteral formulations usually include injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. In certain formulations (for example, solid compositions, such as powder forms), a liquid diluent is not employed. In such formulations, non-toxic solid carriers can be used,

including for example, pharmaceutical grades of trehalose, mannitol, lactose, starch or magnesium stearate.

[0156] Accordingly, suitable excipients and carriers can be selected by those of skill in the art to produce a formulation suitable for delivery to a subject by a selected route of administration.

[0157] Particular examples are given above in Table 1. Additional excipients include, without limitation: glycerol, polyethylene glycol (PEG), glass forming polyols (such as, sorbitol, trehalose) N-lauroylsarcosine (*e.g.*, sodium salt), L-proline, non detergent sulfobetaine, guanidine hydrochloride, urea, trimethylamine oxide, KCl, Ca<sup>2+</sup>, Mg<sup>2+</sup>, Mn<sup>2+</sup>, Zn<sup>2+</sup> (and other divalent cation related salts), dithiothreitol (DTT), dithioerytrol, β-mercaptoethanol, Detergents (including, *e.g.*, Tween80, Tween20, Triton X-100, NP-40, Empigen BB, Octylglucoside, Lauroyl maltoside, Zwittergent 3-08, Zwittergent 3-10, Zwittergent 3-12, Zwittergent 3-14, Zwittergent 3-16, CHAPS, sodium deoxycholate, sodium dodecyl sulphate, and cetyltrimethylammonium bromide.

[0158] In certain favorable examples, the immunogenic composition also includes an adjuvant. Suitable adjuvants for use in immunogenic compositions containing chimeric F2GF1 polypeptides are adjuvants that in combination with the F2GF1 antigens disclosed herein are safe and minimally reactogenic when administered to a subject.

[0159] One suitable adjuvant for use in combination with F2GF1 chimeric antigens is a non-toxic bacterial lipopolysaccharide derivative. An example of a suitable non-toxic derivative of lipid A, is monophosphoryl lipid A or more particularly 3-Deacylated monophosphoryl lipid A (3D-MPL). 3D-MPL is sold under the name MPL by GlaxoSmithKline Biologicals N.A., and is referred throughout the document as MPL or 3D-MPL. See, for example, US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094. 3D-MPL primarily promotes CD4<sup>+</sup> T cell responses with an IFN-γ (Th1) phenotype. 3D-MPL can be produced according to the methods disclosed in GB2220211 A. Chemically it is a mixture of 3-deacylated monophosphoryl lipid A with 3, 4, 5 or 6 acylated chains. In the compositions of the present invention small particle 3D-MPL can be used. Small particle 3D-MPL has a particle size such that it can be sterile-filtered through a 0.22μm filter. Such preparations are described in WO94/21292.

[0160] Said lipopolysaccharide, such as 3D-MPL, can be used at amounts between 1 and 50μg, per human dose of the immunogenic composition. Such 3D-MPL can be used at a level of about

25 $\mu$ g, for example between 20-30 $\mu$ g, suitably between 21-29 $\mu$ g or between 22 and 28 $\mu$ g or between 23 and 27 $\mu$ g or between 24 and 26 $\mu$ g, or 25 $\mu$ g. In another embodiment, the human dose of the immunogenic composition comprises 3D-MPL at a level of about 10 $\mu$ g, for example between 5 and 15 $\mu$ g, suitably between 6 and 14 $\mu$ g, for example between 7 and 13 $\mu$ g or between 8 and 12 $\mu$ g or between 9 and 11 $\mu$ g, or 10 $\mu$ g. In a further embodiment, the human dose of the immunogenic composition comprises 3D-MPL at a level of about 5 $\mu$ g, for example between 1 and 9 $\mu$ g, or between 2 and 8 $\mu$ g or suitably between 3 and 7 $\mu$ g or 4 and  $\mu$ g, or 5 $\mu$ g.

[0161] In other embodiments, the lipopolysaccharide can be a  $\beta$ (1-6) glucosamine disaccharide, as described in US Patent No. 6,005,099 and EP Patent No. 0 729 473 B1. One of skill in the art would be readily able to produce various lipopolysaccharides, such as 3D-MPL, based on the teachings of these references. Nonetheless, each of these references is incorporated herein by reference. In addition to the aforementioned immunostimulants (that are similar in structure to that of LPS or MPL or 3D-MPL), acylated monosaccharide and disaccharide derivatives that are a sub-portion to the above structure of MPL are also suitable adjuvants. In other embodiments, the adjuvant is a synthetic derivative of lipid A, some of which are described as TLR-4 agonists, and include, but are not limited to:

[0162] OM174 (2-deoxy-6-o-[2-deoxy-2-[(R)-3-dodecanoyloxytetradecanoylamino]-4-o-phosphono- $\beta$ -D-glucopyranosyl]-2-[(R)-3-hydroxytetradecanoylamino]- $\alpha$ -D-glucopyranosyldihydrogenphosphate), (WO 95/14026)

[0163] OM 294 DP (3S, 9 R) -3-[(R)-dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9(R)-[(R)-3-hydroxytetradecanoylamino]decan-1,10-diol,1,10-bis(dihydrogenophosphate) (WO 99/64301 and WO 00/0462 )

[0164] OM 197 MP-Ac DP ( 3S-, 9R) -3-[(R) -dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9-[(R)-3-hydroxytetradecanoylamino]decan-1,10-diol,1 -dihydrogenophosphate 10-(6-aminohexanoate) (WO 01/46127)

[0165] Other TLR4 ligands which can be used are alkyl Glucosaminide phosphates (AGPs) such as those disclosed in WO 98/50399 or US Patent No. 6,303,347 (processes for preparation of AGPs are also disclosed), suitably RC527 or RC529 or pharmaceutically acceptable salts of AGPs as disclosed in US Patent No. 6,764,840. Some AGPs are TLR4 agonists, and some are TLR4 antagonists. Both are thought to be useful as adjuvants.

[0166] Other suitable TLR-4 ligands, capable of causing a signaling response through TLR-4 (Sabroe et al, JI 2003 p1630-5) are, for example, lipopolysaccharide from gram-negative bacteria and its derivatives, or fragments thereof, in particular a non-toxic derivative of LPS (such as 3D-MPL). Other suitable TLR agonists are: heat shock protein (HSP) 10, 60, 65, 70, 75 or 90; surfactant Protein A, hyaluronan oligosaccharides, heparan sulphate fragments, fibronectin fragments, fibrinogen peptides and b-defensin-2, and muramyl dipeptide (MDP). In one embodiment the TLR agonist is HSP 60, 70 or 90. Other suitable TLR-4 ligands are as described in WO 2003/011223 and in WO 2003/099195, such as compound I, compound II and compound III disclosed on pages 4-5 of WO2003/011223 or on pages 3-4 of WO2003/099195 and in particular those compounds disclosed in WO2003/011223 as ER803022, ER803058, ER803732, ER804053, ER804057, ER804058, ER804059, ER804442, ER804680, and ER804764. For example, one suitable TLR-4 ligand is ER804057.

[0167] Additional TLR agonists are also useful as adjuvants. The term "TLR agonist" refers to an agent that is capable of causing a signaling response through a TLR signaling pathway, either as a direct ligand or indirectly through generation of endogenous or exogenous ligand. Such natural or synthetic TLR agonists can be used as alternative or additional adjuvants. A brief review of the role of TLRs as adjuvant receptors is provided in Kaisho & Akira, *Biochimica et Biophysica Acta* 1589:1-13, 2002. These potential adjuvants include, but are not limited to agonists for TLR2, TLR3, TLR7, TLR8 and TLR9. Accordingly, in one embodiment, the adjuvant and immunogenic composition further comprises an adjuvant which is selected from the group consisting of: a TLR-1 agonist, a TLR-2 agonist, TLR-3 agonist, a TLR-4 agonist, TLR-5 agonist, a TLR-6 agonist, TLR-7 agonist, a TLR-8 agonist, TLR-9 agonist, or a combination thereof.

[0168] In one embodiment of the present invention, a TLR agonist is used that is capable of causing a signaling response through TLR-1. Suitably, the TLR agonist capable of causing a signaling response through TLR-1 is selected from: Tri-acylated lipopeptides (LPs); phenol-soluble modulin; Mycobacterium tuberculosis LP; S-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys(4)-OH, trihydrochloride (Pam3Cys) LP which mimics the acetylated amino terminus of a bacterial lipoprotein and OspA LP from *Borrelia burgdorferi*.

[0169] In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-2. Suitably, the TLR agonist capable of causing a signaling response

through TLR-2 is one or more of a lipoprotein, a peptidoglycan, a bacterial lipopeptide from *M tuberculosis*, *B burgdorferi* or *T pallidum*; peptidoglycans from species including *Staphylococcus aureus*; lipoteichoic acids, mannuronic acids, Neisseria porins, bacterial fimbriae, Yersina virulence factors, CMV virions, measles haemagglutinin, and zymosan from yeast.

[0170] In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-3. Suitably, the TLR agonist capable of causing a signaling response through TLR-3 is double stranded RNA (dsRNA), or polyinosinic-polycytidylic acid (Poly IC), a molecular nucleic acid pattern associated with viral infection.

[0171] In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-5. Suitably, the TLR agonist capable of causing a signaling response through TLR-5 is bacterial flagellin.

[0172] In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-6. Suitably, the TLR agonist capable of causing a signaling response through TLR-6 is mycobacterial lipoprotein, di-acylated LP, and phenol-soluble modulin. Additional TLR6 agonists are described in WO 2003/043572.

[0173] In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-7. Suitably, the TLR agonist capable of causing a signaling response through TLR-7 is a single stranded RNA (ssRNA), loxoribine, a guanosine analogue at positions N7 and C8, or an imidazoquinoline compound, or derivative thereof. In one embodiment, the TLR agonist is imiquimod. Further TLR7 agonists are described in WO 2002/085905.

[0174] In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-8. Suitably, the TLR agonist capable of causing a signaling response through TLR-8 is a single stranded RNA (ssRNA), an imidazoquinoline molecule with anti-viral activity, for example resiquimod (R848); resiquimod is also capable of recognition by TLR-7. Other TLR-8 agonists which can be used include those described in WO 2004/071459.

[0175] In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-9. In one embodiment, the TLR agonist capable of causing a signaling response through TLR-9 is HSP90. Alternatively, the TLR agonist capable of causing a signaling response through TLR-9 is bacterial or viral DNA, DNA containing unmethylated CpG

nucleotides, in particular sequence contexts known as CpG motifs. CpG-containing oligonucleotides induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Suitably, CpG nucleotides are CpG oligonucleotides. Suitable oligonucleotides for use in the immunogenic compositions of the present invention are CpG containing oligonucleotides, optionally containing two or more dinucleotide CpG motifs separated by at least three, suitably at least six or more nucleotides. A CpG motif is a Cytosine nucleotide followed by a Guanine nucleotide. The CpG oligonucleotides of the present invention are typically deoxynucleotides. In a specific embodiment the internucleotide in the oligonucleotide is phosphorodithioate, or suitably a phosphorothioate bond, although phosphodiester and other internucleotide bonds are within the scope of the invention. Also included within the scope of the invention are oligonucleotides with mixed internucleotide linkages. Methods for producing phosphorothioate oligonucleotides or phosphorodithioate are described in US Patent Nos. 5,666,153, 5,278,302 and WO 95/26204.

[0176] Other adjuvants that can be used in immunogenic compositions with a chimeric F2GF1 polypeptide, *e.g.*, on their own or in combination with 3D-MPL, or another adjuvant described herein, are saponins, such as QS21.

[0177] Saponins are taught in: Lacaille-Dubois, M and Wagner H. (1996. A review of the biological and pharmacological activities of saponins. *Phytomedicine* vol 2 pp 363-386). Saponins are steroid or triterpene glycosides widely distributed in the plant and marine animal kingdoms. Saponins are noted for forming colloidal solutions in water which foam on shaking, and for precipitating cholesterol. When saponins are near cell membranes they create pore-like structures in the membrane which cause the membrane to burst. Haemolysis of erythrocytes is an example of this phenomenon, which is a property of certain, but not all, saponins.

[0178] Saponins are known as adjuvants in vaccines for systemic administration. The adjuvant and haemolytic activity of individual saponins has been extensively studied in the art (Lacaille-Dubois and Wagner, *supra*). For example, Quil A (derived from the bark of the South American tree *Quillaja Saponaria* Molina), and fractions thereof, are described in US 5,057,540 and "Saponins as vaccine adjuvants", Kensil, C. R., *Crit Rev Ther Drug Carrier Syst*, 1996, 12 (1-2):1-55; and EP 0 362 279 B1. Particulate structures, termed Immune Stimulating Complexes (ISCOMS), comprising fractions of Quil A are haemolytic and have been used in the



manufacture of vaccines (Morein, B., EP 0 109 942 B1; WO 96/11711; WO 96/33739). The haemolytic saponins QS21 and QS17 (HPLC purified fractions of Quil A) have been described as potent systemic adjuvants, and the method of their production is disclosed in US Patent No.5,057,540 and EP 0 362 279 B1, which are incorporated herein by reference. Other saponins which have been used in systemic vaccination studies include those derived from other plant species such as Gypsophila and Saponaria (Bomford *et al.*, Vaccine, 10(9):572-577, 1992). QS21 is an Hplc purified non-toxic fraction derived from the bark of Quillaja Saponaria Molina. A method for producing QS21 is disclosed in US Patent No. 5,057,540. Non-reactogenic adjuvant formulations containing QS21 are described in WO 96/33739. The aforementioned references are incorporated by reference herein. Said immunologically active saponin, such as QS21, can be used in amounts of between 1 and 50 $\mu$ g, per human dose of the immunogenic composition. Advantageously QS21 is used at a level of about 25 $\mu$ g, for example between 20–30 $\mu$ g, suitably between 21–29 $\mu$ g or between 22 -28 $\mu$ g or between 23 -27 $\mu$ g or between 24 -26 $\mu$ g, or 25 $\mu$ g. In another embodiment, the human dose of the immunogenic composition comprises QS21 at a level of about 10 $\mu$ g, for example between 5 and 15 $\mu$ g, suitably between 6 -14 $\mu$ g, for example between 7 -13 $\mu$ g or between 8 -12 $\mu$ g or between 9 -11 $\mu$ g, or 10 $\mu$ g. In a further embodiment, the human dose of the immunogenic composition comprises QS21 at a level of about 5 $\mu$ g, for example between 1-9 $\mu$ g, or between 2 -8 $\mu$ g or suitably between 3-7 $\mu$ g or 4 -6 $\mu$ g, or 5 $\mu$ g. Such formulations comprising QS21 and cholesterol have been shown to be successful Th1 stimulating adjuvants when formulated together with an antigen. Thus, for example, chimeric F2GF1 polypeptides can favorably be employed in immunogenic compositions with an adjuvant comprising a combination of QS21 and cholesterol.

[0179] Optionally, the adjuvant can also include mineral salts such as an aluminium or calcium salts, in particular aluminium hydroxide, aluminium phosphate and calcium phosphate. For example, an adjuvant containing 3D-MPL in combination with an aluminium salt (*e.g.*, aluminium hydroxide or “alum”) is suitable for formulation in an immunogenic composition containing a chimeric F2GF1 polypeptide for administration to a human subject.

[0180] Another class of suitable Th1 biasing adjuvants for use in formulations with chimeric F2GF1 polypeptides include OMP-based immunostimulatory compositions. OMP-based immunostimulatory compositions are particularly suitable as mucosal adjuvants, *e.g.*, for intranasal administration. OMP-based immunostimulatory compositions are a genus of

preparations of outer membrane proteins (OMPs, including some porins) from Gram-negative bacteria, such as, but not limited to, *Neisseria* species (see, *e.g.*, Lowell *et al.*, J. Exp. Med. 167:658, 1988; Lowell *et al.*, Science 240:800, 1988; Lynch *et al.*, Biophys. J. 45:104, 1984; Lowell, in "New Generation Vaccines" 2nd ed., Marcel Dekker, Inc., New York, Basil, Hong Kong, page 193, 1997; U.S. Pat. No. 5,726,292; U.S. Pat. No. 4,707,543), which are useful as a carrier or in compositions for immunogens, such as bacterial or viral antigens. Some OMP-based immunostimulatory compositions can be referred to as "Proteosomes," which are hydrophobic and safe for human use. Proteosomes have the capability to auto-assemble into vesicle or vesicle-like OMP clusters of about 20 nm to about 800 nm, and to noncovalently incorporate, coordinate, associate (*e.g.*, electrostatically or hydrophobically), or otherwise cooperate with protein antigens (Ags), particularly antigens that have a hydrophobic moiety. Any preparation method that results in the outer membrane protein component in vesicular or vesicle-like form, including multi-molecular membranous structures or molten globular-like OMP compositions of one or more OMPs, is included within the definition of Proteosome. Proteosomes can be prepared, for example, as described in the art (see, *e.g.*, U.S. Pat. No. 5,726,292 or U.S. Pat. No. 5,985,284). Proteosomes can also contain an endogenous lipopolysaccharide or lipooligosaccharide (LPS or LOS, respectively) originating from the bacteria used to produce the OMP porins (*e.g.*, *Neisseria* species), which generally will be less than 2% of the total OMP preparation.

[0181] Proteosomes are composed primarily of chemically extracted outer membrane proteins (OMPs) from *Neisseria meningitidis* (mostly porins A and B as well as class 4 OMP), maintained in solution by detergent (Lowell GH. Proteosomes for Improved Nasal, Oral, or Injectable Vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds, New Generation Vaccines. New York: Marcel Dekker, Inc. 1997; 193-206). Proteosomes can be formulated with a variety of antigens such as purified or recombinant proteins derived from viral sources, including the chimeric F2GF1 polypeptides disclosed herein, *e.g.*, by diafiltration or traditional dialysis processes. The gradual removal of detergent allows the formation of particulate hydrophobic complexes of approximately 100-200nm in diameter (Lowell GH. Proteosomes for Improved Nasal, Oral, or Injectable Vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds, New Generation Vaccines. New York: Marcel Dekker, Inc. 1997; 193-206).

[0182] "Proteosome: LPS or Protollin" as used herein refers to preparations of proteosomes admixed, *e.g.*, by the exogenous addition, with at least one kind of lipo-polysaccharide to provide an OMP-LPS composition (which can function as an immunostimulatory composition). Thus, the OMP-LPS composition can be comprised of two of the basic components of Protollin, which include (1) an outer membrane protein preparation of Proteosomes (*e.g.*, Projuvant) prepared from Gram-negative bacteria, such as *Neisseria meningitidis*, and (2) a preparation of one or more liposaccharides. A lipo-oligosaccharide can be endogenous (*e.g.*, naturally contained with the OMP Proteosome preparation), can be admixed or combined with an OMP preparation from an exogenously prepared lipo-oligosaccharide (*e.g.*, prepared from a different culture or microorganism than the OMP preparation), or can be a combination thereof. Such exogenously added LPS can be from the same Gram-negative bacterium from which the OMP preparation was made or from a different Gram-negative bacterium. Protollin should also be understood to optionally include lipids, glycolipids, glycoproteins, small molecules, or the like, and combinations thereof. The Protollin can be prepared, for example, as described in U.S. Patent Application Publication No. 2003/0044425.

[0183] Combinations of different adjuvants, such as those mentioned hereinabove, can also be used in compositions with chimeric F2GF1 polypeptides. For example, as already noted, QS21 can be formulated together with 3D-MPL. The ratio of QS21 : 3D-MPL will typically be in the order of 1 : 10 to 10 : 1; such as 1:5 to 5 : 1, and often substantially 1 : 1. Typically, the ratio is in the range of 2.5 : 1 to 1 : 1 3D-MPL: QS21. Another combination adjuvant formulation includes 3D-MPL and an aluminium salt, such as aluminium hydroxide. When formulated in combination, this combination can enhance an antigen-specific Th1 immune response.

[0184] In some instances, the adjuvant formulation includes an oil-in-water emulsion, or a mineral salt such as a calcium or aluminium salt, for example calcium phosphate, aluminium phosphate or aluminium hydroxide.

[0185] One example of an oil-in-water emulsion comprises a metabolisable oil, such as squalene, a tocol such as alpha-tocopherol, and a surfactant, such as polysorbate 80 or Tween 80, in an aqueous carrier, and does not contain any additional immunostimulants(s), in particular it does not contain a non-toxic lipid A derivative (such as 3D-MPL) or a saponin (such as QS21). The aqueous carrier can be, for example, phosphate buffered saline. Additionally the oil-in-water emulsion can contain span 85 and/or lecithin and/or tricaprillin.

[0186] In another embodiment of the invention there is provided a vaccine composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil-in-water emulsion and optionally one or more further immunostimulants, wherein said oil-in-water emulsion comprises 0.5-10 mg metabolisable oil (suitably squalene), 0.5-11 mg tocol (suitably alpha-tocopherol) and 0.4-4 mg emulsifying agent.

[0187] In one specific embodiment, the adjuvant formulation includes 3D-MPL prepared in the form of an emulsion, such as an oil-in-water emulsion. In some cases, the emulsion has a small particle size of less than 0.2µm in diameter, as disclosed in WO 94/21292. For example, the particles of 3D-MPL can be small enough to be sterile filtered through a 0.22micron membrane (as described in European Patent number 0 689 454). Alternatively, the 3D-MPL can be prepared in a liposomal formulation. Optionally, the adjuvant containing 3D-MPL (or a derivative thereof) also includes an additional immunostimulatory component.

[0188] For example, when an immunogenic composition with a chimeric F2GF1 polypeptide antigen is formulated for administration to an infant, the dosage of adjuvant is determined to be effective and relatively non-reactogenic in an infant subject. Generally, the dosage of adjuvant in an infant formulation is lower than that used in formulations designed for administration to adult (*e.g.*, adults aged 65 or older). For example, the amount of 3D-MPL is typically in the range of 1µg-200µg, such as 10-100µg, or 10µg-50µg per dose. An infant dose is typically at the lower end of this range, *e.g.*, from about 1µg to about 50µg, such as from about 2µg, or about 5µg, or about 10µg, to about 25µg, or to about 50µg. Typically, where QS21 is used in the formulation, the ranges are comparable (and according to the ratios indicated above). For adult and elderly populations, the formulations typically include more of an adjuvant component than is typically found in an infant formulation. In particular formulations using an oil-in-water emulsion, such an emulsion can include additional components, for example, such as cholesterol, squalene, alpha tocopherol, and/or a detergent, such as tween 80 or span85. In exemplary formulations, such components can be present in the following amounts: from about 1-50mg cholesterol, from 2 to 10% squalene, from 2 to 10% alpha tocopherol and from 0.3 to 3% tween 80. Typically, the ratio of squalene: alpha tocopherol is equal to or less than 1 as this provides a more stable emulsion. In some cases, the formulation can also contain a stabilizer. Where alum is present, *e.g.*, in combination with 3D-MPL, the amount is typically between about 100µg and 1mg, such as from about 100µg, or about 200µg to about 750µg, such as about 500µg per dose.

[0189] An immunogenic composition typically contains an immunoprotective quantity (or a fractional dose thereof) of the antigen and can be prepared by conventional techniques. Preparation of immunogenic compositions, including those for administration to human subjects, is generally described in *Pharmaceutical Biotechnology*, Vol.61 Vaccine Design-the subunit and adjuvant approach, edited by Powell and Newman, Plenum Press, 1995. *New Trends and Developments in Vaccines*, edited by Voller *et al.*, University Park Press, Baltimore, Maryland, U.S.A. 1978. Encapsulation within liposomes is described, for example, by Fullerton, U.S. Patent 4,235,877. Conjugation of proteins to macromolecules is disclosed, for example, by Likhite, U.S. Patent 4,372,945 and by Armor *et al.*, U.S. Patent 4,474,757.

[0190] Typically, the amount of protein in each dose of the immunogenic composition is selected as an amount which induces an immunoprotective response without significant, adverse side effects in the typical subject. Immunoprotective in this context does not necessarily mean completely protective against infection; it means protection against symptoms or disease, especially severe disease associated with the virus. The amount of antigen can vary depending upon which specific immunogen is employed. Generally, it is expected that each human dose will comprise 1 1000 $\mu$ g of protein, such as from about 1 $\mu$ g to about 100 $\mu$ g, for example, from about 1 $\mu$ g to about 50 $\mu$ g, such as about 1 $\mu$ g, about 2 $\mu$ g, about 5 $\mu$ g, about 10 $\mu$ g, about 15 $\mu$ g, about 20 $\mu$ g, about 25 $\mu$ g, about 30 $\mu$ g, about 40 $\mu$ g, or about 50 $\mu$ g. The amount utilized in an immunogenic composition is selected based on the subject population (*e.g.*, infant or elderly). An optimal amount for a particular composition can be ascertained by standard studies involving observation of antibody titres and other responses in subjects. Following an initial vaccination, subjects can receive a boost in about 4 weeks.

## EXAMPLES

### **Example 1: Exemplary chimeric RSV F2GF1 polypeptide antigens**

[0191] Eight exemplary chimeric F2GF1 polypeptides were constructed based on the combination of three different variant domains. These eight variant F2GF1 polypeptides are illustrated in FIG. 2, and detailed below.

[0192] **F2GF1-1 (P3-1)**. This exemplary chimeric F2GF1 polypeptide is 603 amino acids in length, and includes in an N-terminal to C-terminal orientation: amino acids 24-130 of the F2 domain; amino acids 128-229 of a G protein variant that has a single amino acid substitution of

alanine in the place or asparagines at position 191; and amino acids 161-524 of the F1 domain. Between each of the segments (F2-G and G-F1) is introduced a 6 nucleotide linker encoding two glycines residues.

[0193] **F2GF1-2 (P3-2)**. This exemplary chimeric F2GF1 polypeptide is 559 amino acids in length, and includes in an N-terminal to C-terminal orientation: amino acids 24-107 of the F2 domain; amino acids 149-229 of a G protein variant that has a single amino acid substitution of alanine in the place or asparagines at position 191; and amino acids 161-524 of the F2 domain. Between each of the segments (F2-G and G-F1) is introduced a 6 nucleotide linker encoding two glycines residues. An internal transcription start has been modified to optimize the production of the 559 amino acids full length product.

[0194] **F2GF1-3 (P3-3)**. This exemplary chimeric F2GF1 polypeptide is 580 amino acids in length, and includes in an N-terminal to C-terminal orientation: amino acids 24-107 of the F2 domain; amino acids 129-229 of a G protein variant that has a single amino acid substitution of alanine in the place or asparagines at position 191; and amino acids 161-524 of the F2 domain. Between each of the segments (F2-G and G-F1) is introduced a 6 nucleotide linker encoding two glycines residues.

[0195] **F2GF1-4 (P3-4)**. This exemplary chimeric F2GF1 polypeptide is 582 amino acids in length, and includes in an N-terminal to C-terminal orientation: amino acids 24-130 of the F2 domain; amino acids 149-229 of a G protein variant that has a single amino acid substitution of alanine in the place or asparagines at position 191; and amino acids 161-524 of the F2 domain. Between each of the segments (F2-G and G-F1) is introduced a 6 nucleotide linker encoding two glycines residues.

[0196] **F2GF1-5 (P3-5)**. This exemplary chimeric F2GF1 polypeptide is similar to P3-1, except that the G polypeptide includes the naturally occurring asparagines at position 191. An internal transcription start has been modified to optimize the production of the 603 amino acids full length product.

[0197] **F2GF1-6 (P3-6)**. This exemplary chimeric F2GF1 polypeptide is similar to P3-2, except that the G polypeptide includes the naturally occurring asparagines at position 191.

[0198] **F2GF1-7 (P3-7)**. This exemplary chimeric F2GF1 polypeptide is similar to P3-3, except that the G polypeptide includes the naturally occurring asparagines at position 191.

[0199] **F2GF1-8 (P3-8)**. This exemplary chimeric F2GF1 polypeptide is similar to P3-4, except that the G polypeptide includes the naturally occurring asparagines at position 191.

[0200] **Exemplary Eukaryotic F2GF1 polypeptide**. Exemplary eukaryotic chimeric F2GF1 polypeptides were produced to be similar in design to the F2GF1-2 and F2GF1-6 constructs designed above for prokaryotic expression. It will be understood that any of the variants described above can also be produced in the context of the eukaryotic vectors described herein. The eukaryotic version included the F0 native signal sequence, whereas the prokaryotic constructs described above do not possess a secretion signal. Incorporation of a signal sequence enhances post-translational modifications, such as glycosylation. In exemplary embodiments, one or both furin recognition motifs are removed. In addition, the G and F1 boundaries are slightly different from those of the prokaryotic constructs described above. The G peptide domain includes amino acids 152-229, instead of aa149-229 for the prokaryotic versions, and the F1 domain includes amino acids 151-524, instead of 161-524 present in the prokaryotic versions. Thus, this exemplary eukaryotic chimeric F2GF1 polypeptide includes the following sequence. From the N-terminus, the chimeric polypeptide includes amino acids 1-109 of the F0 polypeptide (including the signal peptide, the F2 domain and the first furin cleavage motif). There is a glycine linker at amino acid 110, followed by amino acids 152-229 of the G protein (either naturally occurring, or incorporating a substitution of alanine in the place of asparagines at position 191) at positions 111-188. Following the G protein domain at positions 189-562 are amino acids 151-524 of the F1 domain. Thus, in this variant, the native pep27, fusion peptide and one or both furin recognition motifs are replaced by the G protein domain.

[0201] This exemplary recombinant protein was designed to be expressed in mammalian Chinese Hamster Ovary (CHO) cells using a GS expression system. CHO cells grown in glutamine-free medium require exogenous glutamine for optimal growth. Following transfection of CHO cells with a pEE14 vector including a polynucleotide sequence encoding a chimeric F2GF1 polypeptide, this system enables selection of stable clones via metabolic deprivation, due to expression of glutamine synthase by the pEE14 vector. Although the constructs described here were produced for expression in CHO cells, these constructs can equally be produced for expression using a Baculovirus Expression Vector System (BEVS). The constructs (coding regions) made for CHO were codon optimized for better translation efficiency in BEVS but the amino acid sequence were kept identical to their CHO homologue. In the BEVS, the RSV

optimized genes are cloned in the shuttle vector pAcSG2. That plasmid is used alone with a linearized Baculovirus genomic sequence to co-transfect insect cells. Specific recombination events occur in the cells and generate the recombinant baculovirus. During the infection process, the gene of interest is expressed at a very late stage under the polyhedrin promoter.

### **Example 2: Neutralization Inhibition in Human Sera by Chimeric F2GF1 polypeptides**

[0202] Human sera obtained from volunteer donors were screened for reactivity against RSV A by ELISA, and used in the neutralization inhibition (NI) assay at relevant dilution based on prior RSV neutralization potential titration. Sera were mixed with exemplary chimeric F2GF1 polypeptides, P3-1, P3-2, P3-3, P3-4 or chimeric FG antigen at concentrations of 0, 2, 10 and 25µg/ml and incubated 1.5 to 2 hours at 37°C. In a round bottom 96-well plate, sera and proteins were mixed with a fixed concentration of RSV A and incubated for 20min at 33°C.

[0203] The sera-inhibitor-virus mixtures was then placed into flat bottom 96-well plates previously seeded with Vero cells, and further incubated for 5-6 days at 33°C with 5% CO<sub>2</sub> until immunofluorescence assay for NI titer detection.

[0204] Titers were calculated using the Reed-Muench method and percentages of NI calculated according to the following formula:

$(\text{NI titer of } 25\mu\text{g/ml inhibitor} - \text{NI titer of } 0\mu\text{g/ml inhibitor}) \div \text{NI titer of } 0\mu\text{g/ml inhibitor} \times 100.$

[0205] The exemplary results shown in FIG. 6 demonstrate that preF is superior to FG in NI in 11/14 donor tested and equal in the remaining three donors.

### **Example 3: Chimeric F2GF1 protects against challenge with RSV**

[0206] Mice were immunized with an immunogenic composition containing F2GF1 polypeptide and an adjuvant comprising MPL and QS21 in a liposomal formulation. Groups of mice were immunized three times at two week intervals with 2µg of chimeric F2GF1 polypeptides (P3-2, P3-3, P3-6 and P3-7) and challenged three weeks after the third IM injection. Infection was assessed by titrating live virus present in lung homogenates four days after challenge.

[0207] As shown in FIG. 7, three doses of an immunogenic composition containing 2µg of F2GF1 antigen, in combination with adjuvant, elicit significant protection against RSV challenge as compared to control mice that received only adjuvant.



**Example 4: Production of neutralizing antibodies following immunization with chimeric F2GF1 antigens.**

[0208] Mice were immunized three times at two weeks interval with 2 $\mu$ g of F2GF1 (rP3-2, rP3-3, rP3-6 and rP3-7) and challenged three weeks after the third IM injection, as indicated above. Serum was collected immediately before challenge to quantitate production of neutralizing antibodies specific for RSV.

[0209] Sera of immunized mice were diluted serially and placed in the presence of fixed amounts of RSV to evaluate neutralizing activity of anti-RSV antibodies. Neutralizing antibody titers were calculated using the Spearman-Kärber method as modified by Finney. The results (illustrated in Table 2 and FIG. 8) demonstrate that superior neutralizing antibodies against RSV were detected in sera of animals immunized with rP3-3 and rP3-7.

Table 2: Neutralization titres elicited by immunization with exemplary F2GF1 antigens

Group	Antigen	Neutralizing Titers (log <sub>2</sub> )
1	P3-2	3.0000
2	P3-3	3.3750
3	P3-6	3.1250
4	P3-7	3.6250
5	Adjuvant only	2.6250

**We claim:**

1. A chimeric respiratory syncytial virus (RSV) polypeptide comprising in an N terminal to C terminal direction:
  - (i) a first F protein polypeptide domain;
  - (ii) a G protein polypeptide domain; and
  - (iii) a second F protein polypeptide domain.
2. The chimeric RSV polypeptide of claim 1, wherein the first F protein polypeptide domain (i) comprises at least an amino acid subsequence of an F protein F2 domain.
3. The chimeric RSV polypeptide of claim 2, wherein the first F protein polypeptide domain (i) comprises an amino acid sequence from residue 24 to residue 107 of a native F protein polypeptide.
4. The chimeric RSV polypeptide of any of claims 1-3, wherein the first F protein polypeptide domain (i) further comprises at least an amino acid subsequence of pep27.
5. The chimeric RSV polypeptide of any of claims 1-4, wherein the first F protein polypeptide domain (i) comprises an amino acid sequence from residue 110 to residue 130 of a native F protein polypeptide.
6. The chimeric RSV polypeptide of any of claims 1-5, further comprising a signal peptide.
7. The chimeric RSV polypeptide of any of claims 1-6, wherein the first F protein polypeptide domain (i) comprises an amino acid sequence from residue 1 to residue 109 of a native F protein polypeptide.
8. The chimeric RSV polypeptide of any of the preceding claims, wherein the first F protein polypeptide domain (i) comprises at least one amino acid modification relative to a naturally occurring RSV F protein polypeptide, wherein at least one amino acid substitution increases solubility or stability of the chimeric RSV antigen.
9. The chimeric RSV polypeptide of any of the preceding claims, wherein the first F protein polypeptide domain (i) comprises an amino acid other than methionine at residue 79 with respect to a native F0 polypeptide.

10. The chimeric RSV polypeptide of claim 9, wherein the first F protein polypeptide domain (i) comprises isoleucine at residue 79.

11. The chimeric RSV polypeptide of claim 8, wherein the at least one amino acid modification comprises an amino acid deletion or substitution that eliminates a furin cleavage site present in a naturally occurring RSV F protein.

12. The chimeric RSV polypeptide of any of the preceding claims, wherein the second F protein polypeptide domain (iii) comprises at least an amino acid subsequence of an F protein F1 domain.

13. The chimeric RSV polypeptide of any of claims 1-12, wherein the second F protein polypeptide domain (iii) comprises an amino acid sequence from residue 161 to residue 524 of a native F protein polypeptide.

14. The chimeric RSV polypeptide of any of claims 1-13, wherein the second F protein polypeptide domain (iii) comprises at least one amino acid modification relative to a naturally occurring RSV F protein polypeptide, wherein at least one amino acid modification increases solubility or stability of the chimeric RSV polypeptide.

15. The chimeric RSV polypeptide of any of claims 1-14, wherein the second F protein polypeptide domain (iii) comprises an amino acid sequence from residue 151 to residue 524 of a native F protein polypeptide.

16. The chimeric RSV polypeptide of any of claims 1-15, wherein the G protein polypeptide domain (ii) comprises at least one immunodominant T-cell epitope of a native G protein polypeptide.

17. The chimeric RSV polypeptide of claim 16, wherein the immunodominant T-cell epitope comprises from amino acid residue 183 to residue 203 of a native G protein polypeptide.

18. The chimeric RSV polypeptide of any of claims 1-17, wherein the G protein polypeptide domain (ii) comprises an amino acid sequence from residue 152 to residue 229 of a native G protein polypeptide.

19. The chimeric RSV polypeptide of any of claims 1-18, wherein the G protein polypeptide domain (ii) comprises an amino acid sequence from residue 149 to residue 229 of a native G protein polypeptide.

20. The chimeric RSV polypeptide of claim 1-19, wherein the G protein polypeptide domain (ii) comprises an amino acid sequence from residue 128 to residue 229 of a native G protein polypeptide.

21. The chimeric RSV polypeptide of any of the preceding claims, wherein the chimeric RSV polypeptide comprises one or more intervening amino acids between the first F protein polypeptide domain (i) and the G protein polypeptide domain (ii), or between the G protein polypeptide domain (ii) and second F protein polypeptide domain (iii), or between both the first F protein polypeptide domain (i) and the G protein polypeptide domain (ii), and between the G protein polypeptide domain (ii) and second F protein polypeptide domain (iii).

22. The chimeric RSV polypeptide of claim 21, wherein the intervening amino acids comprise a linker.

23. The chimeric RSV polypeptide of any of the preceding claims, wherein the chimeric polypeptide comprises at least one amino acid substitution relative to a naturally occurring RSV polypeptide, wherein the amino acid substitution reduces or prevents vaccine enhanced viral disease when the RSV antigen is administered to a subject.

24. The chimeric RSV polypeptide of claim 21, wherein the vaccine enhanced viral disease is reduced or prevented when the RSV antigen is administered to a human subject.

25. The chimeric RSV polypeptide of claim 21 or 24, wherein the chimeric polypeptide comprises a substitution of asparagine by alanine at residue 191 (N191A) of the G protein.

26. The chimeric RSV polypeptide of any of the preceding claims, wherein at least one of the first F protein polypeptide domain (i), the G protein polypeptide domain (ii), and the second F protein polypeptide domain (iii) correspond in sequence to the RSV A Long strain.

27. The chimeric RSV polypeptide of any of the preceding claims, wherein the chimeric polypeptide further comprises a polyhistidine tag.

28. The chimeric RSV polypeptide of claim 1, wherein the chimeric polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, 20 and 45 or a subsequence thereof.

29. The chimeric RSV polypeptide of claim 28, wherein the subsequence omits amino acid residues 1-23 of the selected sequence.

30. The chimeric RSV polypeptide of any of claims 1-27, wherein the chimeric polypeptide comprises an amino acid substitution of at least one cysteine.

31. The chimeric RSV polypeptide of claim 30, wherein the at least one cysteine is selected from residues 40, 72, 291, 392, 401, 412, 422, and 518.

32. The chimeric RSV polypeptide of any of claims 1-27, 30 or 31, wherein the chimeric polypeptide comprises at least one amino acid substitution for a hydrophobic amino acid selected from residues 36 to 41 and/or residues 400 to 401.

33. The chimeric RSV polypeptide of any of the preceding claims, wherein the chimeric RSV polypeptide comprises one or more immunodominant epitopes of a native RSV protein.

34. The chimeric RSV polypeptide of any of the preceding claims, wherein the chimeric RSV polypeptide comprises at least one immunodominant epitope of both an RSV F protein and an RSV G protein.

35. A recombinant RSV antigen comprising a multimer of the chimeric RSV polypeptides of any of the preceding claims.

36. The recombinant RSV antigen of claim 35, wherein the RSV antigen comprises a trimer of chimeric polypeptides.

37. An immunogenic composition comprising the chimeric RSV polypeptide of any of claims 1-34, and a carrier or excipient.

38. The immunogenic composition of claim 37, wherein the carrier or excipient is a pharmaceutically acceptable carrier or excipient.

39. The immunogenic composition of claim 37 or 38, wherein the carrier or excipient comprises a buffer.

40. The immunogenic composition of any of claims 37-39, wherein the carrier or excipient comprises at least one component that stabilizes solubility, stability or both solubility and stability.

41. The immunogenic composition of claim 40, wherein the carrier or excipient comprises a detergent.

42. The immunogenic composition of claim 41, wherein the detergent comprises at least one of lauroyl sarcosine and tween.

43. The immunogenic composition of claim 40, wherein the carrier or excipient comprises arginine

44. The immunogenic composition of claim 40, wherein the carrier or excipient comprises a glass forming polyol.

45. The immunogenic composition of claim 44, wherein the carrier or excipient comprises sucrose.

46. The immunogenic composition of claim 40, comprising a plurality of carriers or excipients.

47. The immunogenic composition of any of claims 37-46, further comprising an adjuvant.

48. The immunogenic composition of claim 47, wherein the adjuvant is suitable for administration to a neonate.

49. The immunogenic composition of claim 47, wherein the adjuvant is capable of enhancing an immune response in a human of at least 65 years of age.

50. The immunogenic composition of any of claims 47-49, wherein the adjuvant is a Th1-biasing adjuvant.

51. The immunogenic composition of claim 50, wherein the adjuvant is a TLR-4 ligand.

52. The immunogenic composition of claim 51, wherein said lipid A derivative is chosen from: 3D-MPL and any synthetic derivative of lipid A.

53. The immunogenic composition of any of claims 50-52, further comprising a particulate carrier.

54. The immunogenic composition of claim 53, wherein said carrier is alum.

55. The immunogenic composition of claim 47-52, wherein the adjuvant comprises an oil-in-water emulsion.

56. The immunogenic composition of any of claims 37-55 for use in medicine.
57. The immunogenic composition of any of claims 37-55, for use in the prevention or reduction of infection with RSV following administration to a human subject.
58. The immunogenic composition of claim 37-55, for use in the prevention or reduction of a pathological response caused by infection with RSV following administration to a human subject.
59. The immunogenic composition of any of claims 37-55, wherein the immunogenic composition reduces or prevents infection with RSV following administration to a human subject.
60. The immunogenic composition of claim 37-55, wherein the immunogenic composition reduces or prevents a pathological response caused by infection with RSV following administration to a human subject.
61. The immunogenic composition of any of claims 37-55, further comprising at least one additional antigen of a pathogenic organism other than RSV.
62. The immunogenic composition of claim 61, wherein the pathogenic organism is a virus other than RSV.
63. The immunogenic composition of claim 62, wherein the immunogenic virus is Parainfluenza virus (PIV).
64. The immunogenic composition of claim 61, wherein the pathogenic organism is selected from: hepatitis B, influenza, diphtheria, tetanus, pertussis, *Hemophilus influenza*, poliovirus, and Pneumococcus.
65. A recombinant nucleic acid comprising a polynucleotide sequence that encodes the chimeric polypeptide of any of claims 1-34.
66. The recombinant nucleic acid of claim 65, wherein the polynucleotide sequence that encodes the chimeric polypeptide comprises at least one codon that is optimized for expression in a selected host cell.
67. A vector comprising the recombinant nucleic acid of claim 65 or claim 66.

68. The vector of claim 67, wherein the vector comprises a prokaryotic or eukaryotic expression vector.

69. A host cell comprising the nucleic acid of claim 65 or 66, or the expression vector of claim 68.

70. The host cell of claim 69, wherein the host cell is selected from the group of: bacterial cells, yeast cells, insect cells, plant cells and mammalian cells.

71. The use of the chimeric RSV polypeptide of any of claims 1-34 or the nucleic acid of any of claims 65-68 in the preparation of a medicament for treating an RSV infection.

72. The use of the chimeric RSV polypeptide or nucleic acid of claim 71, wherein the medicament is administered for the purpose of prophylactically treating an RSV infection.

73. A method for eliciting an immune response against Respiratory Syncytial Virus (RSV), the method comprising:

administering to a subject an immunogenically effective amount of a composition comprising the chimeric RSV polypeptide of any of claims 1-34.

74. The method of claim 73, wherein administering the composition comprising the chimeric RSV polypeptide elicits an immune response specific for RSV without enhancing viral disease following contact with RSV.

75. The method of claim 74, wherein the immune response comprises a Th1-type immune response.

76. The method of claim 74 or 75, wherein the immune response comprises a protective immune response that reduces or prevents infection with a RSV and/or reduces or prevents a pathological response following infection with a RSV.

77. The method of claim 73, wherein the subject is a human subject.

78. The method of claim 73, comprising administering the composition comprising the chimeric RSV polypeptide comprises administering by an intranasal route.

79. The method of claim 73, comprising administering the composition comprising the chimeric RSV polypeptide comprises administering by an intramuscular route.



FIG. 1A




FIG. 1B




FIG. 1C




FIG. 2




FIG. 3




FIG. 4A

```

*           20           *           40           *
RSV_F_Long Str : MELPILKANAITTILAAVTFCFASSQNITEEFYQSTCSAVSKGYLSALRT : 50
AAR14266.1_ : ...L.H.SS..FLT..INALYLT.....F..... : 50
dbj_BAE969I8.1_ : ...L.H.SS..FLT..INALYLT.....F..... : 50
sp_P13843.1_FUS : ...L.H.SS..FLT..VNALYLT.....F..... : 50
gb_AAB82446.1_ : ...L.H.LS..FLT..INALYLT.....F..... : 50
ref_NP_056863.1 : ...L.H.LS..FLT..INALYLT.....F..... : 50
gb_AAS93657.1_ : ...L.H.SS..LLT..INALYLT.....F..... : 50
gb_AAS93662.1_ : ...L.H.SS..FLT.SINALYLT.....F..... : 50
gb_AAS93660.1_ : ...L.H.SS..FLT..INALYLT.....V.....F..... : 50
gb_AAS93661.1_ : ...L.H.SS..FLT..INALYLT.....F..... : 50
gb_AAS93663.1_ : ...L.H.SS..FLT.F.INALYLT.....F..... : 50
gb_AAS93659.1_ : ...V.H.SS..FLT..INALYLT.....F..... : 50
gb_AAS93664.1_ : ...L.H.SS..FLT..INALYLT.....F..... : 50
gb_AAS93666.1_ : ...L.H.SS..FLT..INALYLT..... : 50
gb_AAS93665.1_ : ...L.H.SS..FLT..INALYLT..... : 50
gb_AAS93656.1_ : .....T.....AIL..T..... : 50
gb_AAM44851.1_A : .....L.V..... : 50
emb_CAA26143.1_ : ...L.....T.....G..... : 50
sp_P03420.1_FUS : ...L.....T.....G..... : 50
gb_AAC55970.1_ : ...L.....T.....G..... : 50
gb_AAB38518.1_ : .....I..... : 50
emb_CAA81295.1_ : ..... : 50
gb_ABQ42594.1_ : ..... : 50
gb_AAQ97026.1_ : ..... : 50
gb_AAQ97027.1_ : ..... : 50
gb_AAQ97028.1_ : ..... : 50
gb_AAQ97029.1_ : ..... : 50
gb_AAQ97030.1_ : ..... : 50
gb_AAQ97031.1_ : ..... : 50
prf__1512372A : ..... : 50
sp_P12568.1_FUS : ..... : 50
gb_AAX23994.1_ : ..... : 50
gb_AAS93655.1_ : .....T.....A.L..... : 50
gb_AAB38516.1_ : .....T.....L..... : 50
gb_AAM68157.1_ : .D.....T.....L..... : 50
gb_AAM68160.1_ : .D.....T.....LL..... : 50
gb_ABI35685.1_ : .....T.....L..... : 50
gb_AAS93651.1_ : .....T.....L..... : 50
gb_AAB38519.1_ : .....T.....L.....V.....I : 50
gb_AAB38520.1_ : .....T.....L..... : 50
gb_AAM68154.1_ : .....T.....L..... : 50
gb_AAS93649.1_ : .....T.....L..... : 50
gb_AAS93653.1_ : .....T.....L..... : 50
gb_AAB38517.1_ : .....T...A.....L...G..... : 50
gb_AAC57027.1_ : .....T...A.....L..... : 50
sp_P11209.2_FUS : .....T...A.....L..... : 50
ref_NP_044596.1 : .....T...A.....L..... : 50
gb_AAO72323.1_ : .....T.....L..... : 50
gb_AAO72325.1_ : .....T.....L..... : 50
gb_AAO72324.1_ : .....T.....L..... : 50
prf__1701388A : .....T.T.....L..... : 50

```

FIG. 4B

	60	*	80	*	100	
RSV_F_Long Str	:	GWYTSVITIELSNIKENKNCNGTDAKVKLIKQELDKYKNAVTELQLLMQST	:			100
AARI4266.1	:	.....T.....T.....	:		T.N.	100
dbj_BAE96918.1	:	.....T.....T.....	:		N.	100
sp_P13843.1_FUS	:	.....T.....T.....	:		N.	100
gb_AAB82446.1	:	.....T.....T.....	:		N.	100
ref_NP_056863.1	:	.....T.....T.....	:		N.	100
gb_AAS93657.1	:	.....T.....T.....	:		N.	100
gb_AAS93662.1	:	.....T.....T.....	:		N.	100
gb_AAS93660.1	:	.....T.....T.....	:		N.	100
gb_AAS93661.1	:	.....T.....T.....	:		N.	100
gb_AAS93663.1	:	.....T.....T.....	:		N.	100
gb_AAS93659.1	:	.....T.....T.....	:		N.	100
gb_AAS93664.1	:	.....T.....T.....	:		N.	100
gb_AAS93666.1	:	.....T.....T.....	:		N.	100
gb_AAS93665.1	:	.....T.....T.....	:		N.	100
gb_AAS93656.1	:	.....	:			100
gb_AAM44851.1_A	:	.....	:			100
emb_CAA26143.1	:	.....	:			100
sp_P03420.1_FUS	:	.....	:			100
gb_AAC55970.1	:	.....	:			100
gb_AAB38518.1	:	.....	:			100
emb_CAA81295.1	:	.....	:			100
gb_ABQ42594.1	:	.....	:			100
gb_AAQ97026.1	:	.....	:			100
gb_AAQ97027.1	:	.....	:			100
gb_AAQ97028.1	:	.....	:			100
gb_AAQ97029.1	:	.....	:			100
gb_AAQ97030.1	:	.....	:			100
gb_AAQ97031.1	:	.....	:			100
prf_1512372A	:	.....	:			100
sp_P12568.1_FUS	:	.....	:			100
gb_AAX23994.1	:	.....	:	N.		100
gb_AAS93655.1	:	.....	:			100
gb_AAB38516.1	:	.....	:			100
gb_AAM68157.1	:	.....	:			100
gb_AAM68160.1	:	.....	:			100
gb_ABI35685.1	:	.....	:			100
gb_AAS93651.1	:	.....	:			100
gb_AAB38519.1	:	.....	:			100
gb_AAB38520.1	:	.....	:			100
gb_AAM68154.1	:	.....	:			100
gb_AAS93649.1	:	.....	:			100
gb_AAS93653.1	:	.....	:			100
gb_AAB38517.1	:	.....	:	S.	T.	100
gb_AAC57027.1	:	.....	:	S.		100
sp_P11209.2_FUS	:	.....	:	S.		100
ref_NP_044596.1	:	.....	:	S.		100
gb_AA072323.1	:	.....	:			100
gb_AA072325.1	:	.....	:	A.		100
gb_AA072324.1	:	.....	:			100
prf_1701388A	:	.....	:			100

FIG. 4C

	*	120	*	140	*
RSV_F_Long Str	:	SAANNRRELPRFMNYTLNNTKKTNTVLSKRRRFLGFLGVSIAIAS	:	150	
AAR14266.1	:	P.....A.Q.....T..NL.....	:	150	
dbj_BAE96918.1	:	P.....A.Q.....T..NL.....	:	150	
sp_P13843.1_FUS	:	P.....A.Q.....T..NL.....	:	150	
gb_AAB82446.1	:	P.....A.Q.....T..NL.....	:	150	
ref_NP_056863.1	:	P.....A.Q.....T..NL.....	:	150	
gb_AAS93657.1	:	P.....A.Q.....T..NL.....	:	150	
gb_AAS93662.1	:	P.T.....A.Q.....T..NL.....	:	150	
gb_AAS93660.1	:	P.....A.Q.....T..NL.....	:	150	
gb_AAS93661.1	:	P.....A.Q.....T..NL.....	:	150	
gb_AAS93663.1	:	P.....A.Q.....T..NL.....	:	150	
gb_AAS93659.1	:	P.....A.Q.....T..NL.....	:	150	
gb_AAS93664.1	:	P.....A.H.....T..NL.....	:	150	
gb_AAS93666.1	:	P.....A.Q.....T..NL.....	:	150	
gb_AAS93665.1	:	P.....A.Q.....T..NL.....	:	150	
gb_AAS93656.1	:	P.....A.....N.....	:	150	
gb_AAM44851.1_A	:	P.....A.....N.....	:	150	
emb_CAA26143.1	:	P.T.....A.....	:	150	
sp_P03420.1_FUS	:	PPT.....A.....	:	150	
gb_AAC55970.1	:	P.T.....A.....	:	150	
gb_AAB38518.1	:	P...S.....A.....T..	:	150	
emb_CAA81295.1	:	P.....	:	150	
gb_ABQ42594.1	:	P.....	:	150	
gb_AAQ97026.1	:	.....	:	150	
gb_AAQ97027.1	:	.....	:	150	
gb_AAQ97028.1	:	.....	:	150	
gb_AAQ97029.1	:	.....L.....	:	150	
gb_AAQ97030.1	:	.....A.....	:	150	
gb_AAQ97031.1	:	.....	:	150	
prf__1512372A	:	P.....	:	150	
sp_P12568.1_FUS	:	P.....	:	150	
gb_AAX23994.1	:	.....	:	150	
gb_AAS93655.1	:	P.....N.....	:	150	
gb_AAB38516.1	:	P...S.....N.....	:	150	
gb_AAM68157.1	:	P.....NN.....	:	150	
gb_AAM68160.1	:	P.....NN.....	:	150	
gb_ABI35685.1	:	P.....NN.....	:	150	
gb_AAS93651.1	:	P.....NN.....	:	150	
gb_AAB38519.1	:	P.....N.....	:	150	
gb_AAB38520.1	:	P.....N.....	:	150	
gb_AAM68154.1	:	P.....T.....	:	150	
gb_AAS93649.1	:	P.....N.....	:	150	
gb_AAS93653.1	:	P.....N.....	:	150	
gb_AAB38517.1	:	P.T.....N.....	:	150	
gb_AAC57027.1	:	P.T.....N.....	:	150	
sp_P11209.2_FUS	:	P.T.....N.....	:	150	
ref_NP_044596.1	:	P.T.....N.....	:	150	
gb_AA072323.1	:	P.....N.....	:	150	
gb_AA072325.1	:	P.....N.....	:	150	
gb_AA072324.1	:	P.....N.....	:	150	
prf__1701388A	:	P.....N.....	:	150	

# FIG. 4D

```

                                160          *          180          *          200
RSV_F_Long Str : GTAVSKVLHLEGEVFNKIKSALLSTNKAVVSLNNGVSVLTSKVLDLKNYID : 200
AAR14266.1_ : .I.....N.....S... : 200
dbj_BAE96918.1_ : .I.....N..... : 200
sp_P13843.1_FUS : .I.....N..... : 200
gb_AAB82446.1_ : .I.....N..... : 200
ref_NP_056863.1 : .I.....N..... : 200
gb_AAS93657.1_ : .I.....N..... : 200
gb_AAS93662.1_ : .I.....N..... : 200
gb_AAS93660.1_ : .I.....N..... : 200
gb_AAS93661.1_ : .I.....N..... : 200
gb_AAS93663.1_ : .I.....N..... : 200
gb_AAS93659.1_ : .I.....N..... : 200
gb_AAS93664.1_ : .I.....N..... : 200
gb_AAS93666.1_ : .I.....N..... : 200
gb_AAS93665.1_ : .I.....N..... : 200
gb_AAS93656.1_ : .I.....N..... : 200
gb_AAM44851.1_A : .I.....N..... : 200
emb_CAA26143.1_ : .V..... : 200
sp_P03420.1_FUS : .V..... : 200
gb_AAC55970.1_ : .V..... : 200
gb_AAB38518.1_ : .I..... : 200
emb_CAA81295.1_ : .I..... : 200
gb_ABQ42594.1_ : .I..... : 200
gb_AAQ97026.1_ : ..... : 200
gb_AAQ97027.1_ : ..... : 200
gb_AAQ97028.1_ : ..... : 200
gb_AAQ97029.1_ : ..... : 200
gb_AAQ97030.1_ : ..... : 200
gb_AAQ97031.1_ : ..... : 200
prf__1512372A : ..... : 200
sp_P12568.1_FUS : ..... : 200
gb_AAX23994.1_ : .I..... : 200
gb_AAS93655.1_ : .I..... : 200
gb_AAB38516.1_ : .I..... : 200
gb_AAM68157.1_ : .I..... : 200
gb_AAM68160.1_ : .I..... : 200
gb_ABI35685.1_ : .I..... : 200
gb_AAS93651.1_ : .I..... : 200
gb_AAB38519.1_ : .I.....T... : 200
gb_AAB38520.1_ : .I..... : 200
gb_AAM68154.1_ : .I..... : 200
gb_AAS93649.1_ : .I..... : 200
gb_AAS93653.1_ : .I..... : 200
gb_AAB38517.1_ : .I..... : 200
gb_AAC57027.1_ : .I..... : 200
sp_P11209.2_FUS : .I..... : 200
ref_NP_044596.1 : .I..... : 200
gb_AA072323.1_ : .I..... : 200
gb_AA072325.1_ : .I.....H... : 200
gb_AA072324.1_ : .I..... : 200
prf__1701388A : .I..... : 200

```

FIG. 4E

	*	220	*	240	*					
RSV_F_Long Str	:	KQLLP	IVNKQ	SCRIS	NIETV	IEFQQKNNRLL	LEITREFSVNAGV	TPVSTY	:	250
AAR14266.1	:	N.....	Q.....	.....	S.....	.....	.....	.....	:	250
dbj_BAE96918.1	:	N.....	Q.....	.....	S.....	.....	.....	.....	:	250
sp_P13843.1_FUS	:	NR.....	Q.....	.....	M.S.....	.....	.....	.....	:	250
gb_AAB82446.1	:	N.....	Q.....	.....	G.....	.....	S.....	.....	:	250
ref_NP_056863.1	:	N.....	Q.....	.....	S.....	.....	N.....	.....	:	250
gb_AAS93657.1	:	N.....	Q.....	.....	S.....	.....	.....	.....	:	250
gb_AAS93662.1	:	N.....	Q.....	.....	S.....	.....	.....	.....	:	250
gb_AAS93660.1	:	N.....	Q.....	.....	S.....	.....	.....	.....	:	250
gb_AAS93661.1	:	N.....	Q.....	.....	S.....	.....	.....	.....	:	250
gb_AAS93663.1	:	N.....	Q.....	.....	S.....	.....	.....	.....	:	250
gb_AAS93659.1	:	N.....	Q.....	.....	S.....	.....	.....	.....	:	250
gb_AAS93664.1	:	N.....	Q.....	.....	S.....	.....	.....	.....	:	250
gb_AAS93666.1	:	N.....	Q.....	.....	S.....	.....	.....	.....	:	250
gb_AAS93665.1	:	N.....	Q.....	.....	S.....	.....	.....	.....	:	250
gb_AAS93656.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAM44851.1_A	:	.....	.....	.....	S.....	.....	.....	.....	:	250
emb_CAA26143.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
sp_P03420.1_FUS	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAC55970.1	:	.....	.....	.....	S.....	.....	A.....	.....	:	250
gb_AAB38518.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
emb_CAA81295.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_ABQ42594.1	:	.....	.....	.....	.....	.....	V.....	.....	:	250
gb_AAQ97026.1	:	.....	.....	.....	.....	.....	.....	.....	:	250
gb_AAQ97027.1	:	.....	.....	.....	.....	.....	.....	.....	:	250
gb_AAQ97028.1	:	.....	.....	.....	.....	.....	.....	.....	:	250
gb_AAQ97029.1	:	.....	.....	.....	.....	.....	.....	.....	:	250
gb_AAQ97030.1	:	.....	.....	.....	.....	.....	.....	.....	:	250
gb_AAQ97031.1	:	.....	.....	.....	.....	.....	.....	.....	:	250
prf_1512372A	:	.....	.....	.....	.....	.....	.....	.....	:	250
sp_P12568.1_FUS	:	.....	.....	.....	.....	.....	.....	.....	:	250
gb_AAX23994.1	:	.....	.....	.....	.....	.....	.....	.....	:	250
gb_AAS93655.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAB38516.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAM68157.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAM68160.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_ABI35685.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAS93651.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAB38519.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAB38520.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAM68154.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAS93649.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAS93653.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAB38517.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AAC57027.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
sp_P11209.2_FUS	:	.....	.....	.....	S.....	.....	.....	.....	:	250
ref_NP_044596.1	:	.....	.....	.....	S.....	.....	.....	.....	:	250
gb_AA072323.1	:	.....	.....	.....	S.....	.....	A.....	.....	:	250
gb_AA072325.1	:	..F.....	.....	.....	S.....	.....	A.....	.....	:	250
gb_AA072324.1	:	.....	.....	.....	S.....	.....	A.....	.....	:	250
prf_1701388A	:	.....	.....	.....	S.....	.....	.....	.....	:	250



**FIG. 4F**

	260	*	280	*	300	
RSV_F_Long_Str	:	MLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYV	:			300
AARI4266.1	:	.....S.....	:			300
dbj_BAE96918.1	:	.....S.....	:			300
sp_P13843.1_FUS	:	.....S.....	:			300
gb_AAB82446.1	:	.....S.....	:			300
ref_NP_056863.1	:	.....S.....	:			300
gb_AAS93657.1	:	.....S.....	:			300
gb_AAS93662.1	:	.....S.....	:			300
gb_AAS93660.1	:	.....S.....	:			300
gb_AAS93661.1	:	.....S.....	:			300
gb_AAS93663.1	:	.....S.....	:			300
gb_AAS93659.1	:	.....S.....	:			300
gb_AAS93664.1	:	.....S.....	:			300
gb_AAS93666.1	:	.....S.....	:			300
gb_AAS93665.1	:	.....S.....	:			300
gb_AAS93656.1	:	.....S.....	:			300
gb_AAM44851.1_A	:	.....S.....	:			300
emb_CAA26143.1	:	.....S.....	:			300
sp_P03420.1_FUS	:	.....S.....	:			300
gb_AAC55970.1	:	.....S.....	:			300
gb_AAB38518.1	:	.....S.....	:			300
emb_CAA81295.1	:	.....S.....	:			300
gb_ABQ42594.1	:	.....S.....	:			300
gb_AAQ97026.1	:	.....S.....	:			300
gb_AAQ97027.1	:	.....S.....	:			300
gb_AAQ97028.1	:	.....S.....	:			300
gb_AAQ97029.1	:	.....S.....	:			300
gb_AAQ97030.1	:	.....S.....	:			300
gb_AAQ97031.1	:	.....S.....	:			300
prf__1512372A	:	.....S.....	:			300
sp_P12568.1_FUS	:	.....S.....	:			300
gb_AAX23994.1	:	.....S.....	:			300
gb_AAS93655.1	:	.....S.....	:			300
gb_AAB38516.1	:	.....S.....	:			300
gb_AAM68157.1	:	.....S.....	:			300
gb_AAM68160.1	:	.....S.....	:			300
gb_ABI35685.1	:	.....S.....	:			300
gb_AAS93651.1	:	.....S.....	:			300
gb_AAB38519.1	:	.....S.....	:			300
gb_AAB38520.1	:	.....S.....	:			300
gb_AAM68154.1	:	.....S.....	:			300
gb_AAS93649.1	:	.....S.....	:			300
gb_AAS93653.1	:	.....S.....	:			300
gb_AAB38517.1	:	.....S.....	:			300
gb_AAC57027.1	:	.....S.....	:			300
sp_P11209.2_FUS	:	.....S.....	:			300
ref_NP_044596.1	:	.....S.....	:			300
gb_AAO72323.1	:	.....S.....	:			300
gb_AAO72325.1	:	.....S.....	:			300
gb_AAO72324.1	:	.....S.....	:			300
prf____1701388A	:	.....S.....	:			300

FIG. 4G

	*	320	*	340	*
RSV_F_Long Str	:	VQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTRDRGWYCDNAGSVS	:		350
AAR14266.1	:	.....I.....	:		350
dbj_BAE96918.1	:	.....I.....	:		350
sp_P13843.1_FUS	:	.....I.....	:		350
gb_AAB82446.1	:	.....I.....	:		350
ref_NP_056863.1	:	.....I.....	:		350
gb_AAS93657.1	:	.....H.....	:		350
gb_AAS93662.1	:	.....Q.....	:		350
gb_AAS93660.1	:	.....I.....	:		350
gb_AAS93661.1	:	.....I.....	:		350
gb_AAS93663.1	:	.....I.....	:		350
gb_AAS93659.1	:	.....I.....	:		350
gb_AAS93664.1	:	.....I.....	:		350
gb_AAS93666.1	:	.....I.....	:		350
gb_AAS93665.1	:	.....I.....	:		350
gb_AAS93656.1	:	.....I.....	:		350
gb_AAM44851.1_A	:	.....I.....	:		350
emb_CAA26143.1	:	.....I.....	:		350
sp_P03420.1_FUS	:	.....I.....	:		350
gb_AAC55970.1	:	.....I.....	:		350
gb_AAB38518.1	:	.....S.....	:		350
emb_CAA81295.1	:	.....I.....	:		350
gb_ABQ42594.1	:	.....I.....	:		350
gb_AAQ97026.1	:	.....I.....	:		350
gb_AAQ97027.1	:	.....I.....	:		350
gb_AAQ97028.1	:	.....I.....	:		350
gb_AAQ97029.1	:	.....I.....	:		350
gb_AAQ97030.1	:	.....I.....	:		350
gb_AAQ97031.1	:	.....I.....	:		350
prf_1512372A	:	.....I.....	:		350
sp_P12568.1_FUS	:	.....I.....	:		350
gb_AAX23994.1	:	.....I.....	:		350
gb_AAS93655.1	:	.....E.....	:		350
gb_AAB38516.1	:	.....S.....	:		350
gb_AAM68157.1	:	.....I.....	:		350
gb_AAM68160.1	:	.....I.....	:		350
gb_ABI35685.1	:	.....I.....	:		350
gb_AAS93651.1	:	.....I.....	:		350
gb_AAB38519.1	:	.....I.....	:		350
gb_AAB38520.1	:	.....I.....	:		350
gb_AAM68154.1	:	.....I.....	:		350
gb_AAS93649.1	:	.....I.....	:		350
gb_AAS93653.1	:	.....I.....	:		350
gb_AAB38517.1	:	.....S.....	:		350
gb_AAC57027.1	:	.....I.....	:		350
sp_P11209.2_FUS	:	.....I.....	:		350
ref_NP_044596.1	:	.....I.....	:		350
gb_AAO72323.1	:	.....I.....	:		350
gb_AAO72325.1	:	.....I.....	:		350
gb_AAO72324.1	:	.....I.....	:		350
prf_1701388A	:	.....I.....	:		350

FIG. 4H

	360	*	380	*	400	
RSV_F_Long Str	:	FFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKT	:			400
AAR14266.1	:	.....D.....	:	.....S...T...S.....	:	400
dbj_BAE96918.1	:	.....D.....	:	.....S...T...S.....	:	400
sp_P13843.1_FUS	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAB82446.1	:	.....D.....	:	.....S...T...S.....	:	400
ref_NP_056863.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93657.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93662.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93660.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93661.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93663.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93659.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93664.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93666.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93665.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93656.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAM44851.1_A	:	.....D.....	:	.....S...T...S.....	:	400
emb_CAA26143.1	:	.....D.....	:	.....S...T...S.....	:	400
sp_P03420.1_FUS	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAC55970.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAB38518.1	:	.....D.....	:	.....S...T...S.....	:	400
emb_CAA81295.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_ABQ42594.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAQ97026.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAQ97027.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAQ97028.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAQ97029.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAQ97030.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAQ97031.1	:	.....D.....	:	.....S...T...S.....	:	400
prf_1512372A	:	.....D.....	:	.....S...T...S.....	:	400
sp_P12568.1_FUS	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAX23994.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93655.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAB38516.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAM68157.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAM68160.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_ABI35685.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93651.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAB38519.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAB38520.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAM68154.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93649.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAS93653.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAB38517.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AAC57027.1	:	.....D.....	:	.....S...T...S.....	:	400
sp_P11209.2_FUS	:	.....D.....	:	.....S...T...S.....	:	400
ref_NP_044596.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AA072323.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AA072325.1	:	.....D.....	:	.....S...T...S.....	:	400
gb_AA072324.1	:	.....D.....	:	.....S...T...S.....	:	400
prf_1701388A	:	.....D.....	:	.....S...T...S.....	:	400

FIG. 4I

```

          *           420           *           440           *
RSV_F_Long_Str : DVSSSVITSLGAIVSCYGKTKCTASNKNRGI IKTFSNGCDYVSNKGVDTV : 450
AARI4266.1_ : ..... : 450
dbj_BAE96918.1_ : ..... : 450
sp_P13843.1_FUS : ..... : 450
gb_AAB82446.1_ : ..... : 450
ref_NP_056863.1 : ..... : 450
gb_AAS93657.1_ : ..... : 450
gb_AAS93662.1_ : ..... : 450
gb_AAS93660.1_ : ..... : 450
gb_AAS93661.1_ : ..... : 450
gb_AAS93663.1_ : ..... : 450
gb_AAS93659.1_ : ..... : 450
gb_AAS93664.1_ : ..... : 450
gb_AAS93666.1_ : ..... : 450
gb_AAS93665.1_ : ..... : 450
gb_AAS93656.1_ : ..... : 450
gb_AAM44851.1_A : ..... : 450
emb_CAA26143.1_ : ..... : 450
sp_P03420.1_FUS : ..... : 450
gb_AAC55970.1_ : ..... : 450
gb_AAB38518.1_ : ..... : 450
emb_CAA81295.1_ : ..... : 450
gb_ABQ42594.1_ : ..... : 450
gb_AAQ97026.1_ : ..... : 450
gb_AAQ97027.1_ : ..... : 450
gb_AAQ97028.1_ : ..... : 450
gb_AAQ97029.1_ : ..... : 450
gb_AAQ97030.1_ : ..... : 450
gb_AAQ97031.1_ : ..... : 450
prf__1512372A : .....A..... : 450
sp_P12568.1_FUS : .....A..... : 450
gb_AAX23994.1_ : ..... : 450
gb_AAS93655.1_ : ..... : 450
gb_AAB38516.1_ : ..... : 450
gb_AAM68157.1_ : ..... : 450
gb_AAM68160.1_ : ..... : 450
gb_ABI35685.1_ : ..... : 450
gb_AAS93651.1_ : ..... : 450
gb_AAB38519.1_ : ..... : 450
gb_AAB38520.1_ : ..... : 450
gb_AAM68154.1_ : ..... : 450
gb_AAS93649.1_ : ..... : 450
gb_AAS93653.1_ : ..... : 450
gb_AAB38517.1_ : ..... : 450
gb_AAC57027.1_ : ..... : 450
sp_P11209.2_FUS : ..... : 450
ref_NP_044596.1 : ..... : 450
gb_AAO72323.1_ : ..... : 450
gb_AAO72325.1_ : ..... : 450
gb_AAO72324.1_ : ..... : 450
prf__1701388A : ..... : 450

```



**FIG. 4K**

	*	520	*	540	*	
RSV_F_Long Str	:	QSLAFIRKSDELLHHVNAGKSTTNIMITTIIIVIIIVILLSLIAVGLLLYC	:		:	550
AAR14266.1	:	.....N..T.....	:		:	550
dbj_BAE96918.1	:	.....N..T.....V.....	:		:	550
sp_P13843.1_FUS	:	.....N..T.....	:		:	550
gb_AAB82446.1	:	.....N..T.....	:		:	550
ref_NP_056863.1	:	.....N..T.....	:		:	550
gb_AAS93657.1	:	.....N..T.....A.....	:		:	550
gb_AAS93662.1	:	.....N..T.....A.....	:		:	550
gb_AAS93660.1	:	.....N..T.....A.....	:		:	550
gb_AAS93661.1	:	.....N..T.....A.....	:		:	550
gb_AAS93663.1	:	.....N..T.....A.....	:		:	550
gb_AAS93659.1	:	.....N..T.....A.....	:		:	550
gb_AAS93664.1	:	.....N..T.....A.....	:		:	550
gb_AAS93666.1	:	.....N..T.....A.....	:		:	550
gb_AAS93665.1	:	.....N.....A.....	:		:	550
gb_AAS93656.1	:	.....N..V.....	:		:	550
gb_AAM44851.1_A	:	.....N.....	:		:	550
emb_CAA26143.1	:	.....N.....	:		:	550
sp_P03420.1_FUS	:	.....N.....	:		:	550
gb_AAC55970.1	:	.....N.....I.....	:		:	550
gb_AAB38518.1	:	.....N.....	:		:	550
emb_CAA81295.1	:	.....N.....	:		:	550
gb_ABQ42594.1	:	.....N.....	:		:	550
gb_AAQ97026.1	:	.....N.....	:		:	550
gb_AAQ97027.1	:	.....N.....	:		:	550
gb_AAQ97028.1	:	.....N.....	:		:	550
gb_AAQ97029.1	:	.....N.....	:		:	550
gb_AAQ97030.1	:	.....N.....	:		:	550
gb_AAQ97031.1	:	.....N.....	:		:	550
prf__1512372A	:	.....N.....	:		:	550
sp_P12568.1_FUS	:	.....N.....	:		:	550
gb_AAX23994.1	:	.....N.....	:		:	550
gb_AAS93655.1	:	.....N..V.....	:		:	550
gb_AAB38516.1	:	.....N.....L.....F...	:		:	550
gb_AAM68157.1	:	.....N..V.....L.....F...	:		:	550
gb_AAM68160.1	:	.....N..V.....L.....F...	:		:	550
gb_ABI35685.1	:	.....N..V.....L.....F...	:		:	550
gb_AAS93651.1	:	.....N..V.....L.....F...	:		:	550
gb_AAB38519.1	:	.....N.....L.....	:		:	550
gb_AAB38520.1	:	.....N.....L.....	:		:	550
gb_AAM68154.1	:	.....N.....	:		:	550
gb_AAS93649.1	:	.....N.....	:		:	550
gb_AAS93653.1	:	.....N.....	:		:	550
gb_AAB38517.1	:	.....N.....	:		:	550
gb_AAC57027.1	:	.....N.....	:		:	550
sp_P11209.2_FUS	:	.....N.....	:		:	550
ref_NP_044596.1	:	.....N.....I.....	:		:	550
gb_AAO72323.1	:	.....N.....I.....	:		:	550
gb_AAO72325.1	:	.....N.....I.....	:		:	550
gb_AAO72324.1	:	.....N.....I.....	:		:	550
prf__1701388A	:	.....N..V.....	:		:	550

FIG. 4L

	560	*	
RSV_F_Long Str	: KARSTPVTLKQDLSG-INNIAFSN	: 574	(SEQ ID NO:2)
AAR14266.1	: ...N.....-.....K	: 574	
dbj_BAE96918.1	: ...N.....-.....K	: 574	
sp_P13843.1_FUS	: ...N.....-.....K	: 574	
gb_AAB82446.1	: ...N.....-.....K	: 574	
ref_NP_056863.1	: ...N.....-.....K	: 574	
gb_AAS93657.1	: ...N.....-.....R-	: 573	
gb_AAS93662.1	: ...N.....-.....R-	: 573	
gb_AAS93660.1	: ...N.....-.....R-	: 573	
gb_AAS93661.1	: ...N.....-.....R-	: 573	
gb_AAS93663.1	: ...N.....-.....R-	: 573	
gb_AAS93659.1	: ...N.....-.....R-	: 573	
gb_AAS93664.1	: ...N.....-.....R-	: 573	
gb_AAS93666.1	: ...N.....-.....R-	: 573	
gb_AAS93665.1	: ...N.....-.....R-	: 573	
gb_AAS93656.1	: .....-.....-	: 573	
gb_AAM44851.1_A	: .....-.....S	: 574	
emb_CAA26143.1	: .....-.....-	: 574	
sp_P03420.1_FUS	: .....-.....-	: 574	
gb_AAC55970.1	: .....-.....-	: 574	
gb_AAB38518.1	: .....I.....-	: 575	
emb_CAA81295.1	: .....-.....-	: 574	
gb_ABQ42594.1	: .....-.....-	: 574	
gb_AAQ97026.1	: .....-.....-	: 574	
gb_AAQ97027.1	: .....-.....-	: 574	
gb_AAQ97028.1	: .....-.....-	: 574	
gb_AAQ97029.1	: .....-.....-	: 574	
gb_AAQ97030.1	: .....-.....-	: 574	
gb_AAQ97031.1	: .....-.....-	: 574	
prf_1512372A	: .....-.....-	: 574	
sp_P12568.1_FUS	: .....-.....-	: 574	
gb_AAX23994.1	: .....-.....-	: 574	
gb_AAS93655.1	: .....-.....-	: 573	
gb_AAB38516.1	: .....I.....-	: 575	
gb_AAM68157.1	: .....-.....-	: 574	
gb_AAM68160.1	: .....-.....-	: 574	
gb_ABI35685.1	: .....-.....-	: 574	
gb_AAS93651.1	: .....-.....-	: 573	
gb_AAB38519.1	: .....I.....-	: 575	
gb_AAB38520.1	: .....I.....-	: 575	
gb_AAM68154.1	: .....-.....S	: 574	
gb_AAS93649.1	: .....-.....-	: 573	
gb_AAS93653.1	: .....-.....-	: 573	
gb_AAB38517.1	: .....I.....-	: 575	
gb_AAC57027.1	: .....-.....-	: 574	
sp_P11209.2_FUS	: .....-.....-	: 574	
ref_NP_044596.1	: .....-.....-	: 574	
gb_AAO72323.1	: .....-.....-	: 574	
gb_AAO72325.1	: .....-.....S	: 574	
gb_AAO72324.1	: .....-.....-	: 574	
prf_1701388A	: .....-.....-	: 574	

**FIG. 5A**

	*	20	*	40	*	
RSV_G Long Strain	:	MSKNKDQRTAKTLEKTWDTLNHLLFISSGLYKLNLSIAQITLSILAMII	:		:	50
dbj_BAE96917.1	:	.....V...C.....A.....	:		:	50
gb_AAW79669.1	:	-----	:		:	-
gb_AAW79670.1	:	-----	:		:	-
gb_AAW79661.1	:	-----	:		:	-
gb_AAW79668.1	:	-----	:		:	-
gb_AAW79671.1	:	-----	:		:	-
gb_AAW79672.1	:	-----	:		:	-
gb_AAW79676.1	:	-----	:		:	-
gb_AAR86179.1	:	.....V...C.....A.....	:		:	34
gb_AAR86180.1	:	.....V...C.....A.....	:		:	34
gb_AAW79647.1	:	-----	:		:	-
gb_AAW79629.1	:	-----	:		:	-
gb_AAW79643.1	:	-----	:		:	-
gb_AAW79644.1	:	-----	:		:	-
gb_AAW79645.1	:	-----	:		:	-
gb_AAW79677.1	:	-----	:		:	-
gb_AAW79646.1	:	-----	:		:	-
gb_AAW79655.1	:	-----	:		:	-
gb_AAW79657.1	:	-----	:		:	-
gb_AAW79658.1	:	-----	:		:	-
gb_AAW79648.1	:	-----	:		:	-
gb_AAW79649.1	:	-----	:		:	-
gb_AAW79653.1	:	-----	:		:	-
gb_AAW79659.1	:	-----	:		:	-
gb_AAW79695.1	:	-----	:		:	-
gb_AAW79704.1	:	-----	:		:	-
gb_AAW79707.1	:	-----	:		:	-
gb_AAW79702.1	:	-----	:		:	-
gb_AAW79709.1	:	-----	:		:	-
gb_ABH00984.1	:	...T...I.....C...S.....	:		:	50
gb_AAM68156.1	:	...T.....C.....	:		:	50
gb_AAS90859.1	:	-----	:		:	3
gb_AAM68159.1	:	...T.....C.....	:		:	50
gb_AAS90857.1	:	-----	:		:	3
gb_AAS90858.1	:	-----	:		:	3
gb_AAS90861.1	:	-----	:		:	2
gb_AAS90871.1	:	-----	:		:	-
gb_AAU26087.1	:	-----	:		:	4
gb_AAU26088.1	:	-----L...	:		:	4
gb_AAS90925.1	:	-----	:		:	-
gb_AAS90926.1	:	-----	:		:	-
gb_AAS90907.1	:	-----	:		:	1
gb_AAX08080.1	:	-----P...	:		:	4
gb_AAS90936.1	:	-----	:		:	3
gb_AAU26084.1	:	-----	:		:	4
gb_AAS90938.1	:	-----	:		:	2
gb_AAU26092.1	:	-----L...	:		:	4
gb_AAU26093.1	:	-----	:		:	4
gb_AAS90912.1	:	-----	:		:	3
gb_AAS90906.1	:	-----	:		:	3



FIG. 5B

gb_AAS90914.1_	:	-----	:	3
gb_AAS90878.1_	:	-----	:	3
gb_AAU26095.1_	:	-----L	:	5
gb_AAX08081.1_	:	-----	:	2
gb_AAU26085.1_	:	-----	:	1
gb_AAU26086.1_	:	-----P	:	5
gb_AAU26091.1_	:	-----	:	2
gb_AAU26090.1_	:	-----	:	3
gb_AAS90882.1_	:	-----	:	1
gb_AAS90874.1_	:	-----	:	3
gb_AAS90928.1_	:	-----	:	2
gb_AAX08082.1_	:	-----CP	:	5
gb_AAX08084.1_	:	-----Q	:	5
gb_AAS90886.1_	:	-----	:	3
gb_AAS90922.1_	:	-----	:	3
gb_AAS90919.1_	:	-----	:	3
gb_AAT80628.1_	:	.....C	:	50
sp_P27024_HRSV5	:	...T.....C	:	50
emb_CAA51763.1_	:	..T.....C	:	48
emb_CAA83899.1_	:	...T.....C	:	50
gb_AAF23741.1_	:	-----C	:	31
gb_AAC36325.1_	:	...T.....C	:	50
emb_CAA83877.1_	:	...T.....C	:	50
mb_CAA83862.1_	:	...T.....C	:	50
mb_CAA83857.1_	:	...T.....C	:	50
mb_CAA83866.1_	:	...T.....N.....C	:	50
mb_CAA83873.1_	:	...T.....C	:	50
gb_AAF23727.1_	:	-----C	:	31
gb_AAF23733.1_	:	-----C	:	31
mb_CAA83861.1_	:	...T.....C	:	50
mb_CAA83900.1_	:	...T.....C	:	50
gb_AA014878.2_	:	.....C	:	50
gb_AAD02942.1_	:	...T.....C	:	50
gb_AAD02945.1_	:	-----C	:	45
gb_AAC57026.1_	:	.....C	:	50
ref_NP_044595.1_	:	.....T.....C	:	50
gb_AAF23729.1_	:	-----C.....A	:	31
gb_AAF23731.1_	:	-----C.....A	:	31
gb_AAC36324.1_	:	...T...A.....C	:	50
sp_P27023_VGLG_HRSV4	:	...T.....C	:	50
ssp_P27025_HRSV6	:	...T.....C	:	50
gb_AAF23736.1_	:	-----C	:	31
gb_AAF23728.1_	:	-----C	:	31
gb_AAF23735.1_	:	-----C	:	31
gb_AAF23732.1_	:	-----C	:	31
gb_AAD02946.1_	:	-----C	:	45
gb_AAF23743.1_	:	-----C	:	31
gb_AAF23749.1_	:	-----C	:	31
gb_AAF23745.1_	:	-----C	:	31
sp_P27026_HRSV7	:	...T.....C	:	50
emb_CAA83863.1_	:	...T.....C	:	50
emb_CAA83878.1_	:	...T.....C	:	50
emb_CAA83860.1_	:	...T.....C	:	50
gb_AAM68153.1_	:	...T.....C	:	50

FIG. 5C

gb_AAS90864.1_	:	-----	:	3
gb_AAS90905.1_	:	-----	:	-
gb_AAS90931.1_	:	-----	:	1
gb_AAS90892.1_	:	-----	:	3
gb_AAX08086.1_	:	-----	:	3
gb_AAS90880.1_	:	-----	:	3
gb_AAS90929.1_	:	-----	:	3
gb_AAS90898.1_	:	-----	:	3
gb_AAQ24136.1_	:	...T.....C.....	:	50
gb_AAQ24143.1_	:	...T.....C.....	:	50
gb_AAQ24139.1_	:	...T.....C...F.....	:	50
gb_AAQ24141.1_	:	...T.....C.....	:	50
gb_AAQ24137.1_	:	...T.....C...FF.....	:	50
gb_AAS90863.1_	:	-----	:	3
gb_AAS90924.1_	:	-----	:	3
gb_AAS90921.1_	:	-----	:	3
gb_AAS90927.1_	:	-----	:	3
gb_AAQ24138.1_	:	...T.....C...FF.....	:	50
gb_AAQ24140.1_	:	...T.....C...FF.....	:	50
gb_AAS90867.1_	:	-----	:	3
gb_AAS90884.1_	:	-----	:	3
gb_AAS90885.1_	:	-----	:	3
gb_AAF23746.1_	:	-----C.....	:	31
gb_AAF23747.1_	:	-----C.....	:	31
gb_AAF23748.1_	:	-----C.....	:	31
gb_AAU43726.1_	:	...T.....C.....	:	50
gb_AAU43727.1_	:	...T.....C.....	:	50
gb_AAM44850.2_AF51	:	...T.....C.....	:	50
gb_AAF23730.1_	:	-----C.....	:	31
gb_AAF23737.1_	:	-----C.....	:	31
mb_CAA83867.1_	:	...T.....C.....	:	50
mb_CAA83865.1_	:	...T.....C.....	:	50
mb_CAA83868.1_	:	...T.....C.....	:	50
gb_AAC36326.1_	:	.....A.....C.....	:	50
gb_AAC36328.1_	:	...T...A.....C.....	:	50
gb_AAF23738.1_	:	-----C.....	:	31
gb_AAF23734.1_	:	-----C.....	:	31
_gb_AAQ24144.1_	:	...T.....C.....	:	50
_gb_AAQ24145.1_	:	...T.....C.....	:	50
gb_AAF23744.1_	:	-----C.....	:	31
mb_CAA83858.1_	:	...T.....C.....	:	50
_gb_AAU43729.1_	:	...T.....C.....	:	50
_gb_AAS90862.1_	:	-----	:	3
_gb_AAS90913.1_	:	-----	:	3
mb_CAA83869.1_	:	...T.....C.....	:	50
mb_CAA83859.1_	:	...T.....C.....	:	50
gb_AAF23740.1_	:	-----C.....	:	31
gb_AAF23742.1_	:	-----C.....	:	31
mb_CAA83879.1_	:	...T.....C.....	:	50
mb_CAA83864.1_	:	...T.....C.....	:	50
gb_AAF23739.1_	:	-----C.....	:	31
sp_P20895_VGLG_HRSV	:	.....	:	50
emb_CAA83872.1_	:	.....Y.....	:	50
emb_CAA34937.1_	:	.....Y.....	:	50
_gb_AAX23993.1_	:	.....	:	50

FIG. 5D

sp_P27021_VGLG_HRSV2:	.....C.....	: 50
gb_AAD02941.1_	: .....C.....	: 50
mb_CAA83870.1_	: .....C.....	: 50
mb_CAA83871.1_	: .....C.....	: 50
sp_P27022_VGLG_HRSV3:	.....C.....	: 50
mb_CAA51765.1_	: --.....C.....	: 48
gb_AAD02944.1_	: ----.....C.....	: 45
mb_CAA83874.1_	: .....C.....	: 50
gb_AAC36327.1_	: ...T.....C.....	: 50
mb_CAA83875.1_	: .....C.....	: 50
sp_P03423_VGLG_HRSVA:	.....C.....	: 50
gb_AAD02943.1_	: ----.....C.....	: 45
sp_P20896_VGLG_HRSV1:	...H.....V...C.....A.....	: 50
sp_P23041_VGLG_HRSV8:	...H.....S.....V...C.....A.....	: 50
_gb_AAR14265.1_	: ...H.S.....V...C.....A.....	: 50
_gb_ABC26397.1_	: ...H.....V...C.....A.....	: 50
_gb_ABC26398.1_	: ...H.....V...C.....A.....	: 50
gb_AAC36320.1_	: ...H.....V...C.....A.....	: 50
_gb_AAW79749.1_	: -----	: -
_gb_AAW79750.1_	: -----	: -
_gb_AAW79751.1_	: -----	: -
_gb_AAW79752.1_	: -----	: -
ref_NP_056862.1_	: ...H.....V...C.....A.....	: 50
_gb_AAW79753.1_	: -----	: -
_gb_AAW79754.1_	: -----	: -
_gb_AAW79755.1_	: -----	: -
_gb_AAW79756.1_	: -----	: -
_gb_AAK31912.1_	: -----.....V...C...S.....A.....	: 39
_gb_AAK37424.1_	: -----.....V...C...S.....A.....	: 39
_gb_AAW79743.1_	: -----	: -
_gb_AAW79744.1_	: -----	: -
gb_AAF20082.1_	: -----.....V...C.....A.....	: 31
gb_AAF20084.1_	: -----.....V...C.....A.....	: 31
gb_AAF20085.1_	: -----.....V...C.....A.....	: 31
_gb_AAW79741.1_	: -----	: -
_gb_AAW79742.1_	: -----	: -
gb_AAF20081.1_	: -----.....V...C.....A.....	: 31
gb_AAF20091.1_	: -----.....V...C.....A.....	: 31
gb_AAC36321.1_	: ...H.....V...C.....A.....	: 50
_gb_AAW79745.1_	: -----	: -
_gb_AAW79746.1_	: -----	: -
gb_AAF20083.1_	: -----.....V...C.....A.....	: 31
_gb_AAQ16176.1_	: .....V...C.....A.....	: 50
_gb_AAW79759.1_	: -----	: -
_gb_AAR86181.1_	: -----.....V...C.....A.....	: 34
_gb_AAU26097.1_	: -----	: 1
_gb_AAU26099.1_	: -----	: -
_gb_AAX08076.1_	: -----	: -
_gb_AAX08079.1_	: -----	: -
_gb_AAX08078.1_	: -----	: -
_gb_AAU26101.1_	: -----	: -
_gb_AAW79767.1_	: -----	: -
_gb_AAS90851.1_	: -----	: 2
_gb_AAS90852.1_	: -----	: 1

FIG. 5E

_gb_AAS90853.1	:	-----	:	2
_gb_AAS90856.1	:	-----	:	-
_gb_AAW79761.1	:	-----	:	-
_gb_AAW79762.1	:	-----	:	-
_gb_AAW79765.1	:	-----	:	-
_gb_AAW79763.1	:	-----	:	-
_gb_AAW79764.1	:	-----	:	-
_gb_AAW79768.1	:	-----	:	-
_gb_AAW79769.1	:	-----	:	-
_gb_AAW79748.1	:	-----	:	-
_gb_AAW79772.1	:	-----	:	-
_gb_AAW79777.1	:	-----	:	-
_gb_AAW79778.1	:	-----	:	-
_gb_AAR00216.1	:	...H.....V...C.....A.....	:	50
_gb_AAR00220.1	:	...H.....V...C.....A.....	:	50
_gb_AAR00217.1	:	...H.....V...C.....A.....	:	50
_gb_AAR00219.1	:	...H.....V...C.....A.....	:	50
_gb_AAR00218.1	:	...H.....V...C.....A.....	:	50
_gb_AAW79733.1	:	-----	:	-
_gb_AAW79734.1	:	-----	:	-
_gb_AAW79738.1	:	-----	:	-
_gb_AAF20090.1	:	-----V...C.....A.....	:	31
_gb_AAF20087.1	:	-----V.....A.....	:	31
_gb_AAF20086.1	:	-----V...C.....A.....	:	31
_gb_AAF20088.1	:	-----V...C.....A.....	:	31
_gb_AAF20089.1	:	-----V...C.....A.....	:	31
_gb_ABC26396.1	:	...H.....V...C.....A.....	:	50
_gb_AAQ16177.1	:	.....V...C.....A.....	:	50
_gb_AAQ16178.1	:	.....V...C.....A.....	:	50
_gb_ABB16912.1	:	.....V...C.....A.....	:	50
_dbj_BAC81823.1	:	.....V...C.....A.....	:	50
_gb_AAW79621.1	:	-----	:	-
_gb_AAW79622.1	:	-----	:	-
_gb_AAW79627.1	:	-----	:	-
_gb_AAU26098.1	:	-----	:	-
_gb_AAW79590.1	:	-----	:	-
_gb_AAW79583.1	:	-----	:	-
_gb_AAW79585.1	:	-----	:	-
_gb_AAW79589.1	:	-----	:	-
_gb_ABB16944.1	:	.....V...C.....A.....	:	50
_gb_AAW79580.1	:	-----	:	-
_gb_ABB43013.1	:	-----	:	-
_gb_ABC26395.1	:	...H.....V...C.....A.....	:	50
_gb_ABB16945.1	:	.....V...C.....A.....	:	50
_gb_ABB16919.1	:	.....V...C.....A.....	:	50
_gb_ABB16936.1	:	.....V...C.....A.....	:	50
_gb_ABB16924.1	:	.....V...C.....A.....	:	50
_gb_ABB16930.1	:	.....V...C.....A.....	:	50
_gb_ABB16932.1	:	.....V...C.....A.....	:	50
_gb_ABB16941.1	:	.....V...C.....A.....	:	50
_gb_ABB16939.1	:	.....V...C.....A.....	:	50
_gb_ABB16934.1	:	.....V...C.....A.....	:	50
_gb_ABB16925.1	:	.....V...C.....A.....	:	50
_gb_ABB16937.1	:	.....V...C.....A.....	:	50

FIG. 5F

_gb_ABB16943.1	: .....	V...C.....A.....	: 50
_gb_ABB16946.1	: .....	V...C.....A.....	: 50
_gb_AAW79591.1	: -----		: -
_gb_AAW79613.1	: -----		: -
_gb_AAW79607.1	: -----		: -
_gb_AAW79600.1	: -----		: -
_gb_AAW79606.1	: -----		: -
_gb_AAW79615.1	: -----		: -
_gb_AAW79616.1	: -----		: -
_gb_AAW79618.1	: -----		: -
_gb_AAW79619.1	: -----		: -
_gb_AAW79620.1	: -----		: -
_gb_ABB16926.1	: .....	V...C.....A.....	: 50
_gb_ABB16942.1	: .....	V...C.....A.....	: 50
_gb_ABB16938.1	: .....	R...V...C.....A.....	: 50
_gb_ABB16940.1	: .....	V...C.....A.....	: 50
_gb_ABB16916.1	: .....	V...C.....A.....	: 50
_gb_ABB16923.1	: .....	V...C.....A.....	: 50
_gb_ABB16922.1	: .....	V...C.....A.....	: 50
_gb_ABB16927.1	: .....	V...C.....A.....	: 50
_gb_ABB16928.1	: .....	V...C.....A.....	: 50
_gb_ABB16920.1	: .....	P.V...C.....A.....	: 50
_gb_ABB16917.1	: .....	V...C.....A.....	: 50
_gb_ABB16918.1	: .....	V...C.....A.....	: 50
_gb_AAW79739.1	: -----		: -
_gb_AAW79740.1	: -----		: -
_gb_AAW79679.1	: -----		: -
_gb_AAW79682.1	: -----		: -
_gb_AAW79683.1	: -----		: -
_gb_AAW79719.1	: -----		: -
_gb_AAW79692.1	: -----		: -
_gb_AAW79693.1	: -----		: -
_gb_AAW79694.1	: -----		: -
_gb_AAW79723.1	: -----		: -
_gb_AAW79724.1	: -----		: -
_gb_AAC36322.1	: .....	V...C.....A.....	: 50
_gb_AAC36323.1	: ...H.....	V...C.....A.....	: 50
_gb_AAW79684.1	: -----		: -
_gb_AAW79687.1	: -----		: -
_gb_AAW79688.1	: -----		: -
_gb_AAW79691.1	: -----		: -
_gb_AAW79710.1	: -----		: -
_gb_AAW79714.1	: -----		: -
_gb_AAW79716.1	: -----		: -
_gb_AAW79715.1	: -----		: -
_gb_AAW79729.1	: -----		: -
_gb_AAW79731.1	: -----		: -
_gb_AAW79628.1	: -----		: -
_gb_AAW79712.1	: -----		: -
_gb_AAK49106.1	: .....	V...C.....A.....	: 39
_gb_AAW79720.1	: -----		: -
_gb_AAW79722.1	: -----		: -
_gb_AAW79727.1	: -----		: -

FIG. 5G

	60	*	80	*	100	
RSV_G Long Strain	:	STSLIITAIIFIASANHKVTLTTAI	:	IQDATSQIKNTTPTYLTQDPQLGIS	:	100
dbj_BAE96917.1	:	.....A.....I.....	:	VT..TIKNHTEKNIT.H...VSPE...	:	100
_gb_AAW79669.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPE.A.	:	41
_gb_AAW79670.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPE.A.	:	41
_gb_AAW79661.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79668.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79671.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79672.1	:	-----I.....	:	VT..TIKNHTEKNIT.C...VSPER..	:	41
_gb_AAW79676.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAR86179.1	:	.....A.....I.....	:	VT..TIKNHTEKNIT....VSPER..	:	84
_gb_AAR86180.1	:	.....A.....I.....	:	VT..TIKNHTEKNIT....VSPER..	:	84
_gb_AAW79647.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPERA.	:	41
_gb_AAW79629.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79643.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79644.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPERA.	:	41
_gb_AAW79645.1	:	-----I.....	:	P..VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79677.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79646.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79655.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79657.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79658.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79648.1	:	-----I.....	:	P..VT..TIKNHTEKNIT..P..V..PER..	:	41
_gb_AAW79649.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79653.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79659.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79695.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79704.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79707.1	:	-----I.....	:	IT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79702.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79709.1	:	-----I.....	:	VT..TIKNHTEKNIT....VSPER..	:	41
_gb_ABH00984.1	:	.....V.....N.....	:	.....	:	100
_gb_AAM68156.1	:	.....V.....N.....	:	.....	:	100
_gb_AAS90859.1	:	.....V.....N.....	:	.....	:	53
_gb_AAM68159.1	:	.....V.....N.....	:	.....F...	:	100
_gb_AAS90857.1	:	.....V.....N.....	:	.....	:	53
_gb_AAS90858.1	:	.....V.....N.....	:	.....	:	53
_gb_AAS90861.1	:	.....V.....N.....	:	.....	:	52
_gb_AAS90871.1	:	---V.....N.....	:	.....	:	47
_gb_AAU26087.1	:	.....V.....N.....	:	.....L.....	:	54
_gb_AAU26088.1	:	.....V.....N.....	:	.....L.....	:	54
_gb_AAS90925.1	:	.....V.....N.....	:	.....	:	50
_gb_AAS90926.1	:	---V.....N.....	:	.....	:	48
_gb_AAS90907.1	:	.....V.....N.....	:	.....	:	51
_gb_AAX08080.1	:	.....V.....N.....	:	.....	:	54
_gb_AAS90936.1	:	.....V.....N.....	:	.....	:	53
_gb_AAU26084.1	:	.....V.....N.....	:	.....	:	54
_gb_AAS90938.1	:	.....V.....N.....	:	.....	:	52
_gb_AAU26092.1	:	.....V.....N.....	:	.....	:	54
_gb_AAU26093.1	:	.....V.....N.....	:	.....	:	54
_gb_AAS90912.1	:	.....V.....N.....	:	.....	:	53
_gb_AAS90906.1	:	.....V.....N.....	:	.....	:	53
_gb_AAS90914.1	:	.....V.....N.....	:	.....	:	53

FIG. 5H

_gb_AAS90878.1_	: .....V.....N.....	: 53
_gb_AAU26095.1_	: .....V.....N.....	: 55
_gb_AAX08081.1_	: .....V.....N.....	: 52
_gb_AAU26085.1_	: .....V.....N.....T.....	: 51
_gb_AAU26086.1_	: .....V.....N.....T.....	: 55
_gb_AAU26091.1_	: .....V.....N.....T.....	: 52
_gb_AAU26090.1_	: .....V.....N.....T.....	: 53
_gb_AAS90882.1_	: .....V.....N.....	: 51
_gb_AAS90874.1_	: .....V.....N.....	: 53
_gb_AAS90928.1_	: .....V.....N.....	: 52
_gb_AAX08082.1_	: .....V.....N.....	: 55
_gb_AAX08084.1_	: .....V.....N.....	: 55
_gb_AAS90886.1_	: .....V.....N.....	: 53
_gb_AAS90922.1_	: .....V.....N.....	: 53
_gb_AAS90919.1_	: .....V.....N.....	: 53
_gb_AAT80628.1_	: .....V.....N.....	: 100
sp_P27024_VGLG_HRSV5:	.....A.....N.....	: 100
mb_CAA51763.1_	: .....A.....N.....	: 98
emb_CAA83899.1_	: .....A.....N.....	: 100
gb_AAF23741.1_	: .....A.....N.....	: 81
gb_AAC36325.1_	: .....V.....N.....	: 100
mb_CAA83877.1_	: .....A.....N.....	: 100
mb_CAA83862.1_	: .....A.....N.....	: 100
mb_CAA83857.1_	: .....A.....N.....	: 100
mb_CAA83866.1_	: .....A.....N.....	: 100
mb_CAA83873.1_	: .....A.....N.....Q.....	: 100
gb_AAF23727.1_	: .....A.....N.....	: 81
gb_AAF23733.1_	: .....A.....N.....E.....	: 81
mb_CAA83861.1_	: .....A.....N.....	: 100
mb_CAA83900.1_	: .....A.....N.....	: 100
_gb_AAO14878.2_	: .....A.....N.....N.....	: 100
gb_AAD02942.1_	: .....A.....	: 100
gb_AAD02945.1_	: .....A.....S.....	: 95
gb_AAC57026.1_	: .....A.....	: 100
ref_NP_044595.1_	: .....A.....	: 100
gb_AAF23729.1_	: .....A.....	: 81
gb_AAF23731.1_	: .....A.....	: 81
gb_AAC36324.1_	: .....A.....	: 100
sp_P27023_VGLG_HRSV4:	.....A.....Q.....T.....	: 100
sp_P27025_VGLG_HRSV6:	.....A.....	: 100
gb_AAF23736.1_	: .....A.....	: 81
gb_AAF23728.1_	: .....A.....	: 81
gb_AAF23735.1_	: .....A.....	: 81
gb_AAF23732.1_	: .....A.....	: 81
gb_AAD02946.1_	: .....A.....H.....	: 95
gb_AAF23743.1_	: .....A.....T.....I.....	: 81
gb_AAF23749.1_	: .....A.....T.....	: 81
gb_AAF23745.1_	: .....A.....T.....I.....	: 81
sp_P27026_VGLG_HRSV7:	.....A.....	: 100
mb_CAA83863.1_	: .....A.....	: 100
mb_CAA83878.1_	: .....A.....P.....T.....	: 100
mb_CAA83860.1_	: .....A.....	: 100
_gb_AAM68153.1_	: .....A.....N.....H.....	: 100





FIG. 5J

_gb_AAX23993.1	:	.....	:	100
sp_P27021_VGLG_HRSV2:	.....	A.....S..T.....N.....	:	100
gb_AAD02941.1	:	.....A.....S..T.....N.....	:	100
mb_CAA83870.1	:	.....A.....S..T.....N.....	:	100
mb_CAA83871.1	:	.....A.....S..I..T.....N.....	:	100
sp_P27022_VGLG_HRSV3:	.....	V.....S..T.....N.....	:	100
mb_CAA51765.1	:	.....V.....S..T.....N.....	:	98
gb_AAD02944.1	:	.....V.....S..T.....N.....	:	95
mb_CAA83874.1	:	.....V.....S..T.....N.....	:	100
gb_AAC36327.1	:	.....A.....S..T.....N.....	:	100
mb_CAA83875.1	:	.....A.....S..T.....N.....	:	100
sp_P03423_VGLG_HRSVA:	.....	A.....P.....	:	100
gb_AAD02943.1	:	.....A.....S..T.....	:	95
sp_P20896_VGLG_HRSV1:	.....	A.....I.....VT..TIKNHTEKNIS....V.PER.N	:	100
sp_P23041_VGLG_HRSV8:	.....	A.....I.....VT..TIKNHTGKNIS....V.PER.N	:	100
_gb_AAR14265.1	:	.....A.....I.....VT..TIKNHTEKNIT....VSPER..	:	100
_gb_ABC26397.1	:	.....A.....I.....VT..STIK.HTEKNIT....VSPER..	:	100
_gb_ABC26398.1	:	.....A.....I.....VT..STIKNHTEKNIT....VSPER..	:	100
gb_AAC36320.1	:	.....A.....I.....VT..TIKNHTEKNIT....V.PER..	:	100
_gb_AAW79749.1	:	-----I.....VT..TIKNHTEKNIT....V.PER..	:	41
_gb_AAW79750.1	:	-----I.....VT..TIKNHTEKNIT....V.PER..	:	41
_gb_AAW79751.1	:	-----I.....VT..TIKNHTEKNIT....V.PER..	:	41
_gb_AAW79752.1	:	-----I.....VT..TIKNHTEKNIT....V.PER..	:	41
ref_NP_056862.1	:	.....A.....I.....VT..TIKNHTEKNIT....V.PER..	:	100
_gb_AAW79753.1	:	-----I.....VT..TIKNHTEKNIT....V.PER..	:	41
_gb_AAW79754.1	:	-----I.....VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79755.1	:	-----I.....VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAW79756.1	:	-----I.....VT..TIKNHTEKNIT....VSPER..	:	41
_gb_AAK31912.1	:	.....A.....I.....VT..STIKNHTEKNIT....VSPER..	:	89
_gb_AAK37424.1	:	.....A.....I.....VT..STIKNHTEKNIT....VSPER..	:	89
_gb_AAW79743.1	:	-----I.....VT..STTKNHTEKNIT....VSPER..	:	41
_gb_AAW79744.1	:	-----I.....VT..STIKNHTEKNIT....VSPER..	:	41
gb_AAF20082.1	:	.....A.....I.....VT..STIKNHTEKNIT....VSPER..	:	81
gb_AAF20084.1	:	.....A.....I.....VT..STIKNHTEKNIT....VSPER..	:	81
gb_AAF20085.1	:	.....A.....I.....VT..STIKNHTEKNIN....V.PER..	:	81
_gb_AAW79741.1	:	-----I.....VT..STIKNHTEKNIT....VSPER..	:	41
_gb_AAW79742.1	:	-----I.....VT..STIKNHTEKNIT....VSPEK..	:	41
gb_AAF20081.1	:	.....A.T...I.....P..VT..STIKNHTEKNIT....VSPER..	:	81
gb_AAF20091.1	:	.....A.....I.....VTXXTIKNHTEKNIT....VSPER..	:	81
gb_AAC36321.1	:	.....A.....I.....VT..STIKNHTEKNIT....VSPER..	:	100
_gb_AAW79745.1	:	-----I.....VT..STIKNHTEKNIT....VSPER..	:	41
_gb_AAW79746.1	:	-----I.....VT..STIKNHTEKNIT....VSPER..	:	41
gb_AAF20083.1	:	.....A.....I.....VT..STIKNYTEKNIT....VSPER..	:	81
_gb_AAQ16176.1	:	.....A.....I.....P..VT..TIKNHTEKNIT....HVSPER..	:	100
_gb_AAW79759.1	:	-----I.....VT..TIKNHTEKNIT....HVSPER..	:	41
_gb_AAR86181.1	:	.....A.....I.....P..VT..TIKNHTEKNIT....HVSPDR..	:	84
_gb_AAU26097.1	:	.....A.....I.....P..VT..TIKNHTEKNIT....HVSPDR..	:	51
_gb_AAU26099.1	:	-----A.....I.....P..VT..TIKNHTEKNIT....HVSPDR..	:	44
_gb_AAX08076.1	:	-----A.....I.....P..VT..TIKNHTEKNIT....HVSPDR..	:	45
_gb_AAX08079.1	:	-----A.....I.....P..VT..TIKNHTEKNIT....HVSPDR..	:	44
_gb_AAX08078.1	:	-----A.....I.....P..VT..TIKNHTEKNIT....HVSPDR..	:	44
_gb_AAU26101.1	:	-----A.....I.....P..VT..TIKNHTEKNIT....HVSPDR..	:	48
_gb_AAW79767.1	:	-----I.....VT..TIKNHTEKNI....HVSPDR..	:	41
_gb_AAS90851.1	:	.....A.....I.....VT..TIKNHTEKNIT....HVSPDR..	:	52

FIG. 5K

_gb_AAS90852.1	: .....A.....I.....VT..TIKNHTEKNIT....HVSPDR..	: 51
_gb_AAS90853.1	: .....A.....I.....VT..TIKNHTEKNIT....HVSPDR..	: 52
_gb_AAS90856.1	: .....A.....I.....VT..TIKNHTEKNIT....HVSPDR..	: 49
_gb_AAW79761.1	: -----I.....VT..TIKNHTEKNIT....HVSPER..	: 41
_gb_AAW79762.1	: -----I.....VT..TIKNHTEKNIT....HVSPER..	: 41
_gb_AAW79765.1	: -----I.....VT..TIKNHTEKNIT....HVSPER..	: 41
_gb_AAW79763.1	: -----I.....VT..TIKNHTEKNIT....HVSPER..	: 41
_gb_AAW79764.1	: -----I.....VT..TIKNHTEKNIT....HVSPER..	: 41
_gb_AAW79768.1	: -----I.....VTA.TIKNHTEKNIT....HVSPER..	: 41
_gb_AAW79769.1	: -----I.....VT..TIKNHTEKNIT....HVSPER..	: 41
_gb_AAW79748.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79772.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79777.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79778.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAR00216.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_AAR00220.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_AAR00217.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_AAR00219.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_AAR00218.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_AAW79733.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79734.1	: -----I.....VT..TIKNHTEKNITI....VSPER..	: 41
_gb_AAW79738.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
gb_AAF20090.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 81
gb_AAF20087.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 81
gb_AAF20086.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 81
gb_AAF20088.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 81
gb_AAF20089.1	: .....A.....I.....Y.....VT..TIKNHTEKNIT....VSPER..	: 81
_gb_ABC26396.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPERA..	: 100
_gb_AAQ16177.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_AAQ16178.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16912.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_dbj_BAC81823.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_AAW79621.1	: -----I.S.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79622.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79627.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAU26098.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79590.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79583.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79585.1	: -----I.....VT..TIKNHTEKNITI....VSPER..	: 41
_gb_AAW79589.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_ABB16944.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_AAW79580.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_ABB43013.1	: .....A.....I.....VT..TIKNHTEKNIT..P..V..PERA..	: 50
_gb_ABC26395.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16945.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16919.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16936.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16924.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16930.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16932.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16941.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16939.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16934.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16925.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100

FIG. 5L

_gb_ABB16937.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16943.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16946.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_AAW79591.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79613.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79607.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79600.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79606.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79615.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79616.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79618.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79619.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79620.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_ABB16926.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16942.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16938.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16940.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_ABB16916.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPERA.	: 100
_gb_ABB16923.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPERA.	: 100
_gb_ABB16922.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPERA.	: 100
_gb_ABB16927.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPERA.	: 100
_gb_ABB16928.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPERA.	: 100
_gb_ABB16920.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPERA.	: 100
_gb_ABB16917.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPKA.	: 100
_gb_ABB16918.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_AAW79739.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79740.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79679.1	: -----I.....Q..VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79682.1	: -----I.....Q..VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79683.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79719.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79692.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79693.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79694.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79723.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79724.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
gb_AAC36322.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
gb_AAC36323.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 100
_gb_AAW79684.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79687.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79688.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79691.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79710.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79714.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79716.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79715.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79729.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79731.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAW79628.1	: -----I.....VT..TIKNHTEKNIT..P..VSPERA.	: 41
_gb_AAW79712.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41
_gb_AAK49106.1	: .....A.....I.....VT..TIKNHTEKNIT....VSPER..	: 89
_gb_AAW79720.1	: -----I.....VT..TIKNHTGKNIT....VSPER..	: 41
_gb_AAW79722.1	: -----I.....VT..TIKNHTGKNIT....VSPER..	: 41
_gb_AAW79727.1	: -----I.....VT..TIKNHTEKNIT....VSPER..	: 41

FIG. 5M

```

RSV_G Long Strain : FSNLSEITSQTTTILASTTPGVKSNLQPTTVKTKNTTTTQTQPSKPTTKQ : 150
dbj_BAE96917.1 : P.KQPTA.PPIH.NS..I..NT..KTHH..AQ..SR...P..N.....P : 150
_gb_AAW79669.1 : P.KQPTA.PPIH.NS..I..NT..KTHH..AQ..SR...P..NN.....L : 91
_gb_AAW79670.1 : P.KQPTA.PPIH.NS..I..NT..KTHH..AQ..SR...L..NN.....P : 91
_gb_AAW79661.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..SR...P..NN.....P : 91
_gb_AAW79668.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..SR...P..NN.....P : 91
_gb_AAW79671.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..SR...P..NN.....P : 91
_gb_AAW79672.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..SR...P..NN.....P : 91
_gb_AAW79676.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..SR...P..NN.....P : 91
_gb_AAR86179.1 : P.KQPTT.QPIH.NS..I..NT..ETHH..EQ..SR...P..NN.....NP : 134
_gb_AAR86180.1 : P.KQPTT.QPIH.NS..I..NT..ETHH..EQ..SR...P..NN.....P : 134
_gb_AAW79647.1 : P.KQPTT.QPIH.NS..I..NT..ETHH..EQ..SR...P..NN.....P : 91
_gb_AAW79629.1 : P.TQPTT.PPIH.NS..I..NT..ETHH..AQ..SR...P..NN.....P : 91
_gb_AAW79643.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..SR...P..NN.....P : 91
_gb_AAW79644.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..SR...P..NN.....P : 91
_gb_AAW79645.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..SR...P..NN.....P : 91
_gb_AAW79677.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..SR...P..NN.....P : 91
_gb_AAW79646.1 : T.KQPTT.PPIH.NS..I..NT..ETHH..AQ...R...P..NN.....P : 91
_gb_AAW79655.1 : P..QPTT.PPIH.NS..I..NT..ETHH..AQ...R...P..NN.....P : 91
_gb_AAW79657.1 : P..QPTT.PPIH.NS..I..NT..ETHH..AQ...R...P..NN.....P : 91
_gb_AAW79658.1 : P..QPTT.PPIH.NS..I..NT..ETHH..AQ...R...P..NN.....P : 91
_gb_AAW79648.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P : 91
_gb_AAW79649.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P : 91
_gb_AAW79653.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P : 91
_gb_AAW79659.1 : P.KQPTT.PPIH.NSV.I..NT..ETHH..AQ..GR...P..NN.....P : 91
_gb_AAW79695.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P : 91
_gb_AAW79704.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P : 91
_gb_AAW79707.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P : 91
_gb_AAW79702.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P : 91
_gb_AAW79709.1 : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.Q...P : 91
6_gb_ABH00984.1 : F...GTI...A...P...S.EPI..S.....I...L.... : 150
_gb_AAM68156.1 : F...GTI...A...P...S.EPI..S.....I...L.... : 150
_gb_AAS90859.1 : F...GTI...A...P..SS.EPI..S.....I...L.... : 103
_gb_AAM68159.1 : F...GTI...A...P...S.EPI..S.....I...L.... : 150
_gb_AAS90857.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 103
_gb_AAS90858.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 103
_gb_AAS90861.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 102
_gb_AAS90871.1 : LF...GTI...A.P.P...S.EPIP.S.....I...L.... : 97
_gb_AAU26087.1 : LF...GTI...A.P.P...S.EPIP.S.....IR...L.... : 104
_gb_AAU26088.1 : LF...GTI...A.P.P...S.EPIP.S.....IR...L.... : 104
_gb_AAS90925.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 100
_gb_AAS90926.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 98
_gb_AAS90907.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 101
_gb_AAX08080.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 104
_gb_AAS90936.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 103
_gb_AAU26084.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 104
_gb_AAS90938.1 : LF...GTI.....P.P.I.S.EPIP.S.....I...L.... : 102
_gb_AAU26092.1 : LF...GTI.....P.P...S.EPIP.S.....I.L.L.... : 104
_gb_AAU26093.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 104
_gb_AAS90912.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 103
_gb_AAS90906.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 103
_gb_AAS90914.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 103
_gb_AAS90878.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 103
_gb_AAU26095.1 : LF...GTI.....P.P...S.EPIP.S.....I...L.... : 105

```

# FIG. 5N

_gb_AAX08081.1_	: LF...GTI.....P.P...S.EPIP.S.....I....L....	: 102
_gb_AAU26085.1_	: LF...GTI.....P.P...S.EPIP.S.....I....L....	: 101
_gb_AAU26086.1_	: LF...GTI.....P.P...S.EPIP.S.....I....L....	: 105
_gb_AAU26091.1_	: LF...GTI.....P.P...S.EPIP.S.....I....L....	: 102
_gb_AAU26090.1_	: LF...GTI.....P.P...S.EPIP.S.....I....L....	: 103
_gb_AAS90882.1_	: LF...GTI.....P.P...S.EPIP.S.....I....L....	: 101
_gb_AAS90874.1_	: LF...GTI.....P.P...S.EPIP.S.....I....LI...	: 103
_gb_AAS90928.1_	: LF...GTI.....P.P...S.EPIP.S.....I....LI...	: 102
_gb_AAX08082.1_	: LF...GTI.....P.P...S.EPIP.S.....I....LI...	: 105
_gb_AAX08084.1_	: LF...GTI.....P.P...S.EPIP.S.....I....LI...	: 105
_gb_AAS90886.1_	: LF...GTI.....P.P...S.EPIP.S.....I....LI...	: 103
_gb_AAS90922.1_	: LF...GTI.....P.P...S.EPIP.S.....I....L....	: 103
_gb_AAS90919.1_	: LF...GTI.....P.P...S.EPIP.S.....I....L....	: 103
_gb_AAT80628.1_	: .F...GTI...A...L...S.E.I...S.....I.....	: 150
sp_P27024_VGLG_HRSV5:	.F...GT...A...L...S.E.I...S.....I.....	: 150
mb_CAA51763.1_	: .F...GT...A...L...S.E.I...S.....I.....	: 148
emb_CAA83899.1_	: .F...GT...A...L...S.E.I...S.....I.....	: 150
gb_AAF23741.1_	: .F...GT...A...L...S.E.I...S.....I.....	: 131
gb_AAC36325.1_	: .F...GN...A...L...S.E.I...S.....I.....	: 150
mb_CAA83877.1_	: .F...GN...A...L...S.E.I...S.....I.....	: 150
mb_CAA83862.1_	: .F...GN...A...L...S.E.I...S.....I.....	: 150
mb_CAA83857.1_	: .F...GN...A...L...S.E.I...S.....I.....	: 150
mb_CAA83866.1_	: .F...GT...A...L...S.E.I...S.....I.....	: 150
mb_CAA83873.1_	: .F...GT...A...L...S.E.I...S.....I.....	: 150
gb_AAF23727.1_	: .F...GT...A...L...S.E.I...S.....I.....	: 131
gb_AAF23733.1_	: .F...GT...A...L...S.E.I...S.....I.....	: 131
mb_CAA83861.1_	: .F...GT...A...L...S.E.I...S.....I.....	: 150
mb_CAA83900.1_	: .F...GT...A...L...S.E.I...S.....I.....	: 150
_gb_AAO14878.2_	: .F...GT...A...L...S.E.I...S.....I.....	: 150
gb_AAD02942.1_	: .F...T.....S.E.T...S.....I.....	: 150
gb_AAD02945.1_	: .F...T.....S.E.T...S.....I.....	: 145
gb_AAC57026.1_	: .....T.....S...T...S.....KI.....	: 150
ref_NP_044595.1_	: .....T.....S...T...S.....KI.....	: 150
gb_AAF23729.1_	: .....T.....S.E.T.L.....I...LA...	: 131
gb_AAF23731.1_	: .....T.....S.E.T.L.....I...A...	: 131
gb_AAC36324.1_	: .....T.....S.E.T.LS.....L.....	: 150
sp_P27023_VGLG_HRSV4:	.....T...P..TP.L...SA..TP.S.....I.....	: 150
sp_P27025_VGLG_HRSV6:	.....T...P..TP.P...SAE.TP.S.....I.....	: 150
gb_AAF23736.1_	: .....T...P..TP.L...SAE.TP.S.....K...I.....	: 131
gb_AAF23728.1_	: .....T...P..TP.L...SAE.TP.S.....I.....	: 131
gb_AAF23735.1_	: .....T...P..TP.L...SAE.TP.S.....I.....	: 131
gb_AAF23732.1_	: .....T...P..TP.L...SAE.TP.S...E.....I.....	: 131
gb_AAD02946.1_	: .....T...P..TP.L...SAE.TP.S.....I.....	: 145
gb_AAF23743.1_	: .....T...P..TP.LA...SAE.TP.S.....I.....	: 131
gb_AAF23749.1_	: .....T...P..TP.LA...SAE.TP.S.....I.....	: 131
gb_AAF23745.1_	: .....T...P..TP.LA...SAE.TP.S...P.K...I.....	: 131
sp_P27026_VGLG_HRSV7:	.....T...PA.TP.L...SAE.TP.S.....I.....	: 150
mb_CAA83863.1_	: .....T...P..TP.L...SAE.TP.S.....I.T.....	: 150
mb_CAA83878.1_	: .....T...P..TP.L...SAE.TP.S.....I.T.....	: 150
mb_CAA83860.1_	: .....T...P..TP.L...SAE.TP.S.....I.T.....	: 150
_gb_AAM68153.1_	: .....T...PI..P...SAE.TP.S...I.....M.....	: 150
_gb_AAS90864.1_	: .....T...PI.....SAE.TP.S...I.....M.....	: 103
_gb_AAS90905.1_	: .....T...PI.....SAE.TP.S...I.....M.....	: 97
_gb_AAS90931.1_	: .....T...PI.....SAE.TP.S...I.....M.....	: 101
_gb_AAS90892.1_	: .....T...PI.....SAE.TP.S...I.....M.....	: 103



# FIG. 5P

```

sp_P27022_VGLG_HRSV3: P..P.D...LI....D.....T..S...G.....A..N..... : 150
mb_CAA51765.1_      : P..P.D...LI....D.....T..S...G.....A..N..... : 148
gb_AAD02944.1_     : P..P.....LI....D.....T..S...G.....A..N..... : 145
mb_CAA83874.1_     : P..P.....LI..T.D.....T..S...G.....A..N..... : 150
gb_AAC36327.1_     : P..P.....LI....D.....T..S...G.....A..N..... : 150
mb_CAA83875.1_     : P..P.....LI....D.....T..S...G.....A..N..... : 150
sp_P03423_VGLG_HRSVA: P..P.....I.....T..S..... : 150
gb_AAD02943.1_     : P.KP.....I.....T..S.....I.A..... : 145
sp_P20896_VGLG_HRSV1: S.KQPTT..PIH.NS..I..NT..ETHH..AQ..GRI..S..TN.....S : 150
sp_P23041_VGLG_HRSV8: S.KQPTT..PIH.NS..I..NT..ETHH..AQ..GRI..S..TN.....S : 150
_gb_AAR14265.1_    : S.IQPTT..PIH.NS..I..NT..ETHH..TQA.SRI..S..TN.....S : 150
_gb_ABC26397.1_    : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GRF..P..TN.....P : 150
_gb_ABC26398.1_    : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GRI..P..TN.....P : 150
gb_AAC36320.1_     : S.KQPTT..P.H.DS....NT..ETHH..AQ.P.SR...S..TK.....P : 150
_gb_AAW79749.1_    : S.KQPTT..PIH.NS....NT..ETHH..AQ..GR...S..TN.....P : 91
_gb_AAW79750.1_    : S.KQPTT..PIH.NS....NT..ETHH..AQ..GR...S..TN.....P : 91
_gb_AAW79751.1_    : S.KQPTT..PIH.NS....NT..ETHH..AQ..GR...S..TN.....P : 91
_gb_AAW79752.1_    : S.KQPTT..PIH.NS....NT..ETHH..AQ..GR...S..TN.....P : 91
ref_NP_056862.1_   : S.KQPTT..PIH.NS....NT..ETHH..AQ..GR...S..TN.....P : 150
_gb_AAW79753.1_    : S.KQPTT.LPIH.NS....NT..ETHH..AQ..GR...S..TN.....P : 91
_gb_AAW79754.1_    : S.KQPTT..PIH.SS....NT..ETHH..AQ..GR...S..TN.....P : 91
_gb_AAW79755.1_    : S.KQPTT..PIH.SS....NT..ETHH..AQ..GR...S..TN.....P : 91
_gb_AAW79756.1_    : S.KQPTT..PIH.NS....ST..ETHH..AQ..GR...S..TN.....P : 91
_gb_AAK31912.1_    : P.KQPTT..PIH.NSV.I..NT..ETHH..AQ..GR...P..TN.....P : 139
_gb_AAK37424.1_    : P.KQPTT..PIH.NSV.I..NT..ETHH..AQ..GR...P..TN.....P : 139
_gb_AAW79743.1_    : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..TN.....P : 91
_gb_AAW79744.1_    : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..TN.....P : 91
gb_AAF20082.1_     : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..TN.....P : 131
gb_AAF20084.1_     : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..TN.....P : 131
gb_AAF20085.1_     : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..TN.....P : 131
_gb_AAW79741.1_    : P.KQPTT..PIHINS..I..NT..ETHH..AQ..GR...P..TN.....P : 91
_gb_AAW79742.1_    : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..TN.....P : 91
gb_AAF20081.1_     : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..TN.....P : 131
gb_AAF20091.1_     : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..TN.....P : 131
gb_AAC36321.1_     : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..TN.....P : 150
_gb_AAW79745.1_    : P.KQPTT..PIH.NS..I..NT..ETYH..AQ..GR...P..TN.....P : 91
_gb_AAW79746.1_    : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..TN.....P : 91
gb_AAF20083.1_     : P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...L..TN.....P : 131
_gb_AAQ16176.1_    : P.KQPTT.LPIH.NS..I..NT..ETHH..AQ..GII..P..TN.....P : 150
_gb_AAW79759.1_    : P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GI.....TN.....P : 91
_gb_AAR86181.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN.....P : 134
_gb_AAU26097.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN.....P : 101
_gb_AAU26099.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN.....P : 94
_gb_AAX08076.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN.....P : 95
_gb_AAX08079.1_    : P.KQPTT.PPIH.NST.I..NT..KKHH..AQ..GR...S..TN.....P : 94
_gb_AAX08078.1_    : P.KQPTT.PPIH.NST....NT..PEKHH..AQ..GR...S..TN.....P : 94
_gb_AAU26101.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN.....P : 98
_gb_AAW79767.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN.....P : 91
_gb_AAS90851.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..EQ..GR...S..TN.....P : 102
_gb_AAS90852.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN.....P : 101
_gb_AAS90853.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN.....P : 102
_gb_AAS90856.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN.....P : 99
_gb_AAW79761.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN.....P : 91
_gb_AAW79762.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN.....P : 91
_gb_AAW79765.1_    : P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN.....P : 91

```

FIG. 5Q

__gb_AAW79763.1	: P.KQPTT.PPIH.NST.I..NT..EKHH..AQ..GR...S..TN..N..P	: 91
__gb_AAW79764.1	: P.KQPTT.PPIH.NST.I..NT..EEHH..AQ..GR...S..TN..N..P	: 91
__gb_AAW79768.1	: P.KQPTT.PPIH.NST.I..NT..ETHH..AQ..GR...S..TN....P	: 91
__gb_AAW79769.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..TN....P	: 91
__gb_AAW79748.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P.LTN....P	: 91
__gb_AAW79772.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..TN....P	: 91
__gb_AAW79777.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..TN....P	: 91
__gb_AAW79778.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...PA.TN....P	: 91
__gb_AAR00216.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..TN....P	: 150
__gb_AAR00220.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
__gb_AAR00217.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..TK....P	: 150
__gb_AAR00219.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..TK....P	: 150
__gb_AAR00218.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
__gb_AAW79733.1	: P.KQPTT..SIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 91
__gb_AAW79734.1	: P.KQPTT..SIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 91
__gb_AAW79738.1	: P.KQPTT..SIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 91
gb_AAF20090.1	: P.KQPTT..SIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 131
gb_AAF20087.1	: P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 131
gb_AAF20086.1	: P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 131
gb_AAF20088.1	: P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 131
gb_AAF20089.1	: P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 131
gb_ABC26396.1	: P.KQPTT.PPIH.NS....NT..ETHH..AQ..GR...P..NN....P	: 150
gb_AAQ16177.1	: P.KQLTT.PPIY.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
gb_AAQ16178.1	: P.KQPTT.PPIY.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
gb_ABB16912.1	: P.KQPTT.PPIY.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
dbj_BAC81823.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
__gb_AAW79621.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P.RNN....P	: 91
__gb_AAW79622.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P.RNN....P	: 91
__gb_AAW79627.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 91
__gb_AAU26098.1	: P.KQPTT.PPIH.NS..L..NT..ETHH..AQ..GR...P..NN....P	: 91
__gb_AAW79590.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 91
__gb_AAW79583.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 91
__gb_AAW79585.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 91
__gb_AAW79589.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 91
__gb_ABB16944.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
__gb_AAW79580.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 91
__gb_ABB43013.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 100
__gb_ABC26395.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
__gb_ABB16945.1	: P.KQPTT.PPIH.NS..I..NT.PETHH..AQ..GR...P..NN....P	: 150
__gb_ABB16919.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
__gb_ABB16936.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
__gb_ABB16924.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
__gb_ABB16930.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..A...GR...P..NN....P	: 150
__gb_ABB16932.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..A...GR...P..NN....P	: 150
__gb_ABB16941.1	: P.KQPTT.PPIH.NS..I..NT.PETHH..A...GR...P..NN....P	: 150
__gb_ABB16939.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..A...GR...P..NN....P	: 150
__gb_ABB16934.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..A...GR...P..NN....P	: 150
__gb_ABB16925.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
__gb_ABB16937.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
__gb_ABB16943.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
__gb_ABB16946.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 150
__gb_AAW79591.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 91
__gb_AAW79613.1	: P.KQPTT.PPIH.NS..I..LNT..ETHH..AQ..GR...P..NN....P	: 91
__gb_AAW79607.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN....P	: 91



# FIG. 5R

_gb_AAW79600.1	: P.KQPTT.PPIH.NST.I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79606.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79615.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79616.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79618.1	: P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79619.1	: P.KQPTT..PIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79620.1	: P.KQPTT.PPIR.NS..I..NT..ETHH..AQ.EGR...P..NN.....P	: 91
_gb_ABB16926.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_ABB16942.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_ABB16938.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_ABB16940.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_ABB16916.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_ABB16923.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_ABB16922.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_ABB16927.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_ABB16928.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_ABB16920.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_ABB16917.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_ABB16918.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_AAW79739.1	: P.KQPTT.PPIH.NS..I..NT..ETHH.AAQ..GRI..P..NN.....P	: 91
_gb_AAW79740.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79679.1	: P.KQPT..PPIQ.NS..I..NT..ETHH..AQ..GR...PI.NN.....P	: 91
_gb_AAW79682.1	: P.KQPT..PPIQ.NS..I..NT..ETHH..AQ..GR...LI.NN.....P	: 91
_gb_AAW79683.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79719.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79692.1	: P.KQPTT.PPIHINS..I..NT..ETHH..AQ..GR...P..NK.....P	: 91
_gb_AAW79693.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..A..GR...P..NN.....P	: 91
_gb_AAW79694.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79723.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79724.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAC36322.1	: P.KQPTT.PPIH.NSTII..NT..ETHH..AQ..GR.I.P..NN.....P	: 150
_gb_AAC36323.1	: P.KQPTT.PPIH.NST.I..NT..ETHH..AQ..GR...P..NN.....P	: 150
_gb_AAW79684.1	: P..QPTT.PPIH.NST.I.LNT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79687.1	: P..PTT.PPIH.NST.I..NT..ETHH..AQ..GRI..P..NN.....P	: 91
_gb_AAW79688.1	: P..QPTT.PPIH.NST.I..NT..ETHH..AQ..GRI..P..NN.....P	: 91
_gb_AAW79691.1	: P..QPTT.PPIH.NST.I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79710.1	: P.KQPTT.PSIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79714.1	: P.KQPTT.PPIH.NS..I.SNT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79716.1	: P.KQPTT.PPIH.NS..I.SNT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79715.1	: P.KQPTT.PPIH.NS..I.SNT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79729.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79731.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79628.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79712.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAK49106.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 139
_gb_AAW79720.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79722.1	: P.KQPTT.PPIH.NS..V..NT..ETHH..AQ..GR...P..NN.....P	: 91
_gb_AAW79727.1	: P.KQPTT.PPIH.NS..I..NT..ETHH..AQ..GR...P..NN.....P	: 91

**FIG. 5S**

RSV_G Long Strain	: RQNKPPNKPNDFHFEVFNFPVPCISCSNNPTCWAICKRIPNK--KPGKKT	: 198
dbj_BAE96917.1	: HSKN..K..K.....C..G..QL.KS...T..SN--..K..P	: 198
_gb_AAW79669.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79670.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79661.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79668.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79671.1	: .PKS..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79672.1	: .PKS..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79676.1	: .PKS..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAR86179.1	: .PKN..K..K..H.....G..QL.KS...T..SN--..K..P	: 182
_gb_AAR86180.1	: .PKN..K..K..H.....G..QL.KS...T..SN--..K..P	: 182
_gb_AAW79647.1	: .PKN..K..K..H.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79629.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79643.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79644.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79645.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79677.1	: .PKS..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79646.1	: .PKN..K..K..R.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79655.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79657.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79658.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79648.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79649.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79653.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79659.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79695.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79704.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79707.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79702.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79709.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_ABH00984.1	: .....K.....R.....S.--.....N.	: 198
_gb_AAM68156.1	: .....S.--.....	: 198
_gb_AAS90859.1	: .....S.--.....	: 151
_gb_AAM68159.1	: .....S.--.....	: 198
_gb_AAS90857.1	: .....S.--.....	: 151
_gb_AAS90858.1	: .....S.--.....	: 151
_gb_AAS90861.1	: .....S.--.....	: 150
_gb_AAS90871.1	: .....S.--.....	: 145
_gb_AAU26087.1	: .....S.--.....	: 152
_gb_AAU26088.1	: .....S.--.....	: 152
_gb_AAS90925.1	: .....S.--.....	: 148
_gb_AAS90926.1	: .....S.--.....	: 146
_gb_AAS90907.1	: .....S.--.....	: 149
_gb_AAX08080.1	: .....S.--.....	: 152
_gb_AAS90936.1	: .....S.--.....	: 151
_gb_AAU26084.1	: .....S.--.....	: 152
_gb_AAS90938.1	: .....S.--.....	: 150
_gb_AAU26092.1	: .....S.--.....	: 152
_gb_AAU26093.1	: .....S.--.....	: 152
_gb_AAS90912.1	: .....S.--.....	: 151
_gb_AAS90906.1	: .....S.--.....	: 151
_gb_AAS90914.1	: .....R.....S.--.....	: 151
_gb_AAS90878.1	: .....S.--.....	: 151
_gb_AAU26095.1	: .....S.--.....	: 153

**FIG. 5T**

_gb_AAX08081.1_	:	.....S.--.....	: 150
_gb_AAU26085.1_	:	.....S.--.....	: 149
_gb_AAU26086.1_	:	.....S.--.L....	: 153
_gb_AAU26091.1_	:	.....S.--.....	: 150
_gb_AAU26090.1_	:	.....S.--.....	: 151
_gb_AAS90882.1_	:	.....S.--.....	: 149
_gb_AAS90874.1_	:	.....S.--.....	: 151
_gb_AAS90928.1_	:	.....S.--.....	: 150
_gb_AAX08082.1_	:	.....S.--.....	: 153
_gb_AAX08084.1_	:	.....S.--.....	: 153
_gb_AAS90886.1_	:	.....S.--.....	: 151
_gb_AAS90922.1_	:	.....S.--.....	: 151
_gb_AAS90919.1_	:	.....S.--.....	: 151
_gb_AAT80628.1_	:	.....S.--.....	: 198
sp_P27024_VGLG_HRSV5:	:	.....S.--.....	: 198
emb_CAA51763.1_	:	.....S.--.....	: 196
emb_CAA83899.1_	:	.....S.--.....	: 198
gb_AAF23741.1_	:	.....S.--.....	: 179
gb_AAC36325.1_	:	.....D.....S.--.....	: 198
mb_CAA83877.1_	:	.....S.--.....	: 198
mb_CAA83862.1_	:	.....S.--.....	: 198
mb_CAA83857.1_	:	.....S.--.....	: 198
mb_CAA83866.1_	:	.....S.--.....	: 198
mb_CAA83873.1_	:	H.....S.--.....	: 198
gb_AAF23727.1_	:	H.....S.--.....	: 179
gb_AAF23733.1_	:	H.....S.--.....	: 179
mb_CAA83861.1_	:	.....S.--.....	: 198
mb_CAA83900.1_	:	.....S.--.....	: 198
gb_AAO14878.2_	:	H.....S.--.....	: 198
gb_AAD02942.1_	:	.....S.--.....	: 198
gb_AAD02945.1_	:	.....S.--.....	: 193
gb_AAC57026.1_	:	.....S.--.....	: 198
ref_NP_044595.1_	:	.....S.--.....	: 198
gb_AAF23729.1_	:	.....S.--.....	: 179
gb_AAF23731.1_	:	.....S.--.....	: 179
gb_AAC36324.1_	:	.H.....S.--.....	: 198
sp_P27023_VGLG_HRSV4:	:	..K.....S.--.....	: 198
sp_P27025_VGLG_HRSV6:	:	.....S.--.....	: 198
gb_AAF23736.1_	:	.....S.--.....	: 179
gb_AAF23728.1_	:	.....S.--.....	: 179
gb_AAF23735.1_	:	.....S.--.....	: 179
gb_AAF23732.1_	:	.....S.--.....	: 179
gb_AAD02946.1_	:	.....S.--.....	: 193
gb_AAF23743.1_	:	.....S.--.....	: 179
gb_AAF23749.1_	:	.....S.--.....	: 179
gb_AAF23745.1_	:	.L.....E.....S.--.....	: 179
sp_P27026_VGLG_HRSV7:	:	H.....H.....S.--.....	: 198
emb_CAA83863.1_	:	.....NK.....S.--.....	: 200
emb_CAA83878.1_	:	.....S.--.....	: 198
emb_CAA83860.1_	:	.....S.--.....	: 198
_gb_AAM68153.1_	:	.....Q.....S.--.....	: 198
_gb_AAS90864.1_	:	.....Q.....S.--.....	: 151
_gb_AAS90905.1_	:	.....Q.....S.--.....	: 145
_gb_AAS90931.1_	:	.....Q.....S.--.....	: 149

FIG. 5U

_gb_AAS90892.1_	: .....Q.....	--.....	: 151
_gb_AAX08086.1_	: .....Q.....	--.....	: 151
_gb_AAS90880.1_	: .....Q.....	--.....	: 151
_gb_AAS90929.1_	: .....Q.....	--..A..	: 151
_gb_AAS90898.1_	: .....Q.....	--.....	: 151
_gb_AAQ24136.1_	: .....Q.....	--.....	: 198
_gb_AAQ24143.1_	: .....Q.....	--.....	: 198
_gb_AAQ24139.1_	: .....Q.....	--.....	: 198
_gb_AAQ24141.1_	: .....Q.....	--.....	: 198
_gb_AAQ24137.1_	: .....Q.....	--.....	: 198
_gb_AAS90863.1_	: .....Q.....	--.....	: 151
_gb_AAS90924.1_	: .....Q.....	--.....	: 151
_gb_AAS90921.1_	: .....Q.....	--.....	: 151
_gb_AAS90927.1_	: .....Q.....	--.....	: 151
_gb_AAQ24138.1_	: .....Q.....	--.....	: 198
_gb_AAQ24140.1_	: .....Q.....	--.....	: 198
_gb_AAS90867.1_	: .....Q.....	--..E..	: 151
_gb_AAS90884.1_	: .....Q.....	--..E..	: 151
_gb_AAS90885.1_	: .....Q.....	--..E..	: 151
_gb_AAF23746.1_	: .....Q.....	--.....	: 179
_gb_AAF23747.1_	: .....Q.....	--.....	: 179
_gb_AAF23748.1_	: .....Q.....	--.....	: 179
_gb_AAU43726.1_	: .....Q.....	--.....	: 198
_gb_AAU43727.1_	: .....Q.....	--.....	: 198
_gb_AAM44850.2_AF51	: .....Q.....	--.....	: 198
_gb_AAF23730.1_	: .....Q.....	--.....	: 179
_gb_AAF23737.1_	: .....Q.....	--.....	: 179
_mb_CAA83867.1_	: .....Q.....	--.....	: 198
_mb_CAA83865.1_	: .....Q.....	--.....	: 198
_mb_CAA83868.1_	: .....Q.....	--.....	: 198
_gb_AAC36326.1_	: .....Q.....	--.....	: 198
_gb_AAC36328.1_	: .....Q.....	--.....	: 198
_gb_AAF23738.1_	: .....Q.....	--.....	: 179
_gb_AAF23734.1_	: .....Q.....	--.....	: 179
_gb_AAQ24144.1_	: .....Q.....	--.....	: 198
_gb_AAQ24145.1_	: .....Q.....	--.....	: 198
_gb_AAF23744.1_	: .....Q.....	--..R..	: 179
_mb_CAA83858.1_	: .....Q.....	--.....	: 198
_gb_AAU43729.1_	: .....Q.....	--.....	: 198
_gb_AAS90862.1_	: .....Q.....	--.....	: 151
_gb_AAS90913.1_	: .....Q.....	--.....	: 151
_mb_CAA83869.1_	: .....Q.....	--.....	: 198
_mb_CAA83859.1_	: .....Q.....	--.....	: 198
_gb_AAF23740.1_	: .....Q.....	--.....	: 179
_gb_AAF23742.1_	: .....Q.....	--.....	: 179
_mb_CAA83879.1_	: .....Q.....	--.....	: 198
_mb_CAA83864.1_	: .....Q.....	--.....	: 198
_gb_AAF23739.1_	: .....Q.....	--.....	: 179
_sp_P20895_VGLG_HRSV	: .....S.....	--.....	: 198
_mb_CAA83872.1_	: .....Q.....	--.....	: 198
_b_CAA34937.1_	: .....Q.....	--.....	: 198
_gb_AAX23993.1_	: .....Q.....	--.....	: 198
_sp_P27021_VGLG_HRSV2	: .....S.....	--.....	: 198
_gb_AAD02941.1_	: .....S.....	--.....	: 198

# FIG. 5V

mb_CAA83870.1_	:	.....S.....	--.....	: 198
mb_CAA83871.1_	:	.....S.....	--.....	: 198
sp_P27022_VGLG_HRSV3:	:	.....S.....	--.....	: 198
mb_CAA51765.1_	:	.....S.....	--.....	: 196
gb_AAD02944.1_	:	.....S.....	--.....	: 193
mb_CAA83874.1_	:	.....S.....	--.....	: 198
gb_AAC36327.1_	:	...T..S.....	--.....	: 198
mb_CAA83875.1_	:	.....S.....	--.....	: 198
sp_P03423_VGLG_HRSVA:	:	.....S.....	--.....	: 198
gb_AAD02943.1_	:	.....S.....	--.....	: 193
sp_P20896_VGLG_HRSV1:	:	.SKN..K..K.....G..QL.KS...T..SN--..K..P		: 198
sp_P23041_VGLG_HRSV8:	:	.SKN..K..K.....G..QL.KS...T..SN--..K..P		: 198
_gb_AAR14265.1_	:	.SKN..K..K.....G..QL.KS...T..SN--..K..P		: 198
_gb_ABC26397.1_	:	.PKI..K.--.....G..RL.KS...T..SN--..K..P		: 196
_gb_ABC26398.1_	:	.PKI..K.--.....G..RL.KS...T..SN--..K..P		: 196
_gb_AAC36320.1_	:	.PKS..K..K.....G..QL.KS...T..SN--..K..P		: 198
_gb_AAW79749.1_	:	.LKN..K..K.....G..QL.KS...T..SN--..K..P		: 139
_gb_AAW79750.1_	:	.LKN..K..K.....G..QL.KS...T..SN--..K..P		: 139
_gb_AAW79751.1_	:	.LKN..K..K.....G..QL.KS...T..SN--..K..P		: 139
_gb_AAW79752.1_	:	.LKN..K..K.....G..QL.KS...T..SN--..K..P		: 139
ref_NP_056862.1_	:	.LKN..K..K.....G..QL.KS...T..SN--..K..P		: 198
_gb_AAW79753.1_	:	.PKN..K..K..H.....G..QL.KS...T..SN--..K..P		: 139
_gb_AAW79754.1_	:	.PKN..K.--.....G..QL.KS...T..SN--..K..P		: 137
_gb_AAW79755.1_	:	.PKN..K.--.....G..QL.KS...T..SN--..K..P		: 137
_gb_AAW79756.1_	:	.LKN..K.--.....G..QL.KS...T..SN--..K..P		: 137
_gb_AAK31912.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 187
_gb_AAK37424.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 187
_gb_AAW79743.1_	:	HPKI..K..K.....G..QL.KS...T..SN--..K..P		: 139
_gb_AAW79744.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 139
gb_AAF20082.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 179
gb_AAF20084.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..L		: 179
gb_AAF20085.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 179
_gb_AAW79741.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 139
_gb_AAW79742.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 139
gb_AAF20081.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 179
gb_AAF20091.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 179
gb_AAC36321.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 198
_gb_AAW79745.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 139
_gb_AAW79746.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 139
gb_AAF20083.1_	:	.PKI..K..K.....G..QL.KS...T..SN--..K..P		: 179
_gb_AAQ16176.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 198
_gb_AAW79759.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 139
_gb_AAR86181.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 182
_gb_AAU26097.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 149
_gb_AAU26099.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 142
_gb_AAX08076.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 143
_gb_AAX08079.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 142
_gb_AAX08078.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 142
_gb_AAU26101.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 146
_gb_AAW79767.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 139
_gb_AAS90851.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 150
_gb_AAS90852.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 149
_gb_AAS90853.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 150
_gb_AAS90856.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 147
_gb_AAW79761.1_	:	.PKN..K..K.....G..QL.KS...T..SN--..K..P		: 139

FIG. 5W

_gb_AAW79762.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79765.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79763.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79764.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79768.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79769.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79748.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79772.1	: .PKN..K..K.....G..QL.KS.....SN--..K..P	: 139
_gb_AAW79777.1	: .PKN..K..K.....G..QL.KS.....SN--..K..P	: 139
_gb_AAW79778.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAR00216.1	: .PKS..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_AAR00220.1	: .PKS..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_AAR00217.1	: .PKS..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_AAR00219.1	: .PKS..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_AAR00218.1	: .PKS..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_AAW79733.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79734.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79738.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAF20090.1	: .PKN..K..K.....G..KL.KS...T..SN--..K..P	: 179
_gb_AAF20087.1	: .PKN..K..K.....G..KL.KS...T..SN--..K..P	: 179
_gb_AAF20086.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 179
_gb_AAF20088.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 179
_gb_AAF20089.1	: .PKN..K.LK.....G..QL.KS...T..SN--..K..P	: 179
_gb_ABC26396.1	: .PKN..K..K.....G..QL.RS...T..SN--..K..P	: 198
_gb_AAQ16177.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_AAQ16178.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16912.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_dbj_BAC81823.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_AAW79621.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79622.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79627.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAU26098.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79590.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_AAW79583.1	: .PKN..K--K.....G..QL.KS...T..SN--..K..P	: 137
_gb_AAW79585.1	: .PKN..K--K.....G..QL.KS...T..SN--..K..P	: 137
_gb_AAW79589.1	: .PKN..K--K.....G..QL.KS...T..SN--..K..P	: 137
_gb_ABB16944.1	: .PKN..K.--.....G..QL.KS...T..SN--..K..P	: 196
_gb_AAW79580.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139
_gb_ABB43013.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 148
_gb_ABC26395.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16945.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16919.1	: HPKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16936.1	: HPKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16924.1	: HPKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16930.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16932.1	: .LKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16941.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16939.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16934.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16925.1	: HPKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16937.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16943.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_ABB16946.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 198
_gb_AAW79591.1	: .PKN..K..K.....G..QL.KS...T..SN--..K..P	: 139

FIG. 5X

```

_gb_AAW79613.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79607.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79600.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79606.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79615.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79616.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79618.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79619.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79620.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_ABB16926.1 : .PKN..K..K.....G..QL.KS...T..N--..K..P : 198
_gb_ABB16942.1 : .PKN..K..K.....G..QL.KS...T..N--..K..P : 198
_gb_ABB16938.1 : .PKN...K.....G..QL.KS...T..N--..K..P : 198
_gb_ABB16940.1 : .PKN...K.....G..QL.KS...T..N--..K..P : 198
_gb_ABB16916.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 198
_gb_ABB16923.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 198
_gb_ABB16922.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 198
_gb_ABB16927.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 198
_gb_ABB16928.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 198
_gb_ABB16920.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 198
_gb_ABB16917.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 198
_gb_ABB16918.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 198
_gb_AAW79739.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79740.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79679.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79682.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79683.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79719.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79692.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79693.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79694.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79723.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79724.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAC36322.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 198
_gb_AAC36323.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 198
_gb_AAW79684.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79687.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79688.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79691.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79710.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79714.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79716.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79715.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79729.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79731.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79628.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79712.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAK49106.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 187
_gb_AAW79720.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79722.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139
_gb_AAW79727.1 : .PKN..K..K.....G..QL.KS...T..SN--..K..P : 139

```

FIG. 5Z

RSV_G_Long Strain	: TTKPTKKPTFKTTKK-DHKPQTTKPKKE-VPTTKPTE-EPTINTTKT----	: 241
dbj_BAE96917.1	: .I...N..PT...N.R.P.TPAKTL.K-ET..N..K-K..PK..EG----	: 242
_gb_AAW79669.1	: .I...N..PT...N.R.P.TPAKTL.K-ET..N..K-K..PK..EG----	: 183
_gb_AAW79670.1	: .I...N..PT...N.R.P.TPAKTL.K-ET..N..K-K..PK..EG----	: 183
_gb_AAW79661.1	: .I...N..PT...N.R.P.TLAKTL.K-EN..N..K-K..PK..ER----	: 183
_gb_AAW79668.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 183
_gb_AAW79671.1	: .I...N..PT...N.R.P.TPAKTL.K-ET..N..K-K..SK..ER----	: 183
_gb_AAW79672.1	: .I...N..PT...N.R.P.TPAKTL.K-ET..N..K-K..SK..ER----	: 183
_gb_AAW79676.1	: .I...N..PT...N.R.P.TPAKTL.K-ET..N..K-K..SK..ER----	: 183
_gb_AAR86179.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 226
_gb_AAR86180.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 226
_gb_AAW79647.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 183
_gb_AAW79629.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 183
_gb_AAW79643.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 183
_gb_AAW79644.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 183
_gb_AAW79645.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 183
_gb_AAW79647.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 183
_gb_AAW79646.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 183
_gb_AAW79655.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 183
_gb_AAW79657.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 183
_gb_AAW79658.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..K..ER----	: 183
_gb_AAW79648.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 183
_gb_AAW79649.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER----	: 183
_gb_AAW79653.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-KL.PK..ER----	: 183
_gb_AAW79659.1	: .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PKI.ER----	: 183
_gb_AAW79695.1	: .I...N..PT...N.R.P.TLAKTL.K-EI..N..K-K..PK..GR----	: 183
_gb_AAW79704.1	: .I...N..PT...N.R.P.TLAKTL.K-EI..N..K-K..PK..GR----	: 183
_gb_AAW79707.1	: .I...N..PT...N.R.P.TLAKTL.K-EI..N..K-K..PK..GR----	: 183
_gb_AAW79702.1	: .I...N..PT...N.R.P.TLAKTL.K-EI..N..K-K..SK..GR----	: 183
_gb_AAW79709.1	: .I...N..PT...N.R.P.TLAKTL.K-EI..N..K-K..PKI.ER----	: 183
_gb_ABH00984.1	: .....Q.I.....-L.....-A.....G-K....I..P----	: 241
_gb_AAM68156.1	: .....Q.I.....-L.....-A.....-K....I..P----	: 241
_gb_AAS90859.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 194
_gb_AAM68159.1	: .....Q.I.....-L.....-A.....-K....I..P----	: 241
_gb_AAS90857.1	: .....Q.I.....-I.L.....-A.....-K....I..P----	: 194
_gb_AAS90858.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 194
_gb_AAS90861.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 193
_gb_AAS90871.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 188
_gb_AAU26087.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 195
_gb_AAU26088.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 195
_gb_AAS90925.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 191
_gb_AAS90926.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 189
_gb_AAS90907.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 192
_gb_AAX08080.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 195
_gb_AAS90936.1	: .....Q.I.....-I.....-A.....-K.I..I..P----	: 194
_gb_AAU26084.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 195
_gb_AAS90938.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 193
_gb_AAU26092.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 195
_gb_AAU26093.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 195
_gb_AAS90912.1	: .....-I.....-I.....-A.....-K....I..P----	: 193
_gb_AAS90906.1	: .....E.Q.I.....-I.....-A.....-K....I..P----	: 194
_gb_AAS90914.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 194
_gb_AAS90878.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 194
_gb_AAU26095.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 196
_gb_AAX08081.1	: .....Q.I.....-I.....-A.....-K....I..P----	: 193



FIG. 5AA

_gb_AAU26085.1	: .....	Q.I.....-I.....-A.....-K...I..P----	: 192
_gb_AAU26086.1	: .....	Q.I.....-I.....-A.....-K...I..P----	: 196
_gb_AAU26091.1	: .....	Q.I.....-I.....-A.....-K...I..P----	: 193
_gb_AAU26090.1	: .....	Q.I.....-I.....-A.....-K...I..P----	: 194
_gb_AAS90882.1	: .....	Q.I.....-I.....-A.....-K...I..P----	: 192
_gb_AAS90874.1	: .....	Q.I.....-I.....-A.....-K...I..P----	: 194
_gb_AAS90928.1	: .....	Q.I.....-I.....-A.....-K...I..P----	: 193
_gb_AAX08082.1	: .....	Q.I.....-I.....-A.....-K...I..P----	: 196
_gb_AAX08084.1	: .....	Q.I.....-I.....-A.....-K...I..P----	: 196
_gb_AAS90886.1	: .....	Q.I.....-I.....-A.....-K...I..P----	: 194
_gb_AAS90922.1	: .....	Q.I.....-I.....-A.....-K...I..P----	: 194
_gb_AAS90919.1	: .....	Q.I.....-I.....G-A.....-K...I..P----	: 194
_gb_AAT80628.1	: .....	I.....-L.....-A.....-K...I..P----	: 241
sp_P27024_VGLG_HRSV5:	.....	I.....-L.....-A.....-K...I..P----	: 241
emb_CAA51763.1	: .....	I.....-L.....-A.....-K...I..P----	: 239
emb_CAA83899.1	: .....	I.....-L.....-A.....A.-K...I..P----	: 241
gb_AAF23741.1	: .....	I.....-L.....-AS.....-K...I..P----	: 222
gb_AAC36325.1	: .....	I.....-L.....-A.....-K...I..P----	: 241
mb_CAA83877.1	: .....	I.....-L.....-A.....-K...I..P----	: 241
mb_CAA83862.1	: .....	I.....-L.....-A.....-K...I..P----	: 241
mb_CAA83857.1	: .....	I.....-L.....P.....-A.....-K...I..P----	: 241
mb_CAA83866.1	: .....	I.....-L.....-A.....-K...I..P----	: 241
mb_CAA83873.1	: .....	I.....-L.....-A.....-K...I..P----	: 241
gb_AAF23727.1	: .....	I.....-L.....-A.....-K...I..P----	: 222
gb_AAF23733.1	: .....	I.....-L.....-A.....-K...I..P----	: 222
mb_CAA83861.1	: .....	I.....-L.....-A.....-K...I..P----	: 241
mb_CAA83900.1	: .....	I.....-L.....-AL.....-K...I..P----	: 241
_gb_AAO14878.2	: .....	I.....-L.....G-AS.....-K...I..P----	: 241
gb_AAD02942.1	: .....	I.....-L.....-A.....-K.....P----	: 241
gb_AAD02945.1	: .....	I.....-L.....-A.....-K...I..P----	: 236
gb_AAC57026.1	: .....	I.....-L.....-K.....P----	: 241
ref_NP_044595.1	: .....	I.....-L.....-K.....P----	: 241
gb_AAF23729.1	: .....	T.I.....-L.....-KS.....P----	: 222
gb_AAF23731.1	: .....	T.I.....-L.....-KS.....P----	: 222
gb_AAC36324.1	: .....	T.....-L.....G-TL.....-KS...A.....P----	: 241
sp_P27023_VGLG_HRSV4:	.....	I.....-L.....-L.....-K.....P----	: 241
sp_P27025_VGLG_HRSV6:	.....	I.....-L.....-L.....-K.....P----	: 241
gb_AAF23736.1	: .....	I.....-L.....-K.....P----	: 222
gb_AAF23728.1	: .....	I.....-L.....L...-L.....-K.....P----	: 222
gb_AAF23735.1	: .....	N.....I.....-L.....L...-L.....-K.....P----	: 222
gb_AAF23732.1	: .....	I.....-L.....L...-L.....-K.....P----	: 222
gb_AAD02946.1	: .....	I.....-L.....-L.....-K.....P----	: 236
gb_AAF23743.1	: .....	I.....-L.....-L.....-K.....P----	: 222
gb_AAF23749.1	: .....	I.....-L.....-L.....-K.....P----	: 222
gb_AAF23745.1	: .....	I.....-L.....-L.....-K.....P----	: 222
sp_P27026_VGLG_HRSV7:	.....	I.....-L.....-L.....-K.....P----	: 241
emb_CAA83863.1	: .....	I.....-L.....-L.....-K.....P----	: 243
emb_CAA83878.1	: .....	I.....-F.....-L.....-K.....P----	: 241
emb_CAA83860.1	: .....	I.....-F.....-L.....-K.....P----	: 241
_gb_AAM68153.1	: .....	I.....-P.....-L.....-K.....P----	: 241
_gb_AAS90864.1	: .....	I.....-P.....-L.....-K.....P----	: 194
_gb_AAS90905.1	: .....	I.....-P.....-L.....-K.....P----	: 188
_gb_AAS90931.1	: .....	I.....-P.....-L.....-K.....P----	: 192
_gb_AAS90892.1	: .....	I.....-P.....-L.....-K.....P----	: 194

FIG. 5BB

_gb_AAX08086.1_	:	.....I.....-P.....-L.....-K.....	----	: 194
_gb_AAS90880.1_	:	.....I.....-P.....-L.....-K.....	----	: 194
_gb_AAS90929.1_	:	.....I.....-P.....-L.....-K.....	----	: 194
_gb_AAS90898.1_	:	.....I.....-P.....-L.....-K.....	----	: 194
_gb_AAQ24136.1_	:	.....I.....-P.....-L.....-K.....	----	: 241
_gb_AAQ24143.1_	:	.....I.....-P.....-L.....-K.....	----	: 241
_gb_AAQ24139.1_	:	.....I.....-P.....-L.....-R.....	----	: 241
_gb_AAQ24141.1_	:	.....I.....-P.....-L.....-R.....	----	: 241
_gb_AAQ24137.1_	:	.....I.....-P.....-L.....-K.....	----	: 241
_gb_AAS90863.1_	:	.....I.....-P..L.....-L.....-K.....	----	: 194
_gb_AAS90924.1_	:	.....I.....-P..L.....-L.....-K.....	----	: 194
_gb_AAS90921.1_	:	.....I.....-P.....-L.....-K.....	----	: 194
_gb_AAS90927.1_	:	.....I.....-P.....-L.....-K.....	----	: 194
_gb_AAQ24138.1_	:	.....I.....-P.....-L.....-K.....	----	: 241
_gb_AAQ24140.1_	:	.....I.....-P.....-AL.....-K.....	----	: 241
_gb_AAS90867.1_	:	.....T.....-P.....-AL.....-K.....	----	: 194
_gb_AAS90884.1_	:	.....T.....-P.....-AL.....-K.....	----	: 194
_gb_AAS90885.1_	:	.....T.....-P.....-AL.....-K.....	----	: 194
gb_AAF23746.1_	:	.....I.....-P.....-L.....-K.....	----	: 222
gb_AAF23747.1_	:	.....I.....-P.....-L.....-K.....	----	: 222
gb_AAF23748.1_	:	.....I.....-P.....-L.....-K.....	----	: 222
_gb_AAU43726.1_	:	.....I.....-P.....-L.....-K.....	----	: 241
_gb_AAU43727.1_	:	.....I.....-P.....-L.....-K.....	----	: 241
_gb_AAM44850.2_AF51	:	.....I.....-L.....S.....-L.....-K.....	----	: 241
gb_AAF23730.1_	:	.....I.....-L.....-L.....-K.....	----	: 222
gb_AAF23737.1_	:	.....I.....-L.....-L.A.L.....-K.....	----	: 222
emb_CAA83867.1_	:	.....I.....-L.....I.....-L.....-K.....	----	: 241
emb_CAA83865.1_	:	.....I.....-L.....-L.....-K.....	----	: 241
emb_CAA83868.1_	:	.....I.....-L.....-L.....-K.....	----	: 241
gb_AAC36326.1_	:	.....I.....-L.....-L.....S.....-K.....	----	: 241
gb_AAC36328.1_	:	.....I.....-L.....-L.....S.....-K.....	----	: 241
gb_AAF23738.1_	:	.....I.....-L.....-L.....-K.....	----	: 222
gb_AAF23734.1_	:	.....I.....-L.....-L.....-K.....	----	: 222
_gb_AAQ24144.1_	:	.....I.....-L.....-L.....-K.....	----	: 241
_gb_AAQ24145.1_	:	.....I.....-L.....-V-AL.....-K.....	----	: 241
gb_AAF23744.1_	:	.....II.....-L.....-L.....-K...S.....	----	: 222
emb_CAA83858.1_	:	.....I.....-L.....-L.....-K.....	----	: 241
_gb_AAU43729.1_	:	.....T.....-L.....-L.....K.-KQ.....	----	: 241
_gb_AAS90862.1_	:	.....I.....-P.....Q.....-L.....-K.....	----	: 194
_gb_AAS90913.1_	:	.....I.....-P.....Q.....-L.....-K.....	----	: 194
emb_CAA83869.1_	:	.....E..I.....-L.....Q.....-K.....	----	: 241
emb_CAA83859.1_	:	.....I.....-P.....Q.....-L.....-K.....	----	: 241
gb_AAF23740.1_	:	.....I.....-L.....Q.....-L.....-K.....	----	: 222
gb_AAF23742.1_	:	.....I.....-L.....Q.....-AL.....-K.....	----	: 222
emb_CAA83879.1_	:	.....I.....-I.....-L.....-K.....	----	: 241
emb_CAA83864.1_	:	.....I.....-L.....-L.....I.-K.....	----	: 241
gb_AAF23739.1_	:	.....T.....-LT.....-L.....-K.....	----	: 222
sp_P20895_VGLG_HRSV	:	.....L.....-L.....-L.....-L.....	----	: 241
emb_CAA83872.1_	:	.....L.....-L.....-L.....-L.....	----	: 241
sb_CAA34937.1_	:	.....L.....-L.....-L.....-L.....	----	: 241
_gb_AAX23993.1_	:	.....L.....-L.....-L.....-L.....	----	: 241
sp_P27021_VGLG_HRSV2:	:	.....L.....-P.....SE.....-L.....	----	: 241
gb_AAD02941.1_	:	.....L.....-P.....S.....-L.....	----	: 241
emb_CAA83870.1_	:	.....L.....-P.....S.....-L.....	----	: 241

# FIG. 5CC

emb_CAA83871.1	: .....	L.....-GP.....S...-.....-.....-.....-.....	: 241
sp_P27022_VGLG_HRSV3:	.....P.....-GP.....S...-A.....-.....-.....-.....	: 241	
emb_CAA51765.1	: .....	P.....-GP.....S...-A.....-.....-.....-.....	: 239
gb_AAD02944.1	: .....	P.....-GP.....S...-.....-.....-.....-.....	: 236
emb_CAA83874.1	: .....	P.....-GP.....S...K-AL.....-.....-.....-.....	: 241
gb_AAC36327.1	: .....	L.....-P.....S...-A.....-.....-.....-.....	: 241
emb_CAA83875.1	: .....	L.....-P.....S...-A.....-.....-.....-.....	: 241
sp_P03423_VGLG_HRSVA:	.....L.....-P.....S...-.....-.....-.....-.....	: 241	
gb_AAD02943.1	: .....	P.....-P.....TS...-.....-.....-.....-.....	: 236
sp_P20896_VGLG_HRSV1:	.I...N...T...N.R.P.TPAKM..K-EII.N.AK-K...K..ER----	: 242	
sp_P23041_VGLG_HRSV8:	.I...N...T...N.R.P.TPAKM..K-EII.N..K-K...K..ER----	: 242	
gb_AAR14265.1	: .I...N...V...N.R.P.TPAKMM.K-ET..N..K-K...K..EG----	: 242	
gb_ABC26397.1	: .I...N...T...N.I.P.TPAKT.EK-ET..NS.K-K...KI.EK----	: 240	
gb_ABC26398.1	: .I...N...T...N.I.P.TPAKT..K-ET..N..K-K...KI.EK----	: 240	
gb_AAC36320.1	: .I...N...T...N.RAP.TPAKTT.K-ET..N..K-K...E..ER----	: 242	
gb_AAW79749.1	: .I...N...T...N.R.P.TPAKTTEK-ET..N..K-K...K..ER----	: 183	
gb_AAW79750.1	: .I...N...T...S.R.P.TPAKTTEK-ET..N..K-K...K..ER----	: 183	
gb_AAW79751.1	: .I...N...T...N.R.P.TPAKTTEK-ET..N..K-K...K..ER----	: 183	
gb_AAW79752.1	: .I...N...T...N.R.P.TPAKTTEK-ET..N..K-K...K..ER----	: 183	
ref_NP_056862.1	: .I...N...T...N.R.P.TPAKTT.K-ET..N..K-K...T..ER----	: 242	
gb_AAW79753.1	: .I...N...T...N.R.P.TPAKTT.K-ET..N..K-K...K..ER----	: 183	
gb_AAW79754.1	: .I...N...Q.T...N.R.P.TPAKTT.K-ET..N..K-K...K..ER----	: 181	
gb_AAW79755.1	: .I...N...T...N.R.P.TPAKTT.K-ET..N..K-K...K..ER----	: 181	
gb_AAW79756.1	: .I...N...T...N.R.P.TPAKTT.K-ET..N..K-K...K..ER----	: 181	
gb_AAK31912.1	: .I...N...T...N.R.S.TSAKAL.K-ET..D..K-...K..ER----	: 231	
gb_AAK37424.1	: .I...N...T...N.R.S.TSAKAL.K-ET..D..K-...K..ER----	: 231	
gb_AAW79743.1	: .I...N...T...N.R.S.TSAKAL.K-ET..D..K-...K..ER----	: 183	
gb_AAW79744.1	: .I...N...T...N.R.S.TSAKAL.K-ET..D..K-...K..ER----	: 183	
gb_AAF20082.1	: .I...N...T...N.R.S.TSAKAL.K-ET..DL.K-..I.K..ER----	: 223	
gb_AAF20084.1	: .I...N...T...N.R.S.TSAKAL.K-ET..D..K-...K.AER----	: 223	
gb_AAF20085.1	: .I...N...T...N.R.S.TSAKAL.K-ET..D..K-...K..ER----	: 223	
gb_AAW79741.1	: .I...N...T...N.RGP.TSAKAL.K-ET..D..K-...FK..ER----	: 183	
gb_AAW79742.1	: .I...N...T...N.RGS.TSAKAL.K-ET..D..K-...FK..ER----	: 183	
gb_AAF20081.1	: .I...N...T...N.R.S.TSAKAL.K-ET..D..K-...K..ER----	: 223	
gb_AAF20091.1	: .I...N...IT...N.R.S.TSAKAL.K-ES..D..K-...FK..ER----	: 223	
gb_AAC36321.1	: .I...N...T...N.R.P.TPAKTL.K-ET..N..K-K...K..ER----	: 242	
gb_AAW79745.1	: .I...N...T...N.R.P.TPAKTL.K-ET..N..K-K...K..ER----	: 183	
gb_AAW79746.1	: .I...N...T...N.R.P.TPAKTLEK-ET..N..K-K...K..ER----	: 183	
gb_AAF20083.1	: .I...N...T...N.R.P.TPAKTL.K-ET..N..K-K...K..ER----	: 223	
gb_AAQ16176.1	: .I...N...T...N.R.P.TLAKTL.K-EN..N.-TKK...K..ER----	: 242	
gb_AAW79759.1	: .I...N...T...N.R.P.TTAKTL.K-ET..N..TKK.I.K..ER----	: 184	
gb_AAR86181.1	: .I...N...T...N.K.P.TPAKTL.K-ET..N.-TKKL...K..ER----	: 226	
gb_AAU26097.1	: .I...N...T...N.K.P.TPAKTL.K-ET..N.-TKKL...K..ER----	: 193	
gb_AAU26099.1	: .I...N...T...N.K.P.TPAKTL.K-ET..N.-TKKL...K..ER----	: 186	
gb_AAX08076.1	: .I...N...T...N.K.P.TPAKTL.K-ET..N.-TKKL...K..ER----	: 187	
gb_AAX08079.1	: .I...N...T...N.K.P.TPAKTL.K-ET..N.-TKKL...K..ER----	: 186	
gb_AAX08078.1	: .I...N...T...N.K.P.TPAKTL.K-ET..N.-TKKL...K..ER----	: 186	
gb_AAU26101.1	: .I...N...T...N.K.P.TPAKTL.K-ET..N.-TKKL...K..ER----	: 190	
gb_AAW79767.1	: .I...N...T...N.K.P.TPAKTLEK-ET..N.-TKK...PK..ER----	: 183	
gb_AAS90851.1	: .I...N...T...N.R.P.TPAKTL.K-ET..N.-TKKL...K..ER----	: 194	
gb_AAS90852.1	: .I...N...T...N.R.P.TPAKTL.K-ET..N.-TKKL...K..ER----	: 193	
gb_AAS90853.1	: .I...N...T...N.R.P.TPAKTL.K-ET..N.-TKKL...K..ER----	: 194	
gb_AAS90856.1	: .I...N...T...N.R.P.TPAKTL.K-ET..N.-TKKL...K..ER----	: 191	
gb_AAW79761.1	: .I...N...T...N.R.P.TPAKTL.K-ET..N.-TKKL...K..ER----	: 183	
gb_AAW79762.1	: .I...N...T...N.R.Q.TPAKTL.K-ET..N.-TKKL...K..ER----	: 183	

FIG. 5DD

_gb_AAW79765.1	: .I...N...T...N.R.P.TPAKTL.K-ET..Y.-TKKL..K..ER----	: 183
_gb_AAW79763.1	: .I...N...PT...N.R.P.TPAKTL.K-ET..Y.-TKKL..K..ER----	: 183
_gb_AAW79764.1	: .I...N...PT...N.R.P.TPAKTL.K-ET..Y.-TKKL..K..ER----	: 183
_gb_AAW79768.1	: .I...N...T...N.R.P.TPAKPL.K-ET..N.-TKKL..K..ER----	: 183
_gb_AAW79769.1	: .I...N...T...N.R.P.TPAKTL.K-ET..N.-TKKL..K..ER----	: 183
_gb_AAW79748.1	: .I...N...T...N.R.P.TPAKTL.K-ET..NS.K-K...K..ER----	: 183
_gb_AAW79772.1	: .I...N...T...N.R.P.TPAKTL.K-ET..N..K-K...K..ER----	: 183
_gb_AAW79777.1	: .I...N...T...N.R.P.TPAKTL.K-ET..N..K-K...K..ER----	: 183
_gb_AAW79778.1	: .I...N...T...N.R.P.TPAKTL.K-ET..N..K-K...K..ER----	: 183
_gb_AAR00216.1	: .I...N...PT...N.R.P.TLAKTL.K-ET..N...-K..PK..EG----	: 242
_gb_AAR00220.1	: .I...N...PT...N.R.P.TLAKTL.K-ET..N...-K..PK..EG----	: 242
_gb_AAR00217.1	: .I.....I.....R.P.TPAKTL.K-ET..N...-K..PK.KER----	: 242
_gb_AAR00219.1	: .I.....I.....R.P.TPAKTL.K-ET..N...-K..PK.KER----	: 242
_gb_AAR00218.1	: .I.....I.....R.P.TPAKTL.K-ET..N...-K..PK.KER----	: 242
_gb_AAW79733.1	: .I...N...PT...N.R.P.TLAKTL.K-ET..N...-K..PK..EG----	: 183
_gb_AAW79734.1	: .I...N...PT...N.R.P.TLAKTL.K-ET..N...-K..PK..EG----	: 183
_gb_AAW79738.1	: .I...N...PT...N.R.P.TLAKTL.K-ET..N...-K..PK..EG----	: 183
_gb_AAF20090.1	: .I...N...PT...N.R.P.TPAKTL.K-ET..N...-K..PK..EG----	: 223
_gb_AAF20087.1	: .I...N...PT...N.R.P.TLAKTL.K-ET..N...-K..PK..EG----	: 223
_gb_AAF20086.1	: .I...N...PT...N.R.P.TLAKTL.K-ET..N...-K..PK..EG----	: 223
_gb_AAF20088.1	: .I...N...PT...N.R.P.TLAKTL.K-ET..N...-K..PK..EG----	: 223
_gb_AAF20089.1	: .I...N...PT...N.R.P.TLAKTL.K-ET..N...-K..PK..EG----	: 223
_gb_ABC26396.1	: .I...N...PT...N.R.P.TPAKPL.K-ET..N..K-K..PK..ER----	: 242
_gb_AAQ16177.1	: .I...N...PT...N.R.P.KLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_AAQ16178.1	: .I...N...PT...N.R.P.KLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_ABB16912.1	: .I...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_dbj_BAC81823.1	: .I...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..EGDTST	: 246
_gb_AAW79621.1	: NI...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..EGDTST	: 187
_gb_AAW79622.1	: NI...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..EGDTST	: 187
_gb_AAW79627.1	: .I...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 187
_gb_AAU26098.1	: .I...N...PT...N.R.P.TL.KTL.K-EN.IN..K-K..PR..ERDTST	: 187
_gb_AAW79590.1	: .I...N...PT...N.R.P.TLAKTL.K-E.IIN..K-K..PK..ERDTST	: 187
_gb_AAW79583.1	: .I...N...PT...N.R.P.TLAKT..K-ET.IN..K-K..PK..ERDTST	: 185
_gb_AAW79585.1	: .I...N...PT...N.R.P.TLAKT..K-ET.IN..K-K..PK..ERDTST	: 185
_gb_AAW79589.1	: .I...N...PT...N.R.P.TLAKT..K-ET.IN..K-K..PK..ERDTST	: 185
_gb_ABB16944.1	: .I...N...PT...N.R.P.TLAKT..K-ET.IN..K-K..PK..ERDTST	: 244
_gb_AAW79580.1	: .I...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 187
_gb_ABB43013.1	: .I...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 196
_gb_ABC26395.1	: .I...N...PT...T.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_ABB16945.1	: .I...N...PT...N.R.P.TLAKTL.K-ET.IN..K-KL.PK..ERDTST	: 246
_gb_ABB16919.1	: .I...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_ABB16936.1	: .I...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_ABB16924.1	: .I...N...PT...N.R.S.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_ABB16930.1	: .I...N...PT...N.R.S.TLAKTL.K-ET.IN..K-K..PK...RDTST	: 246
_gb_ABB16932.1	: .I...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_ABB16941.1	: .I...N...PT...N.R.S.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_ABB16939.1	: .....N...PT...N.R.S.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_ABB16934.1	: .I...N...PT...N.R.S.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_ABB16925.1	: .I...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_ABB16937.1	: .I...N...PT...N.R.S.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_ABB16943.1	: .I...N...PT...N.R.S.TPAKT..K-ET.IN..K-K..PK..ERDTST	: 246
_gb_ABB16946.1	: .I...N...PT...N.R.S.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 246
_gb_AAW79591.1	: .I...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 187
_gb_AAW79613.1	: .I...N...PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 187
_gb_AAW79607.1	: .I...N...PT...NQR.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST	: 187

FIG. 5EE

```

_gb_AAW79600.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST : 187
_gb_AAW79606.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDTST : 187
_gb_AAW79615.1_ : .I...N..PT...N.R.P.TPAKTL.K-ET.IN..K-K..PK..ERDTST : 187
_gb_AAW79616.1_ : .I...N..PT...N.R.P.TPAKTL.K-ET.IN..K-K..PK..ERDTST : 187
_gb_AAW79618.1_ : .I...N..PT...N.R.P.TPAKTL.K-ET.IN..K-K..PK..ERDTST : 187
_gb_AAW79619.1_ : .I...N..PT...N.R.P.TPAKTL.K-ET.IN..K-K..PK..ERDTST : 187
_gb_AAW79620.1_ : .....N..PT...N.R.P.TPAKT.EK-ET.IN..K-K..PK..ERDTST : 187
_gb_ABB16926.1_ : .....N..PT...N.R.P.TPAKTL.K-ET.IN..TKK..PK..ERDTST : 247
_gb_ABB16942.1_ : .....N..PT...N.R.P.TPAKTL.K-ET.IN..TKK..PK..ERDTST : 247
_gb_ABB16938.1_ : .....N..PT...N.R.P.TPAKTL.K-ET.IN..T-KL.PK..ERDTSI : 246
_gb_ABB16940.1_ : .....N..PT...N.R.P.TPAKTL.K-ET.IN..TKKL.PK..ERDTSI : 247
_gb_ABB16916.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDVST : 246
_gb_ABB16923.1_ : .I...N..PT...N.R.P.TLAKTL.K-ETPFN..K-K..PK..ERDVST : 246
_gb_ABB16922.1_ : .I...N..PT...N.R.P.TLAKTL.K-E..IN..K-K..PK..ERDTST : 246
_gb_ABB16927.1_ : .I...N..PT...N.R.P.TLAKTL.K-E..IN..K-K..PK..ERDVST : 246
_gb_ABB16928.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDAST : 246
_gb_ABB16920.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDVST : 246
_gb_ABB16917.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDVST : 246
_gb_ABB16918.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET.IN..K-K..PK..ERDVST : 246
_gb_AAW79739.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79740.1_ : .I...N..PT...T.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79679.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..K..ER---- : 183
_gb_AAW79682.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..K..ER---- : 183
_gb_AAW79683.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..NS.K-K..PK..EG---- : 183
_gb_AAW79719.1_ : .I...T..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79692.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79693.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79694.1_ : .I...N..PT...N.R.P.TPAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79723.1_ : .I...N..PT...N.R.P.TPAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79724.1_ : .I...N..PT...N.R.P.TPAKTL.K-ET..N..K-K..PK..EK---- : 183
_gb_AAC36322.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 242
_gb_AAC36323.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 242
_gb_AAW79684.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79687.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79688.1_ : .I...N..PT...N.G.P.TPAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79691.1_ : .I...N..PT...NER.P.TL.KTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79710.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79714.1_ : .V...N..PT.I.N.R.P.TLAKTL.KEET..N..K-K..PK..ER---- : 184
_gb_AAW79716.1_ : .V...N..PT.I.N.R.P.TLAKTL.KEET..N..K-K..PK..ER---- : 184
_gb_AAW79715.1_ : .V...N..PT.I.N.R.P.TLAKTL.KEET..N..K-K..PK..ER---- : 184
_gb_AAW79729.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79731.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79628.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAW79712.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183
_gb_AAK49106.1_ : .I...N..PT...N.R.P.TLAKILEK-ET..N..K-K..PK..ER---- : 231
_gb_AAW79720.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK.IER---- : 183
_gb_AAW79722.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK.IER---- : 183
_gb_AAW79727.1_ : .I...N..PT...N.R.P.TLAKTL.K-ET..N..K-K..PK..ER---- : 183

```

# FIG. 5FF

RSV_G Long Strain	: -----NIITLLTNNTGNPKLTSQMETFHSTSSSEGNLS	: 275
dbj_BAE96917.1	: -----TS.PQS.VLD.ATSGH.I.Q..P...P.NTPN	: 276
_gb_AAW79669.1	: -----TS.PQS.VLD.ATSGH.I.Q..P...P.NTPN	: 217
_gb_AAW79670.1	: -----TS.PQS.VLD.TTSGH.I.Q..P...PKNTPN	: 217
_gb_AAW79661.1	: -----TS.PQS.VLD.ATSGH.I.Q..L...PKNTPN	: 217
_gb_AAW79668.1	: -----TS.PQS.VLD.ATSGH.I.Q..P...P.NTPN	: 217
_gb_AAW79671.1	: -----TS.PQS.VLD.TTSGH.I.Q..L...P..TP.	: 217
_gb_AAW79672.1	: -----TS.PQS.VLD.TTSGH.I.Q..L...P..TP.	: 217
_gb_AAW79676.1	: -----TS.PQS.VLD.TTSGH.I.Q..L....NTPN	: 217
_gb_AAR86179.1	: -----TS..QS.VLD.ATSGHAI.Q..L...P.NTPN	: 260
_gb_AAR86180.1	: -----TS..QS.VLD.ATSGHAI.Q..L...P.NTPN	: 260
_gb_AAW79647.1	: -----TS..QS.VLD.ATSGHAI.Q..L...P.NTPN	: 217
_gb_AAW79629.1	: -----TS..QS.VLD.AT.GH.I.Q..L...P.NTPN	: 217
_gb_AAW79643.1	: -----TS..QS.VLD.AT.GH.I.Q..L...P.NTPN	: 217
_gb_AAW79644.1	: -----ETS..QS.VLDMAT.GH.I.Q..L...P.NTPN	: 217
_gb_AAW79645.1	: -----TS..QS.VLN.AT.GH.I.Q..L...P.NTPN	: 217
_gb_AAW79648.1	: -----TS..QS.VLD.ATSGH.I.Q..L...P.NTPN	: 217
_gb_AAW79646.1	: -----TS..QS.VLD.ATSGH.I.Q..L...P.NTPN	: 217
_gb_AAW79655.1	: -----TS..QS.VLD.ATSGY.I.Q..L...LKNTNPN	: 217
_gb_AAW79657.1	: -----TS..QS.VLD.ATSGY.I.Q..L...LKNTNPN	: 217
_gb_AAW79658.1	: -----TS..QS.VLD.ATSGH.I...L...L.NTPN	: 217
_gb_AAW79648.1	: -----TS..QS.VLD.ATSGH.I.Q..L...P.NTPN	: 217
_gb_AAW79649.1	: -----TS..QS.VLD.ATSGH.I.Q..L...P.NTPN	: 217
_gb_AAW79653.1	: -----TS..QS.VLD.ATSGH.I.Q..L...P.NTPN	: 217
_gb_AAW79659.1	: -----TS..QS.VLD.ATSGH.I.Q..LY...P.NTPN	: 217
_gb_AAW79695.1	: -----NS..QS.VLD.TTSEH.I.Q..L...P.NTPN	: 217
_gb_AAW79704.1	: -----NS..QS.VLD.TTSEH.I.Q..L...P.NTPN	: 217
_gb_AAW79707.1	: -----NS..QS.VLD.TTSEH.I.Q..L...P.NTPN	: 217
_gb_AAW79702.1	: -----NS..QS.VLD.TTSEH.I.Q..L...P.NTPN	: 217
_gb_AAW79709.1	: -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN	: 217
_gb_ABH00984.1	: -----R.....S....L-----	: 256
_gb_AAM68156.1	: -----R.....S....LEH...E..L.....T.	: 275
_gb_AAS90859.1	: -----R.....S....LEH...E..L.....T.	: 228
_gb_AAM68159.1	: -----R.....S....LEH...E..L.....T.	: 275
_gb_AAS90857.1	: -----R.....S....LEH...E..L.....T.	: 228
_gb_AAS90858.1	: -----R.....S....LEH...E..L.....T.	: 228
_gb_AAS90861.1	: -----R.....S....LEH...E..L.....T.	: 227
_gb_AAS90871.1	: -----R.....S....LEH...E..L.....T.	: 222
_gb_AAU26087.1	: -----R.....S....LEH...E..L.....T.	: 229
_gb_AAU26088.1	: -----R.....S....LEH...E..L.....T.	: 229
_gb_AAS90925.1	: -----R.....S....LEH...E..L.....T.	: 225
_gb_AAS90926.1	: -----R.....S....LEH...E..L.....T.	: 223
_gb_AAS90907.1	: -----R.....S....LEH...E..L.....T.	: 226
_gb_AAX08080.1	: -----R.....S....LEH...E..L.....T.	: 229
_gb_AAS90936.1	: -----R.....S....LEH...E..L.....T.	: 228
_gb_AAU26084.1	: -----R.....S....LEH...E..L.....T.	: 229
_gb_AAS90938.1	: -----R.....S....LEH...E..L.....T.	: 227
_gb_AAU26092.1	: -----R.....S....LER...E..L.....T.	: 229
_gb_AAU26093.1	: -----R.....S....LER...E..L.....T.	: 229
_gb_AAS90912.1	: -----R.....S....LEH...E..L.....T.	: 227
_gb_AAS90906.1	: -----R.....S....LEH...E..L.....T.	: 228
_gb_AAS90914.1	: -----R.....S....LEH...E..L.....T.	: 228
_gb_AAS90878.1	: -----R.....S....LEH...E..L.....T.	: 228
_gb_AAU26095.1	: -----R.....S....LEH...E..L.....T.	: 230
_gb_AAX08081.1	: -----R.....S....LEH...E..L.....T.	: 227

FIG. 5GG

_gb_AAU26085.1	: -----	.R.....S....LEH...E..L.....T	: 226
_gb_AAU26086.1	: -----	.R.....S....LEH...E..L.....T	: 230
_gb_AAU26091.1	: -----	.R.....S....LEH...E..L.....T	: 227
_gb_AAU26090.1	: -----	.R.....S....LEH...E..L.....T	: 228
_gb_AAS90882.1	: -----	.R.....S....LEH...E..L.....T	: 226
_gb_AAS90874.1	: -----	.R.....S....LEH...E..L.....T	: 228
_gb_AAS90928.1	: -----	.R.....S....LEH...E..L.....T	: 227
_gb_AAX08082.1	: -----	.R.....S....LEH...E..L.....T	: 230
_gb_AAX08084.1	: -----	.R.....S....LEH...E..L.....T	: 230
_gb_AAS90886.1	: -----	.R.....S....LEH...E..L.....T	: 228
_gb_AAS90922.1	: -----	.R.....S....LEH...E..L.....T	: 228
_gb_AAS90919.1	: -----	.R.....S....LEH...E..L.....T	: 228
_gb_AAT80628.1	: -----	.R.....S....LEH...E..L.....T	: 275
sp_P27024_VGLG_HRSV5:	-----	.R.....S....LEH...E..L.....T	: 275
emb_CAA51763.1	: -----	.R.....S....LEH...E..L.....T	: 273
emb_CAA83899.1	: -----	.R.....S....LEH...E..L.....T	: 275
gb_AAF23741.1	: -----	.R.....S....LEH...E..L.....T	: 256
gb_AAC36325.1	: -----	.R.....S....LEH...E..L.....T	: 275
mb_CAA83877.1	: -----	.R.....S....LEH...E..L.....T	: 275
mb_CAA83862.1	: -----	.R.....S....LEH...E..L.....T	: 275
mb_CAA83857.1	: -----	.R.....S....LEH...E..L.....T	: 275
mb_CAA83866.1	: -----	.R.....S....LEH...E..L.....T	: 275
mb_CAA83873.1	: -----	.R.....S....LEH...E..L...P...T	: 275
gb_AAF23727.1	: -----	.R.....S....LEH...E..L...F...T	: 256
gb_AAF23733.1	: -----	.R.....S....LEH...E..L.....T	: 256
mb_CAA83861.1	: -----	.R.....S....LEH...D..L...F...T	: 275
mb_CAA83900.1	: -----	.R.....S....EH...E..L.....T	: 275
_gb_AAO14878.2	: -----	.R.....S....LEH...E..L.....T	: 275
gb_AAD02942.1	: -----	.R.....S...S.EH...K..L.....P	: 275
gb_AAD02945.1	: -----	.R.....S....LEH...E..L.....P	: 270
gb_AAC57026.1	: -----	.R.....S....EH...K.G.L...D..P	: 275
ref_NP_044595.1	: -----	.R.....S....EH...K.G.L...D..P	: 275
gb_AAF23729.1	: -----	.R.M.....EH...K..L.....P	: 256
gb_AAF23731.1	: -----	.R.....S....EH...K..L.....P	: 256
gb_AAC36324.1	: -----	.R..PI.....EN...K..L.....P	: 275
sp_P27023_VGLG_HRSV4:	-----	.R.....T....EY...K..L...P...P	: 275
sp_P27025_VGLG_HRSV6:	-----	.R.....T....EY...K..L...P...P	: 275
gb_AAF23736.1	: -----	.R.....T....EY...K..L...P...P	: 256
gb_AAF23728.1	: -----	.R.....T....EY...K..L...P...P	: 256
gb_AAF23735.1	: -----	.R.....T....EY...K..L...P...P	: 256
gb_AAF23732.1	: -----	.R.....T...R..EY...K..L...P...P	: 256
gb_AAD02946.1	: -----	.R.....T....EY...K..L...P...P	: 270
gb_AAF23743.1	: -----	.G.....T....EY...K..L...P...P	: 256
gb_AAF23749.1	: -----	.G.....T....EY...K..L...P...P	: 256
gb_AAF23745.1	: -----	.G.....T....EY...K..L...P...P	: 256
sp_P27026_VGLG_HRSV7:	-----	.R.....T....EY...K..L...P...P	: 275
emb_CAA83863.1	: -----	.K.....T....EY...K..L...P...P	: 277
emb_CAA83878.1	: -----	.K.....T....EH...K..L...P...P	: 275
emb_CAA83860.1	: -----	.K.....T....EH...K..L...P...P	: 275
_gb_AAM68153.1	: -----	.K.....S...E.EH...K..L...P...P	: 275
_gb_AAS90864.1	: -----	.K.....S...R.EH...K..L...P...P	: 228
_gb_AAS90905.1	: -----	.K.....S...R.EH...K..L...P...P	: 222
_gb_AAS90931.1	: -----	.K.....S...R.EH...K..L...P...P	: 226
_gb_AAS90892.1	: -----	.K.....S...R.EH...K..L...P...P	: 228
_gb_AAX08086.1	: -----	.K.....S....EH...K..L...P...P	: 228

FIG. 5HH

\_gb\_AAS90880.1 : ----- .K . . . . .S . . . . .EH . . .K . .L . . . . .P . : 228

\_gb\_AAS90929.1 : ----- .K . . . . .S . . . . .EH . . .K . .L . . . . .P . : 228

\_gb\_AAS90898.1 : ----- .K . . . . .S . . . . .EH . . .K . .L . . . . .P . : 228

\_gb\_AAQ24136.1 : ----- .K . . . . .S . . . . .E . .EH . . .K . .L . . . . .P . : 275

\_gb\_AAQ24143.1 : ----- .K . . . . .S . . . . .E . .EH . . .K . .L . . . . .P . : 275

\_gb\_AAQ24139.1 : ----- .K . . . . .P . . . . .EH . . .K . .L . . . . .P . : 275

\_gb\_AAQ24141.1 : ----- .K . . . . .S . . . . .EH . . .K . .L . . . . .P . : 275

\_gb\_AAQ24137.1 : ----- .R . . . . .P . . . . .EH . . .K . .L . . . . .P . : 275

\_gb\_AAS90863.1 : ----- .R . . . . .P . . . . .EH . . .K . .L . . . . .P . : 228

\_gb\_AAS90924.1 : ----- .R . . . . .P . . . . .EH . . .K . .L . . . . .P . : 228

\_gb\_AAS90921.1 : ----- .R . . . . .P . . . . .EH . . .K . .L . . . . .P . : 228

\_gb\_AAS90927.1 : ----- .R . . . . .P . . . . .EH . . .K . .L . . . . .P . : 228

\_gb\_AAQ24138.1 : ----- .R . . . . .P . . . . .EH . . .K . .L . . . . .P . : 275

\_gb\_AAQ24140.1 : ----- .R . . . . .P . . . . .EH . . .K . .L . . . . .P . : 275

\_gb\_AAS90867.1 : ----- .RI . . . . .S . . . . .EH . . .K . .L . . . . .P . : 228

\_gb\_AAS90884.1 : ----- .RI . . . . .S . . . . .EH . . .K . .L . . . . .P . : 228

\_gb\_AAS90885.1 : ----- .RI . . . . .S . . . . .EH . . .K . .L . . . . .P . : 228

gb\_AAF23746.1 : ----- .NR . . . . .S . . . . .EH . . .K . .L . . . . .P . : 256

gb\_AAF23747.1 : ----- .R . . . . .S . . . . .EH . . .K . .L . . . . .P . : 256

gb\_AAF23748.1 : ----- .R . . . . .S . . . . .EH . . .K . .L . . . . .P . : 256

\_gb\_AAU43726.1 : ----- .R . . . . .S . . . . .EH . . .E . .L . . . . .P . : 275

\_gb\_AAU43727.1 : ----- .G . . . . .S . . . . .EN . . .K . .L . . . . .Q . : 275

\_gb\_AAM44850.2\_AF51 : ----- .R . . . . .IS . . . . .EH . . .K . .L . . . . .P . : 275

gb\_AAF23730.1 : ----- .RA . . . . .S . . . . .EH . . .K . .L . . . . .P . : 256

gb\_AAF23737.1 : ----- .RA . . . . .S . . . . .EQ . . .K . .L . . . . .P . : 256

emb\_CAA83867.1 : ----- .R . . . . .S . . . . .EH . . .K . .L . . . . .P . : 275

emb\_CAA83865.1 : ----- .R . . . . .S . . . . .EH . . .K . .L . . . . .P . : 275

emb\_CAA83868.1 : ----- .R . . . . .S . . . . .EH . . .K . .L . . . . .P . : 275

gb\_AAC36326.1 : ----- .R . . . . .S . . . . .EH . . .K . .L . . . . .PR : 275

gb\_AAC36328.1 : ----- .R . . . . .S . . . . .EH . . .K . .L . . . . .P . : 275

gb\_AAF23738.1 : ----- .R . . . . .S . . . . .EH . . .K . .L . . . . .P . : 256

gb\_AAF23734.1 : ----- .RA . . . . .SSA . .G . .EH . . .E . .L . . . . .P . : 256

\_gb\_AAQ24144.1 : ----- .S .R . . . . .S . . . . .EH . . .K . .L . . . . .P . : 275

\_gb\_AAQ24145.1 : ----- .S .R . . . . .S . . . . .EH . . .K . .L . . . . .P . : 275

gb\_AAF23744.1 : ----- .S .R . . . . .P . . . . .EH . . .K . .L . . . . .P . : 256

emb\_CAA83858.1 : ----- .R . . . . .Q . . . . .LEH . . .K . .L . . . . .P . : 275

\_gb\_AAU43729.1 : ----- .R . . . . .S . . . . .EH . . .K . .L . . . . .P . : 275

\_gb\_AAS90862.1 : ----- .R . . . . .T . . . . .EH . . .K . .L . . . . .S .P . : 228

\_gb\_AAS90913.1 : ----- .R . . . . .T . . . . .EH . . .K . .L . . . . .P . : 228

emb\_CAA83869.1 : ----- .S . . . . .T . . . . .EH . . .K . .L . . . . .D .P . : 275

emb\_CAA83859.1 : ----- .R . . . . .T . . . . .EH . . .K . .L . . . . .P . : 275

gb\_AAF23740.1 : ----- .R . . . . .T . . . . .EH . . .K . .L . . . . .P . : 256

gb\_AAF23742.1 : ----- .R . . . . .T . . . . .EH . . .K . .L . . . . .P . : 256

emb\_CAA83879.1 : ----- .R . . . . .T . . . . .EH .N .R . .L . . . . .T . : 275

emb\_CAA83864.1 : ----- .R . . . . .T . . . . .EH . . .ED .L . . . . .P . : 275

gb\_AAF23739.1 : ----- .R . . . . .S . . . . .EH . . .K . .L . . . . .P . : 256

sp\_P20895\_VGLG\_HRSV : ----- .T . . . . . : 275

emb\_CAA83872.1 : ----- .T . . . . . : 275

b\_CAA34937.1 : ----- .T . . . . . : 275

\_gb\_AAX23993.1 : ----- .T . . . . . : 275

sp\_P27021\_VGLG\_HRSV2 : ----- .P .S . .AR . .E . . . . .P . : 275

gb\_AAD02941.1 : ----- .S . . . . .R . .E . . . . .P . : 275

emb\_CAA83870.1 : ----- .S . . . . .R . .E . . . . .P . : 275

emb\_CAA83871.1 : ----- .S . . . . .R . .E . . . . .P . : 275

sp\_P27022\_VGLG\_HRSV3 : ----- .S . . . . .R . .E . . . . .P . : 275



FIG. 5II

emb\_CAA51765.1\_ : -----S...R..E.....P : 273

gb\_AAD02944.1\_ : -----S...R..E.....P : 270

emb\_CAA83874.1\_ : -----S...R..E.....P : 275

gb\_AAC36327.1\_ : -----T..PF.S...R..E.....P : 275

emb\_CAA83875.1\_ : -----T..P..S...R..E.....P : 275

sp\_P03423\_VGLG\_HRSVA: -----S.....E.....P : 275

gb\_AAD02943.1\_ : -----S...R..E.....P : 270

sp\_P20896\_VGLG\_HRSV1: -----TSI.QS.VLD.IT..Y.I.Q..L.....NTP : 276

sp\_P23041\_VGLG\_HRSV8: -----TS..QS.VLD.IT..Y.I.Q..L.....NTP : 276

\_gb\_AAR14265.1\_ : -----TS..QS.VLD.TTS.H.I.Q..L..I...NTPN : 276

\_gb\_ABC26397.1\_ : -----TS..QS.MLD.TT.NH.I.Q..L....PDNTPN : 274

\_gb\_ABC26398.1\_ : -----TS..QS.MLD.TK.NH.I.Q.YL....PDNTPN : 274

gb\_AAC36320.1\_ : -----TS..QS.VLD.TTL.H.I.Q..L....P.NTPN : 276

\_gb\_AAW79749.1\_ : -----TG..QS.VLD.TTL.H.I.Q..L....P.NTPN : 217

\_gb\_AAW79750.1\_ : -----TG..QS.VLD.TTL.H.I.Q..L....P.NTPN : 217

\_gb\_AAW79751.1\_ : -----TG..QS.VLD.TTL.H.I.Q..L....P.NTPN : 217

\_gb\_AAW79752.1\_ : -----TS..QS.VLD.TTL.H.I.Q..L....P.NTPN : 217

ref\_NP\_056862.1\_ : -----TS..QS.VLD.TTLEH.I.Q..L....P.NTPN : 276

\_gb\_AAW79753.1\_ : -----TS..QS.VLD.TTS.Y.I.QK.L....P.NTPN : 217

\_gb\_AAW79754.1\_ : -----TS..PQS.ALD.TT.EH.I.Q..L.P..P.NTPN : 215

\_gb\_AAW79755.1\_ : -----TS..QS.ALD.TTLEH.I.Q..L....P.NTPN : 215

\_gb\_AAW79756.1\_ : -----TS..QS.ALD.TTL.H.I.Q..L....P.NTPN : 215

\_gb\_AAK31912.1\_ : -----TS..RS.VLD.TTSDH.V.Q..L....L.NTPN : 265

\_gb\_AAK37424.1\_ : -----TS..RS.VLD.TTSDH.V.Q..L....L.NTPN : 265

\_gb\_AAW79743.1\_ : -----TS..RS.VLD.TTSDH.V.Q..L....P.NTPN : 217

\_gb\_AAW79744.1\_ : -----TS..RS.VLD.TTSDH.V.Q..L....P.NTPN : 217

gb\_AAF20082.1\_ : -----TS..RS.VLD.TTSDH.V.Q..L....P.NTPN : 257

gb\_AAF20084.1\_ : -----TS..RS.VLD.TTSDH.V.Q..L....P.NTPN : 257

gb\_AAF20085.1\_ : -----TS..RS.VLD.TTSDH.V.Q..L....P.NTPN : 257

\_gb\_AAW79741.1\_ : -----TS..RSNVLD.TTSDH.V.Q..L..IP.NTPN : 217

\_gb\_AAW79742.1\_ : -----TS..RSNALD.TTSDH.V.Q..L....P.NTPN : 217

gb\_AAF20081.1\_ : -----TS..RS.VLD.TTSDH.V.Q..L....P.NTPN : 257

gb\_AAF20091.1\_ : -----TS..RS.VLD.TTSDH.I.Q..L....P.NTPN : 257

gb\_AAC36321.1\_ : -----TS..PQS.VLD.TT.NH.I.Q..L....P.NTPN : 276

\_gb\_AAW79745.1\_ : -----TS..QS.VLD.TTSNH.I.Q..L....P.NTPN : 217

\_gb\_AAW79746.1\_ : -----TS..QS.VLD.TTSNH.I.Q..L....P.NTPN : 217

gb\_AAF20083.1\_ : -----TS..QS.VLD.TTSNH.I.Q..L....P.NTPN : 257

\_gb\_AAQ16176.1\_ : -----TS..PQS.VLD.TTS.H.I.Q..L....P.NTPN : 276

\_gb\_AAW79759.1\_ : -----TS..QS.VLD.TTS.H.I.Q..L....P.NTPN : 218

\_gb\_AAR86181.1\_ : -----TS..LQS.VLD.TTS.H..LQ..L....P.NTPN : 260

\_gb\_AAU26097.1\_ : -----TS..LQS.VLD.TTS.H..LQ..L....P.NTPN : 227

\_gb\_AAU26099.1\_ : -----TS..LQS.VLD.TTS.H..LQ..L....P.NTPN : 220

\_gb\_AAX08076.1\_ : -----TS..LQS.VLD.TTS.H..LQ..L....P.NTPN : 221

\_gb\_AAX08079.1\_ : -----TS..LQS.VLN.TTS.H..LQ..L....P.NTPN : 220

\_gb\_AAX08078.1\_ : -----TS..LQS.VLD.TTS.H..LQ..L....P.NTPN : 220

\_gb\_AAU26101.1\_ : -----TS..LQS.VLD.TTS.H..LQ..L....P.NTPN : 224

\_gb\_AAW79767.1\_ : -----TS..LQS.VLD.TTS.H..LQ..L.P..P.NTPN : 217

\_gb\_AAS90851.1\_ : -----TS..PQS.ALD.TTS.H..PQ..L....P.NTPN : 228

\_gb\_AAS90852.1\_ : -----TS..QS.VLD.TTS.H..LQ..L....PKNTPN : 227

\_gb\_AAS90853.1\_ : -----TS..QS.VLD.TTS.H..LQ..L....PKNTPN : 228

\_gb\_AAS90856.1\_ : -----TS..QS.VLD.TTS.H..LQ..L....PKNTPN : 225

\_gb\_AAW79761.1\_ : -----TS..QS.VLD.TTS.H..LQ..L....P.NTPN : 217

\_gb\_AAW79762.1\_ : -----TS..QS.VLD.TTS.H..LQ..L....P.NTPN : 217

\_gb\_AAW79765.1\_ : -----TS..QS.VLD.TTS.H..LQ..L....P.NTPN : 217

\_gb\_AAW79763.1\_ : -----TS..QS.VLD.TTS.H..LQ..L....P.NTPN : 217

FIG. 5JJ

```

_gb_AAW79764.1 : -----TS..QS.VLD.TTS.H..LQ..L...P.NTPN : 217
_gb_AAW79768.1 : -----TS..QS.VLD.TTS.H.I.LQ..L...P.NTPN : 217
_gb_AAW79769.1 : -----TS..QS.VLD.TTS.H.I.LQ..L...P.NTPN : 217
_gb_AAW79748.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79772.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.YTPN : 217
_gb_AAW79777.1 : -----TS..QS.VLD.TTS.R.I.Q..L...P.YTPN : 217
_gb_AAW79778.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAR00216.1 : -----TS..QS.VLD.TASEH.V.Q..L...P.NTPN : 276
_gb_AAR00220.1 : -----TS..QS.VLD.TASEH.V.Q..L...P.NTPN : 276
_gb_AAR00217.1 : -----TS..QS.VLD.TASEH.V.Q..L...P.NTPN : 276
_gb_AAR00219.1 : -----TS..QS.VLD.TASEH.V.Q..L...P.NTPN : 276
_gb_AAR00218.1 : -----TS..QS.VLD.TASEH.V.Q..L...P.NTPN : 276
_gb_AAW79733.1 : -----TS..QS.VLD.TASEH.V.Q..L...P.NTPN : 217
_gb_AAW79734.1 : -----TS..QS.ALD.TASEH.V.Q..L...P.NTPN : 217
_gb_AAW79738.1 : -----TS.PQS.VLD.TASEH.V.Q..P...P.NTPN : 217
_gb_AAF20090.1 : -----TS..QS.VLD.TASEH.V.Q..L...P.NTPN : 257
_gb_AAF20087.1 : -----TS..QS.VLD.TASEH.V.Q..L...P.NTPN : 257
_gb_AAF20086.1 : -----TS..QS.VLD.TASEH.V.Q..L...P.NTPN : 257
_gb_AAF20088.1 : -----TS..QS.VLD.TASEY.V.Q..L...P.NTPN : 257
_gb_AAF20089.1 : -----TS..QS.VLD.TASEH.V.Q..L...P.NTPN : 257
_gb_ABC26396.1 : -----SS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 276
_gb_AAQ16177.1 : SQSTVLDTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_AAQ16178.1 : SQSTVLDTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16912.1 : SQSTVLDTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 296
_dbj_BAC81823.1 : SQSTVLDTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..LY...P.NTPN : 296
_gb_AAW79621.1 : SQSTVLDTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..LY...P.NTPN : 237
_gb_AAW79622.1 : SQSTVLDTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..LY...P.NTPN : 237
_gb_AAW79627.1 : SQSTVLDTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 237
_gb_AAU26098.1 : PQSTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..LY...LKNTPN : 237
_gb_AAW79590.1 : PQSTVLDTTTSKHTER.TS..QSIALD.TTS.H.I.Q..LY...P.NTPN : 237
_gb_AAW79583.1 : PQSTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..LY...P.NTPN : 235
_gb_AAW79585.1 : PQSTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..LY...P.NTPN : 235
_gb_AAW79589.1 : PQSTVLDTTTSKHTER..S..QSIVLD.TTS.H.I.Q..LY...P.NTPN : 235
_gb_ABB16944.1 : PQSTVLDTTTSKHTER.PS.LQSIALD.TTS.H.I.Q..LY...P.NTPN : 294
_gb_AAW79580.1 : PQSTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..LY...P.NTPN : 237
_gb_ABB43013.1 : PQSTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..LY...P.NTPN : 246
_gb_ABC26395.1 : PQSTVLDTTTSKHTGR.TS..QSIVLD.TTS.H.I.Q..LY...P.NTPN : 296
_gb_ABB16945.1 : PQSTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..LY...P.NTPN : 296
_gb_ABB16919.1 : PQSTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16936.1 : PQSTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16924.1 : PQFTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16930.1 : PQFTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16932.1 : PQSTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16941.1 : PQFTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16939.1 : PQFTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16934.1 : PQFTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16925.1 : PQFTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16937.1 : PQSTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16943.1 : PQSTVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16946.1 : LQSIVLDTTTSKHTER.TS..QSIVLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_AAW79591.1 : PQSTVLDTTTSKHTER.TS.PQS.VLD.TTS.H.I.Q..L...P.NTPN : 237
_gb_AAW79613.1 : PQSTVLDTTTSKHTER.TS.PQS.VLD.TTS.H.I.----- : 223
_gb_AAW79607.1 : PQSTVLDTTTSKHTER.TS.PQS.VLD.TTS.H.I.Q..L...P.NTPN : 237
_gb_AAW79600.1 : PQSTVLDTTTSKHTER.TS.PQS.VLD.TTS.H.I.Q..L...P.NTPN : 237
_gb_AAW79606.1 : PQSTVLDTTTSKHTER.TS.PQS.VLD.TTS.H.I.Q..L...P.NTPN : 237

```

FIG. 5KK

```

_gb_AAW79615.1 : PQSTMLDTTTTSKHTER.TS..QS.VLN.TTS.H.I.Q..LY...PDNTPN : 237
_gb_AAW79616.1 : PQSTVLDTTTTSKHTER.TS..QS.VLN.TTS.H.I.Q..LY...PDNTPN : 237
_gb_AAW79618.1 : PQSTALDTTTTSKHTER.TS..QS.VLN.TTS.H.I.Q..L...PDNTPN : 237
_gb_AAW79619.1 : PQSTVLDTTTTSKHTER.TS..QS.VLN.TTS.H.I.Q..L...PDNTPN : 237
_gb_AAW79620.1 : PQSTVPDTTTTLKHTER.TS.PQS.VLN.TTS.H.I.Q..L...PKNTPN : 237
_gb_ABB16926.1 : PQSTVLDTTTTSKHTER.TS.PQS.VLD.TTS.H.I.Q..L...P.NTPN : 297
_gb_ABB16942.1 : PQSTVLDTTTTSKHTER.TS.PQS.VLD.TTS.H.I.Q..L...P.NTPN : 297
_gb_ABB16938.1 : PQSTVLDTTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16940.1 : PQSTVLDTTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 297
_gb_ABB16916.1 : SQSTVLDTTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16923.1 : SQSTVLDTTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16922.1 : SQSTVLDTTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16927.1 : SQSTVLDTTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16928.1 : SQSTVLDTTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16920.1 : SQSTVLDTTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16917.1 : SQSTVLDTTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_ABB16918.1 : SQSTVLDTTTTSKHTER.TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 296
_gb_AAW79739.1 : -----TS..QS.VLD.TAS.H.I.Q..L...P.NTPN : 217
_gb_AAW79740.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79679.1 : -----NS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79682.1 : -----NS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79683.1 : -----TSI.QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79719.1 : -----TS..QS.VLD.TTS.Y.I.Q..L...P.NTPN : 217
_gb_AAW79692.1 : -----TN..QS.VLD.TTS.H.I.Q..P...P.NTPN : 217
_gb_AAW79693.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79694.1 : -----TS.LQS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79723.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79724.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAC36322.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 276
_gb_AAC36323.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 276
_gb_AAW79684.1 : -----TSI.QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79687.1 : -----TSI.QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79688.1 : -----TSIPQS.VLD.TTS.H.I.Q..P...P.NTPN : 217
_gb_AAW79691.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79710.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79714.1 : -----TS..QSAVLD.TTS.H.I.Q.FL...P.DTP. : 218
_gb_AAW79716.1 : -----TS..QSAVLD.TTS.H.I.Q.FL...P.DTP. : 218
_gb_AAW79715.1 : -----TS..QSAVLD.TTS.H.I.QKFL...P.DTP. : 218
_gb_AAW79729.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79731.1 : -----TS..QS.VHD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79628.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79712.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAK49106.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 265
_gb_AAW79720.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79722.1 : -----TS..QS.VLD.TTS.H.I.Q..L...P.NTPN : 217
_gb_AAW79727.1 : -----TS..QP.VLD.TTS.H.I.Q..L...P.NTPN : 217
    
```

FIG. 5LL

	*	320	
RSV_G_Long Strain	:	PSQVSTTSEHPSQPSSPPNTTRQ-----	: 298
dbj_BAE96917.1	:	S..TP.A..P-----TS...QKLQSYA	: 299
_gb_AAW79669.1	:	S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79670.1	:	F..TP.A..P-----TS...Q.L----	: 236
_gb_AAW79661.1	:	S..TP.A..P-----TS...Q.F----	: 236
_gb_AAW79668.1	:	S..TP.A..P-----PTS...QKF----	: 236
_gb_AAW79671.1	:	S..TP.A..P-----TS.....	: 233
_gb_AAW79672.1	:	S..TP.A..P-----TS.....	: 233
_gb_AAW79676.1	:	S..TP.A..P-----TS...QKL----	: 236
_gb_AAR86179.1	:	S..TP.A..P-----TS...QKL----	: 279
_gb_AAR86180.1	:	S..TP.A..P-----TS...QKL----	: 279
_gb_AAW79647.1	:	S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79629.1	:	SK.TP.A..P-----PTS...QKL----	: 236
_gb_AAW79643.1	:	S..TP.A..P-----PTS...QKL----	: 236
_gb_AAW79644.1	:	S..TP.A..P-----PTS...QKL----	: 236
_gb_AAW79645.1	:	S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79677.1	:	S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79646.1	:	S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79655.1	:	S..TP.A..P-----TS...QKH----	: 236
_gb_AAW79657.1	:	S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79658.1	:	S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79648.1	:	S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79649.1	:	S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79653.1	:	S..TP.A..P-----T...QKL----	: 236
_gb_AAW79659.1	:	S..TP.A..P-----TS...QKLQSYA	: 240
_gb_AAW79695.1	:	S..TLAA..P-----TS...QKL----	: 236
_gb_AAW79704.1	:	S..TLAA..P-----TS.F.QKL----	: 236
_gb_AAW79707.1	:	S..TLAA..L-----TS...QKL----	: 236
_gb_AAW79702.1	:	S..TLAA..P-----TS...QKL----	: 236
_gb_AAW79709.1	:	S..TPAA..P-----TS...QKL----	: 236
_gb_ABH00984.1	:	-----	: -
_gb_AAM68156.1	:	...Y...YL...P..S.I.D.-----	: 298
_gb_AAS90859.1	:	...Y...YL...P..S.I.D.-----	: 251
_gb_AAM68159.1	:	...Y...YL...P..SS.I.D.-----	: 298
_gb_AAS90857.1	:	...Y...YL...P..S.I.D.-----	: 251
_gb_AAS90858.1	:	...Y...YL...P..S.I.D.-----	: 251
_gb_AAS90861.1	:	...Y...YL...P..S.I.D.-----	: 250
_gb_AAS90871.1	:	...Y...YL...P..S.I.D.-----	: 245
_gb_AAU26087.1	:	...Y...YL...P..S.I.D.-----	: 252
_gb_AAU26088.1	:	...Y...YL...P..S.I.D.-----	: 252
_gb_AAS90925.1	:	...Y...YL...P..S.I.D.-----	: 248
_gb_AAS90926.1	:	...Y...YL...P..S.I.D.-----	: 246
_gb_AAS90907.1	:	...Y...YL...P..S.I.D.-----	: 249
_gb_AAX08080.1	:	...Y...YL...P..S.I.D.-----	: 252
_gb_AAS90936.1	:	...Y...YL...P..S.I.D.-----	: 251
_gb_AAU26084.1	:	...Y...YL...P..S.I.D.-----	: 252
_gb_AAS90938.1	:	...Y...YL...P..S.I.D.-----	: 250
_gb_AAU26092.1	:	...Y...YL...P..S.I.D.-----	: 252
_gb_AAU26093.1	:	...Y...YL...P..S.I.D.-----	: 252
_gb_AAS90912.1	:	...Y...YL...P..S.I.D.-----	: 250
_gb_AAS90906.1	:	...Y...YL...P..S.I.D.-----	: 251
_gb_AAS90914.1	:	...Y...YL...P..S.I.D.-----	: 251
_gb_AAS90878.1	:	...Y...YL...P..S.I.D.-----	: 251
_gb_AAU26095.1	:	...Y...YL...P..S.I.D.-----	: 253

FIG. 5MM

_gb_AAX08081.1_	: . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 250
_gb_AAU26085.1_	: . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 249
_gb_AAU26086.1_	: . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 253
_gb_AAU26091.1_	: . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 250
_gb_AAU26090.1_	: . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 251
_gb_AAS90882.1_	: . . . . Y . . . . YL . . . P . . S . I . G . - - - -	: 249
_gb_AAS90874.1_	: . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 251
_gb_AAS90928.1_	: . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 250
_gb_AAX08082.1_	: . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 253
_gb_AAX08084.1_	: . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 253
_gb_AAS90886.1_	: . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 251
_gb_AAS90922.1_	: . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 251
_gb_AAS90919.1_	: S . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 251
_gb_AAT80628.1_	: . . . . Y . . . . YL . . . P . . S . I . D . - - - -	: 298
sp_P27024_VGLG_HRSV5:	. . . . Y . . . . YL . . . . . S . I . N . - - - -	: 298
emb_CAA51763.1_	: . . . . Y . . . . YL . . . . . S . I . N . - - - -	: 296
emb_CAA83899.1_	: . . . . AY . . . . YL . . . . L . . S . I . N . - - - -	: 298
gb_AAF23741.1_	: . . . . AY . . . . YL . . . P . . S . I . N . - - - -	: 279
gb_AAC36325.1_	: . . . . Y . . . . YL . . . P . . S . I . N . - - - -	: 298
mb_CAA83877.1_	: . . . . Y . . . . YL . . . P . . S . I . N . - - - -	: 298
mb_CAA83862.1_	: . . . . Y . . . . YL . . . P . . S . I . N . - - - -	: 298
mb_CAA83857.1_	: . . . . Y . . . . YL . . . P . . S . I . N . - - - -	: 298
mb_CAA83866.1_	: . . . . Y . . . . YL . . . P . . S . I . N . - - - -	: 298
mb_CAA83873.1_	: . . . . Y . . . . YL . . . P . . S . I . N . - - - -	: 298
gb_AAF23727.1_	: . . . . Y . . . . YL . . . P . . S . I . N . - - - -	: 279
gb_AAF23733.1_	: . . . . Y . . . . YL . . . P . . S . I . N . - - - -	: 279
emb_CAA83861.1_	: . . . . Y . . . . YQ . . . P . . S . I . N . - - - -	: 298
emb_CAA83900.1_	: . . . . Y . . . . YL . . . P . . S . I . N . - - - -	: 298
_gb_AAO14878.2_	: SP . . . . Y . . . . YL . . . P . . S . I . N . - - - -	: 298
gb_AAD02942.1_	: . . . . Y . . . . KYL . . . P . . S . I . N . - - - -	: 298
gb_AAD02945.1_	: S . . . . Y . . . . YL . . . P . . S . I . N . - - - -	: 293
gb_AAC57026.1_	: . . . . Y . . . . YL . . . P . . S . . . N . - - - -	: 298
ref_NP_044595.1_	: . . . . Y . . . . YL . . . P . . S . . . N . - - - -	: 298
gb_AAF23729.1_	: . . . . Y . . . . YL . . . . . S . . . NH - - - -	: 279
gb_AAF23731.1_	: . . . . Y . . . . YL . . . P . . S . . . N . - - - -	: 279
gb_AAC36324.1_	: . . . . PH . Y . . . . Y . . . . P . . F . . . A - - - -	: 297
sp_P27023_VGLG_HRSV4:	. . . . Y . . . . Y . . . . P . . S . . . N . - - - -	: 297
sp_P27025_VGLG_HRSV6:	. . . . Y . . . . Y . . . . P . . S . . . N . - - - -	: 297
gb_AAF23736.1_	: . . . . Y . . . . Y . . . . P . . S . . . N . - - - -	: 278
gb_AAF23728.1_	: . . . . Y . . . . Y . . . . P . . S . . . N . - - - -	: 278
gb_AAF23735.1_	: . . . . Y . . . . Y . . . . P . . S . . . N . - - - -	: 278
gb_AAF23732.1_	: . . . . Y . . . . Y . . . . P . . S . . . N . - - - -	: 278
gb_AAD02946.1_	: . . . . Y . . . . YL . . . P . . S . . . KN - - - -	: 292
gb_AAF23743.1_	: . . . . Y . . . . Y . . . . P . . S . . . N . - - - -	: 279
gb_AAF23749.1_	: . . . . Y . . . . Y . . . . P . . S . . . N . - - - -	: 279
gb_AAF23745.1_	: . . . . Y . . . . Y . . . . P . . QS . . . NK - - - -	: 279
sp_P27026_VGLG_HRSV7:	. . . . Y . . . . Y . . . . P . . S . . . D . - - - -	: 297
emb_CAA83863.1_	: . . . . Y . . . . Y . . . . P . . S . . . D . - - - -	: 299
emb_CAA83878.1_	: . . . . Y . . . . Y . . . . P . . S . . . D . - - - -	: 297
emb_CAA83860.1_	: . . . . Y . . . . Y . . . . P . . S . . . D . - - - -	: 297
_gb_AAM68153.1_	: . . . . Y . . . . YL . . . SL . . S . . . W - - - -	: 298
_gb_AAS90864.1_	: . . . . Y . . . . YL . . . SP . . S . . . W - - - -	: 251
_gb_AAS90905.1_	: . . . . Y . . . . YL . . . SP . . S . . . W - - - -	: 245
_gb_AAS90931.1_	: . . . . Y . . . . YL . . . SP . . S . . . W - - - -	: 249
_gb_AAS90892.1_	: . . . . Y . . . . YL . . . SP . . S . . . W - - - -	: 251

FIG. 5NN

```

_gb_AAX08086.1_ : ....Y....YL..SP..S....W----- : 251
_gb_AAS90880.1_ : ....Y....YL..SL..S....W----- : 251
_gb_AAS90929.1_ : ....Y....YL..SL..S....W----- : 251
_gb_AAS90898.1_ : S...Y....YL..SL..S....W----- : 251
_gb_AAQ24136.1_ : ....Y....YL..SL..S....L----- : 298
_gb_AAQ24143.1_ : ....Y....YL..SL..S....----- : 297
_gb_AAQ24139.1_ : ....Y....YL..SL..S....----- : 297
_gb_AAQ24141.1_ : ....Y....YL..SL..S....----- : 297
_gb_AAQ24137.1_ : ....Y....YL..SP..S....----- : 297
_gb_AAS90863.1_ : ....Y....YL..SP..S....W----- : 251
_gb_AAS90924.1_ : ....Y....YL..SP..S....W----- : 251
_gb_AAS90921.1_ : ....Y....YL..SP..S....W----- : 251
_gb_AAS90927.1_ : ....Y....YL..SP..S....W----- : 251
_gb_AAQ24138.1_ : ....Y....YL..SL..S....L----- : 298
_gb_AAQ24140.1_ : ....Y....YL..SP..S....E----- : 297
_gb_AAS90867.1_ : ....Y....YL..SPY.S....W----- : 251
_gb_AAS90884.1_ : ....Y....YL..SPY.S....W----- : 251
_gb_AAS90885.1_ : ....Y....YL..SPH.S....W----- : 251
_gb_AAF23746.1_ : ....Y.I..YL..SL..S....W----- : 279
_gb_AAF23747.1_ : ....Y....YL..SL..S....W----- : 279
_gb_AAF23748.1_ : ....Y....YL..SL..S....W----- : 279
_gb_AAU43726.1_ : ....Y....YL..SP.SS....----- : 297
_gb_AAU43727.1_ : ....Y....YL..SP..S....Y----- : 298
_gb_AAM44850.2_AF51 : ....Y....YL..SL..S...YY----- : 298
_gb_AAF23730.1_ : ....Y....YL..SL..S...NY----- : 279
_gb_AAF23737.1_ : ....Y....YL..SL..S...NY----- : 279
_emb_CAA83867.1_ : ....Y....YL..SL..S...N----- : 297
_emb_CAA83865.1_ : ....Y....YL..SL..S...N----- : 297
_emb_CAA83868.1_ : ....Y....YL..SL..S...N----- : 297
_gb_AAC36326.1_ : ....Y....YL..SL..S...N----- : 297
_gb_AAC36328.1_ : ....Y....YL..SL..S...N----- : 297
_gb_AAF23738.1_ : ....H....Y...YL..S...N----- : 278
_gb_AAF23734.1_ : ....Y....YL..SL..S...NY----- : 279
_gb_AAQ24144.1_ : ....Y....YL..SP..S....----- : 297
_gb_AAQ24145.1_ : ....Y....YL..SP..S...NW----- : 298
_gb_AAF23744.1_ : .P..Y....YL..SP..S...N----- : 278
_emb_CAA83858.1_ : ....Y....YL..SL..S...N----- : 297
_gb_AAU43729.1_ : ....Y....Y...SL..S...YY----- : 298
_gb_AAS90862.1_ : S...Y..F..L..SP..S...NL----- : 251
_gb_AAS90913.1_ : S...Y..F..L..SP..S...NL----- : 251
_emb_CAA83869.1_ : ....Y....YL..SP..S...NL----- : 298
_emb_CAA83859.1_ : ....Y..F.YL..SP..S...NL----- : 298
_gb_AAF23740.1_ : ....Y....YL..SP..S...NL----- : 279
_gb_AAF23742.1_ : ....Y....YL..SP..S...NL----- : 279
_emb_CAA83879.1_ : ....Y....YL..SP..S...N----- : 297
_emb_CAA83864.1_ : ....Y....YL..SP.SS...N----- : 297
_gb_AAF23739.1_ : S...Y....YL..SP..S...IN----- : 278
_sp_P20895_VGLG_HRSV : ..... : 298
_emb_CAA83872.1_ : ..... : 298
_emb_CAA34937.1_ : ..... : 298
_gb_AAX23993.1_ : ..... : 298
_sp_P27021_VGLG_HRSV2 : .....I...Y.P.....P.----- : 297
_gb_AAD02941.1_ : .....I...Y.....P.----- : 297
_emb_CAA83870.1_ : .....I...Y.....----- : 297
_emb_CAA83871.1_ : .....I...Y.....----- : 297

```

# FIG. 500

sp_P27022_VGLG_HRSV3:	.....I...Y.....P-----	: 297
emb_CAA51765.1_	: .....I...Y.....P-----	: 295
gb_AAD02944.1_	: .....I...Y.....P-----	: 292
emb_CAA83874.1_	: .....I...Y.....P-----	: 297
gb_AAC36327.1_	: ...F.....Y.....P-----	: 297
emb_CAA83875.1_	: ...F.I...Y.....P-----	: 297
sp_P03423_VGLG_HRSVA:	.....Y.....P.....	: 298
gb_AAD02943.1_	: .....I...YL.....P.....	: 293
sp_P20896_VGLG_HRSV1:	S...P.A..P-----,TL.PN-----	: 292
sp_P23041_VGLG_HRSV8:	S...P.A..P-----,TS.P-----	: 292
_gb_AAR14265.1_	: S...P.A..A-----,TS.....	: 292
_gb_ABC26397.1_	: S..TP.A..P-----,TS...QKV----	: 293
_gb_ABC26398.1_	: S..TP.A..P-----,TS...Q.V----	: 293
gb_AAC36320.1_	: S..TP.A..P-----,TS...QNTQSRD	: 299
_gb_AAW79749.1_	: S..TP.A..P-----,TS...QNTQSHA	: 240
_gb_AAW79750.1_	: S..TP.A..P-----,TS...QNTQSHA	: 240
_gb_AAW79751.1_	: S..TP.A..P-----,TS...QNTQSHA	: 240
_gb_AAW79752.1_	: S..TP.A..P-----,TS...QNTQSHA	: 240
ref_NP_056862.1_	: S..TP.A..P-----,TS...QNTQSHA	: 299
_gb_AAW79753.1_	: S..AP.A..P-----,TS...QNTQSHA	: 240
_gb_AAW79754.1_	: S..TP.A..P-----,T...QKTQPHA	: 238
_gb_AAW79755.1_	: S..TP.A..P-----,T...QKTQPHA	: 238
_gb_AAW79756.1_	: S..TP.A..P-----,TS...QKT----	: 234
_gb_AAK31912.1_	: S..TP.A..P-----,TS...QGA----	: 284
_gb_AAK37424.1_	: S..TP.A..P-----,TS...QGA----	: 284
_gb_AAW79743.1_	: S..TP.A..P-----,TS...QGA----	: 236
_gb_AAW79744.1_	: S..TP.A..P-----,TS...QGA----	: 236
gb_AAF20082.1_	: S..TP.A..P-----,TS...QG-----	: 275
gb_AAF20084.1_	: S..TP.A..P-----,TS...QG-----	: 275
gb_AAF20085.1_	: S..TP.A..P-----,TS...QG-----	: 275
_gb_AAW79741.1_	: S.HTP.A..P-----,TS...QGA----	: 236
_gb_AAW79742.1_	: S..TP.A..P-----,TS...QGA----	: 236
gb_AAF20081.1_	: S..TP.A..P-----,TS...QG-----	: 275
gb_AAF20091.1_	: S..TP.A..P-----,TS...QG-----	: 275
gb_AAC36321.1_	: S..TP.A..P-----,TS...QKA----	: 295
_gb_AAW79745.1_	: S..TP.A..P-----,TS...QKA----	: 236
_gb_AAW79746.1_	: S..TP.A..P-----,TS...QKA----	: 236
gb_AAF20083.1_	: S..TP.A..P-----,TS...QK-----	: 275
_gb_AAQ16176.1_	: S...P.A..P-----,TS...QKI----	: 295
_gb_AAW79759.1_	: S..TP.A..P-----,TS...QKI----	: 237
_gb_AAR86181.1_	: F..TP.A..P-----,TS...Q.AQSYA	: 283
_gb_AAU26097.1_	: F..TP.A..P-----,TS...Q.AQSYA	: 250
_gb_AAU26099.1_	: F..TP.A..P-----,TS...Q.AQSYA	: 243
_gb_AAX08076.1_	: F..TP.A..P-----,TS...Q.AQSYA	: 244
_gb_AAX08079.1_	: F..TP.A..P-----,TS...Q.AQSYA	: 243
_gb_AAX08078.1_	: F..TP.A..P-----,TS...Q.AQSYA	: 243
_gb_AAU26101.1_	: F..TP.A..P-----,TS...Q.AQSYA	: 247
_gb_AAW79767.1_	: ...TP.A..P-----,TS...Q.AQSYA	: 240
_gb_AAS90851.1_	: F..TP.A..P-----,TS...Q.A----	: 247
_gb_AAS90852.1_	: F..TP.A..P-----,TS...Q.A----	: 246
_gb_AAS90853.1_	: F..TP.A..P-----,TS...Q.A----	: 247
_gb_AAS90856.1_	: F..TP.A..P-----,TS...QVA-----	: 244
_gb_AAW79761.1_	: F..TP.A..P-----,TS...Q.A----	: 236
_gb_AAW79762.1_	: L..TP.A..P-----,TS...Q.A----	: 236
_gb_AAW79765.1_	: F..TP.A..P-----,TS...Q.A----	: 236

**FIG. 5PP**

_gb_AAW79763.1	: F..TP.A..P-----TS...Q.A----	: 236
_gb_AAW79764.1	: F..TP.A..P-----TS...Q.A----	: 236
_gb_AAW79768.1	: F..TP.A..P-----TS...Q.A----	: 236
_gb_AAW79769.1	: F..TP.A..P-----TS...QKA----	: 236
_gb_AAW79748.1	: S..TP.A..P-----TS...QKA----	: 236
_gb_AAW79772.1	: S..TP.A..P-----TS...QKT----	: 236
_gb_AAW79777.1	: S..TP.A..P-----TS...QKT----	: 236
_gb_AAW79778.1	: S..TP.A..P-----TS...Q.T----	: 236
_gb_AAR00216.1	: S..TP.A..P-----TS...QKP----	: 295
_gb_AAR00220.1	: S..TP.A..P-----TS...QKP----	: 295
_gb_AAR00217.1	: S..TP.A..P-----TS...QNP----	: 295
_gb_AAR00219.1	: S..TP.A..P-----TS...QNTQSRD	: 299
_gb_AAR00218.1	: S..TP.A..P-----TL...QNTQSRD	: 299
_gb_AAW79733.1	: S..TP.A..P-----TS...QKP----	: 236
_gb_AAW79734.1	: S..TP.A..P-----TS...QKP----	: 236
_gb_AAW79738.1	: S..TP.A..P-----TS...QKP----	: 236
gb_AAF20090.1	: S..TP.A..P-----TS...QK-----	: 275
gb_AAF20087.1	: S..TP.A..P-----TS...QK-----	: 275
gb_AAF20086.1	: S..TP.A..P-----TS...QK-----	: 275
gb_AAF20088.1	: S..TP.A..P-----TS...QK-----	: 275
gb_AAF20089.1	: S..TP.A..P-----TS...AQK-----	: 275
_gb_ABC26396.1	: S..TP.A..P-----TS...Q.P-----	: 295
_gb_AAQ16177.1	: S..TP.A..P-----TS...QKL-----	: 315
_gb_AAQ16178.1	: S..TP.A..P-----TS...QKL-----	: 315
_gb_ABB16912.1	: S..TP.A..P-----TS...QKL-----	: 315
_dbj_BAC81823.1	: S..TP.A..P-----TS...QKL-----	: 315
_gb_AAW79621.1	: S..TP.A..P-----TS...QKL-----	: 256
_gb_AAW79622.1	: S..TP.A..P-----TS...QKL-----	: 256
_gb_AAW79627.1	: S..TP.A..P-----TS...QKL-----	: 256
_gb_AAU26098.1	: S..TP.A..P-----T...QRL-----	: 256
_gb_AAW79590.1	: S..TP.A..P-----TS...QKL-----	: 256
_gb_AAW79583.1	: S..TP.A..P-----TS...QKLQSYA	: 258
_gb_AAW79585.1	: S..TP.A..P-----TS...QKLQSYA	: 258
_gb_AAW79589.1	: S..TP.A..P-----TS...QKLQSYA	: 258
_gb_ABB16944.1	: F..TP.A..P-----TS...-----	: 310
_gb_AAW79580.1	: S..TP.A..P-----TS...-----	: 253
_gb_ABB43013.1	: S..TPIA..P-----TS...QKL-----	: 265
_gb_ABC26395.1	: S..TP.A..P-----TS...QKL-----	: 315
_gb_ABB16945.1	: S..TP.A..P-----TS...-----	: 312
_gb_ABB16919.1	: S..TP.A..P-----TS..NQKL-----	: 315
_gb_ABB16936.1	: S..TP.A..P-----TS..NQKL-----	: 315
_gb_ABB16924.1	: S..TP.A..P-----TS..NQKL-----	: 315
_gb_ABB16930.1	: S..TP.A..P-----TS..NQKL-----	: 315
_gb_ABB16932.1	: S..TP.A..P-----TS..NQKL-----	: 315
_gb_ABB16941.1	: S..TP.A..P-----TS..NQKL-----	: 315
_gb_ABB16939.1	: S..TP.A..P-----TS..NQKL-----	: 315
_gb_ABB16934.1	: S..TP.A..P-----TS..NQKL-----	: 315
_gb_ABB16925.1	: S..TP.A..P-----TS..NQKL-----	: 315
_gb_ABB16937.1	: S..TP.A..P-----TS..NQKL-----	: 315
_gb_ABB16943.1	: S..TP.A..P-----TS..NQKL-----	: 315
_gb_ABB16946.1	: S..TP.A..P-----TS..NQKL-----	: 315
_gb_AAW79591.1	: S..TP.A..P-----TS...QKLQSYA	: 260
_gb_AAW79613.1	: -----	: -
_gb_AAW79607.1	: S..TP.A..P-----TS...QKLQSYA	: 260
_gb_AAW79600.1	: S..TP.A..P-----TS...QKLQSYA	: 260



FIG. 5QQ

_gb_AAW79606.1_	: S..TP.A..P-----TS...QKLQSYA	: 260
_gb_AAW79615.1_	: S..TP.A..P-----TS...QKL----	: 256
_gb_AAW79616.1_	: S..TP.A..P-----TS...QKL----	: 256
_gb_AAW79618.1_	: S..TP.A..P-----TS...QKL----	: 256
_gb_AAW79619.1_	: S..TP.A..P-----TS...QKL----	: 256
_gb_AAW79620.1_	: S..TP.A.DP-----TS...QKL----	: 256
_gb_ABB16926.1_	: S..TP.A..P-----TS...QKL----	: 316
_gb_ABB16942.1_	: S..TP.A..P-----PTS...QKL----	: 316
_gb_ABB16938.1_	: S..TP.A..P-----TS...QKL----	: 315
_gb_ABB16940.1_	: S..TP.A..P-----TS...QKL----	: 316
_gb_ABB16916.1_	: S..TP.A..P-----TS...QKL----	: 315
_gb_ABB16923.1_	: S..TP.E..P-----TS...QKL----	: 315
_gb_ABB16922.1_	: S..TP.A..P-----TS...QKL----	: 315
_gb_ABB16927.1_	: S..TP.A..P-----TS...QKL----	: 315
_gb_ABB16928.1_	: S..TP.A..P-----TS...QKL----	: 315
_gb_ABB16920.1_	: S..TP.A..P-----TS...QKL----	: 315
_gb_ABB16917.1_	: S..TP.A..P-----TS...QKL----	: 315
_gb_ABB16918.1_	: S..TP.A..P-----TS...QKL----	: 315
_gb_AAW79739.1_	: S..TP.A..P-----TS...QKP----	: 236
_gb_AAW79740.1_	: S..TP.A..P-----TS...QKP----	: 236
_gb_AAW79679.1_	: S..TP.A..P-----TS...QKFQSYA	: 240
_gb_AAW79682.1_	: S..TP.A..P-----TS...QKFQSYA	: 240
_gb_AAW79683.1_	: S..TP.A..P-----TS...QKF----	: 236
_gb_AAW79719.1_	: SA.TP.A..P-----TS...QKF----	: 236
_gb_AAW79692.1_	: S..TP.A..P-----TS...QNL----	: 236
_gb_AAW79693.1_	: S..TP.A..P-----TS...QNL----	: 236
_gb_AAW79694.1_	: S..TP.A..P-----TS...QNL----	: 236
_gb_AAW79723.1_	: S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79724.1_	: S..TP.A..P-----TS...QKL----	: 236
gb_AAC36322.1_	: S..TP.A..P-----TS...QKL----	: 295
gb_AAC36323.1_	: S..TP.A..P-----TS...QKL----	: 295
_gb_AAW79684.1_	: S..AP.A..P-----TS...QKL----	: 236
_gb_AAW79687.1_	: S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79688.1_	: S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79691.1_	: S..TP.A..P-----TS...QNL----	: 236
_gb_AAW79710.1_	: S..TP.A..L-----TS...QKL----	: 236
_gb_AAW79714.1_	: S.....	: 220
_gb_AAW79716.1_	: S..TP.A..P-----TS...QKL----	: 237
_gb_AAW79715.1_	: S..TP.A..P-----TS...QKL----	: 237
_gb_AAW79729.1_	: S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79731.1_	: S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79628.1_	: S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79712.1_	: S..TP.A..P-----TS...QKL----	: 236
_gb_AAK49106.1_	: S..TP.A..P-----TS...QKL----	: 284
_gb_AAW79720.1_	: S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79722.1_	: S..TP.A..P-----TS...QKL----	: 236
_gb_AAW79727.1_	: S..TP.A..P-----TS...QKL----	: 236

FIG. 6




FIG. 7




FIG. 8

